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1.0 Introduction
1.1 Scope and purpose
The overall purpose of these guidelines is to provide
guidance on best clinical practice in the treatment and
management of adults with HIV infection on antiretrovi-
ral therapy (ART). The scope includes: (i) guidance on the
initiation of ART in those previously na€ıve to therapy; (ii)
support of people living with HIV (PLWH) on treatment;
(iii) management of individuals experiencing virological
failure; and (iv) recommendations in specific populations
where other factors need to be taken into consideration.
The guidelines are aimed at clinical professionals directly
involved with and responsible for the care of adults with
HIV infection, and at community advocates responsible
for promoting the best interests and care of HIV-positive
adults. They should be read in conjunction with other
published BHIVA guidelines.
1.2 Methodology
1.2.1 Guideline development process
BHIVA fully revised and updated the association’s guide-
line development manual in 2011. Further updates have
been carried out subsequently [1]. Full details of the
guideline development process, including conflict of
interest policy, are outlined in the manual. BHIVA has
adopted the modified Grading of Recommendations
Assessment, Development and Evaluation (GRADE) sys-
tem for the assessment, evaluation and grading of evi-
dence and development of recommendations (see below
and Appendix 1) [2,3].
The scope, purpose and guideline topics were agreed
by the writing group. Questions concerning each guide-
line topic were drafted and a systematic literature search
was undertaken by an information scientist. Details of the
search questions and strategy (including the definition of
populations, interventions and outcomes) are outlined in
Appendix 2. BHIVA guidelines for the treatment of HIV-
1-infected adults with antiretroviral therapy were last
published in 2013 [4]. For the 2015 guidelines Medline,
Embase and the Cochrane library were searched between
October 2011 and August 2014. Abstracts from selected
conferences (see Appendix 2) were searched between 1
January 2011 and July 2015. For each topic and health-
care question, evidence was identified and evaluated by
writing group members with expertise in the field. Using
the modified GRADE system, writing group members
were responsible for assessing and grading the quality of
evidence for predefined outcomes across studies and
developing and grading the strength of recommendations.
An important aspect of evaluating evidence is an under-
standing of the design and analysis of clinical trials,
including the use of surrogate marker data. Decisions
regarding the clinical importance of difference in out-
comes are made by the writing group.
For a number of questions, GRADE evidence profile
and summary of findings tables were constructed, using
predefined and rated treatment outcomes (Appendix 3), to
help achieve consensus for key recommendations and aid
transparency of the process. Before final approval by the
writing group, the guidelines were published online for
public consultation and an external peer review was
commissioned.
1.2.2 Involvement of PLWH
BHIVA views the involvement of PLWH and community
representatives in the guideline development process as
essential. The writing group included two representatives
appointed through the UK HIV Community Advisory
Board (UK-CAB) who were involved in all aspects of the
guideline development process. Community groups were
invited to participate in the draft guideline consultation
process and a community consultation was held on 6th
August 2015.
1.2.3 GRADE
The GRADE Working Group [3] has developed an
approach to grading evidence that moves away from ini-
tial reliance on study design to consider the overall qual-
ity of evidence across outcomes. BHIVA has adopted the
modified GRADE system for its guideline development.
The advantages of the modified GRADE system are (i)
the grading system provides an informative, transparent
summary for clinicians, PLWH and policy makers by
combining an explicit evaluation of the strength of the
recommendation with a judgement of the quality of the
evidence for each recommendation, and (ii) the two-level
grading system of recommendations has the merit of sim-
plicity and provides clear direction to PLWH, clinicians
and policy makers.
The strength of recommendation is graded as 1 or 2 as
follows:
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• A Grade 1 recommendation is a strong recommenda-
tion to do (or not do) something, where the benefits
clearly outweigh the risks (or vice versa) for most, if
not all PLWH. Most clinicians and HIV-positive indi-
viduals should and would want to follow a strong rec-
ommendation unless there is a clear rationale for an
alternative approach. A strong recommendation usually
starts with the standard wording ‘we recommend’.
• A Grade 2 recommendation is a weaker or conditional
recommendation, where the risks and benefits are more
closely balanced or are more uncertain. Most clinicians
and PLWH would want to follow a weak or conditional
recommendation but many would not. Alternative
approaches or strategies may be reasonable depending
on the individual HIV-positive individual’s circum-
stances, preferences and values. A weak or conditional
recommendation usually starts with the standard word-
ing ‘we suggest’.
The strength of a recommendation is determined not
only by the quality of evidence for defined outcomes but
also the balance between desirable and undesirable
effects of a treatment or intervention, differences in val-
ues and preferences and, where appropriate, resource use.
Each recommendation concerns a defined target popula-
tion and is actionable.
The quality of evidence is graded from A to D and for
the purpose of these guidelines is defined as the follow-
ing:
• Grade A evidence means high-quality evidence that
comes from consistent results from well-performed
randomised controlled trials (RCTs), or overwhelming
evidence of some other sort (such as well-executed
observational studies with consistent strong effects and
a low likelihood of uncorrected bias). Grade A implies
confidence that the true effect lies close to the estimate
of the effect.
• Grade B evidence means moderate-quality evidence
from randomised trials that suffer from serious flaws
in conduct, inconsistency, indirectness, imprecise esti-
mates, reporting bias, or some combination of these
limitations, or from other study designs with special
strengths such as observational studies with consistent
effects and exclusion of most potential sources of bias.
• Grade C evidence means low-quality evidence from
controlled trials with several very serious limitations or
observational studies with limited evidence on effects
and exclusion of most potential sources of bias.
• Grade D evidence on the other hand is based only on
case studies, expert judgement or observational studies
with inconsistent effects and a potential for substantial
bias, such that there is likely to be little confidence in
the effect estimate.
1.2.4 Good practice points
In addition to graded recommendations, the BHIVA writ-
ing group has also included good practice points (GPP),
which are recommendations based on the clinical judge-
ment and experience of the working group. GPPs empha-
sise an area of important clinical practice for which there
is not, nor is there likely to be, any significant research
evidence. They address an aspect of treatment and care
that is regarded as such sound clinical practice that
healthcare professionals are unlikely to question it and
where the alternative recommendation is deemed unac-
ceptable. It must be emphasised that GPPs are not an
alternative to evidence-based recommendations.
1.2.5 Dissemination and implementation
The following measures have or will be undertaken to
disseminate and aid implementation of the guidelines:
• E-publication on the BHIVA website and the journal
HIV Medicine.
• Publication in HIV Medicine.
• Shortened version detailing concise summary of rec-
ommendations.
• Shortened version for BHIVA guidelines app.
• E-learning module accredited for CME.
• Educational slide set to support local and regional edu-
cational meetings.
• National BHIVA audit programme.
1.2.6 Guideline updates and date of next review
The guidelines will be next fully updated and revised in
2017. However, the writing group will continue to meet
regularly to consider new information from high-quality
studies and publish amendments and addendums to the
current recommendations before the full revision date
where this is thought to be clinically important to ensure
continued best clinical practice.
1.3 Treatment aims
The primary aim of ART is the prevention of the mortal-
ity and morbidity associated with chronic HIV infection
at low cost of drug toxicity. Treatment should improve
the physical and psychological well-being of PLWH. The
effectiveness and tolerability of ART has improved signif-
icantly over the last 15 years. The overwhelming majority
of PLWH attending HIV services in the UK and receiving
ART experience long-term virological suppression and
good treatment outcomes [5], which compare very
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favourably with other developed countries. Notably, in
2013 around 90% of those diagnosed with HIV in the UK
had initiated ART, with 93% of those on ART having a
suppressed viral load [5].
A UK analysis of individuals commencing ART
between 2000 and 2010 demonstrates that the expected
age at death for HIV-positive men from ART start was
68, 73 and 77 years at exact ages 20, 35 and 50 years,
respectively, compared with 77, 78 and 79 years in the
general population [6]. The corresponding expected age
at death for HIV-positive women was 69, 74 and
78 years, compared with 81, 82 and 83 years in the gen-
eral population. The same study shows that life expec-
tancy in men and women with an undetectable viral load
and CD4 cell count greater than 350 cells/lL is the same
as, or slightly better than, that for the general population
[6]. Modelling has suggested that for HIV-positive men
who have sex with men (MSM) living in a developed
country with extensive access to HIV care and assuming
a high rate of HIV diagnosis, the life expectancy is
75 years [7]. The authors concluded that the greatest risk
of excess mortality is due to delays in HIV diagnosis.
Decreasing late diagnosis (and consequently starting ART
earlier), maintaining individuals in care and reducing
long-term drug toxicity and non-aquired immune defi-
ciency syndrome (AIDS) co-morbidities are crucial to fur-
ther improving life expectancy and the well-being of
people living with HIV infection.
A further aim of treatment is the reduction in sexual
transmission of HIV. The use of ART to prevent mother-
to-child transmission is universally accepted and best
practice is addressed in the BHIVA guidelines for the
management of HIV infection in pregnant women [8].
Recently, the size of the effect of ART on reducing the
risk of sexual transmission of HIV has been estimated at
>95% [9,10]. The PARTNER study investigated the risk of
HIV transmission within serodifferent couples where the
HIV-positive partner was on suppressive ART (viral load
less than 200 copies/mL) and demonstrated no transmis-
sions compared with a predicted 86 new infections had
the positive partner not been on effective ART [11]. The
upper 95% confidence interval for risk of transmission
was 0.4 per 100 couple years for any sex and 1.0 per 100
couple years for anal sex. At a population level, ART is
likely to be important in reducing the incidence of HIV
infection.
1.4 Resource use
ART is extremely cost-effective and compares favourably
with the cost of management of many other chronic
diseases. Estimates of the cost-effectiveness of ART have
been assessed in studies in North America and Europe
[12–14]. Their findings have been consistent with an esti-
mated incremental cost-effectiveness ratio of about US
$20,000 per quality adjusted life year (QALY) for combi-
nation ART compared with no therapy based on drug
costs and treatment patterns in the USA and Europe [15].
The primary aim of these guidelines is to summarise and
base recommendations on the clinical benefits of ART
and different ART options.
The number of people living with HIV in the UK con-
tinues to increase and by the end of 2013 was estimated
to be 107,800 (95% credible interval 101,600–115,800),
of whom 24% were undiagnosed. In 2013, 90% (73,290/
81,510) of people seen for HIV care were prescribed ART
[5]. With ongoing HIV transmission, increased HIV testing
and a reduction in the undiagnosed fraction, the number
of people diagnosed with HIV and accessing HIV services
will continue to increase. It has been estimated that the
annual population treatment and care costs rose from
£104 million in 1997 to £483 million in 2006, rising to a
projected annual cost of £721 million in 2013 [16]. It is
likely this estimated projected cost is an overestimate due
to various factors, including earlier diagnosis and a lower
proportion of individuals with symptoms. However, in
the current economic climate containing and reducing
costs without affecting the current high standards of care
and treatment outcomes will be an immense challenge to
commissioners, healthcare professionals and PLWH alike.
A collaborative approach is required.
In the UK, higher annual treatment and care costs have
been associated with late diagnosis and initiation of ART
at lower CD4 cell counts than the BHIVA guidelines rec-
ommend [17,18]. In addition to earlier diagnosis and ini-
tiation of ART, reducing inpatient episodes, decreasing
drug toxicity, preventing HIV-associated co-morbidities
and innovations in models of care are likely to have a
beneficial effect on costs. However, the cost of antiretro-
viral (ARV) drugs remains the major factor contributing
to treatment and care costs. With the increasing availabil-
ity of generic drugs and the introduction of a standard
tariff for HIV services (in England), commissioners and
the NHS will be faced with difficult choices about the
value and benefit of different ARV drugs.
The BHIVA writing group recognises that cost of drugs
is an important issue in the choice of ART regimens. In
addition to drug acquisition costs there are costs associ-
ated with, for example, multidisciplinary team meetings,
switching ART, co-morbidities and management of drug–
drug interactions. There are limited cost-effectiveness
data in the UK comparing different ARV drugs and for
this reason we did not include cost-effectiveness as an
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outcome in ART comparisons. However, the writing
group believes that decreasing the risks of virological
failure, drug resistance and drug-associated toxicity are
likely to have a beneficial impact on long-term cost-
effectiveness and resource use. In the setting of similar
virological efficacy, determining the acceptable threshold
at which differences in the risk of toxicity, tolerability
and convenience outweigh differences in resource use
and cost will be important. These thresholds may differ
among clinicians and PLWH alike.
In developing the recommendations in these guidelines,
we have taken into account differences in critical treat-
ment outcomes between different drug regimens in deter-
mining preferred and alternative treatment regimens. We
recognise and support that commissioning arrangements
and local drug costs will and should influence ART
choice where outcomes, across a range of clinical mea-
sures, are similar between individual drugs in the treat-
ment of defined populations. However, we believe that
reducing treatment costs should not be at the cost of an
increased risk of poorer treatment outcomes and quality
of care, not least as these are likely to have a detrimental
impact on long-term cost.
1.5 Implications for research
In reviewing quality of evidence, guidelines will identify
areas of treatment and care where there is an absence of
evidence or limited confidence in the size of effect to
influence choice of treatments or determine treatment
and management strategies. For this reason, it is not the
intention of these guidelines to stifle clinical research but
rather to help promote continued research with the aim
to further improve clinical care and treatment outcomes.
The development and provision of HIV clinical trials
within the UK are supported, and participation in a clini-
cal trial should be open and offered to PLWH where
appropriate.
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2.0 Summary of recommendations
3.0 Involvement of people living with HIV in decision-making
3.1 Recommendations
• We recommend PLWH are given the opportunity to be involved in
making decisions about their treatment (GPP).
• Provision of treatment-support resources should include in-house,
independent and community information providers and peer-support
resources (GPP).
4.0 When to start
4.1 Chronic infection
4.1.1 Recommendations
• We recommend people with HIV start ART (1A).
4.2 Individuals presenting with AIDS or a major infection
4.2.1 Recommendation
• We recommend that individuals presenting with an AIDS-defining
infection, or with a serious bacterial infection and a CD4 cell count
<200 cells/µL, start ART within 2 weeks of initiation of specific antimi-
crobial chemotherapy (1B).
4.3 Treatment of primary HIV infection
4.3.1 Recommendation
• We recommend all individuals with suspected or diagnosed PHI are
reviewed promptly by an HIV specialist and offered immediate ART
(1B).
4.4 Impact of treatment on prevention of onward transmission
4.4.1 Recommendations
• We recommend that ART is offered to all PLWH for the prevention of
onward transmission (1A).
• We recommend the evidence that treatment with ART substantially
lowers the risk of transmission is discussed with all PLWH (GPP).
• An assessment of the risk of transmission to others should be made at
diagnosis and subsequent visits (GPP).
5.0 What to start
5.1 Summary recommendations
• We recommend that therapy-na€ıve PLWH start ART containing two
nucleoside reverse transcriptase inhibitors (NRTIs) plus one of the
following: ritonavir-boosted protease inhibitor (PI/r), non-nucleoside
reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI)
(1A).
Table 5.1.1 Summary recommendations for choice of ART
Preferred Alternative
NRTI backbone Tenofovir-DF and
emtricitabine
Abacavir and
lamivudinea,b
Third agent (alphabetical
order)
Atazanavir/r Efavirenz
Darunavir/r
Dolutegravir
Elvitegravir/cc
Raltegravir
Rilpivirined
/r: boosted with ritonavir; /c: boosted with cobicistat.
aAbacavir is contraindicated if an individual is HLA-B*57:01 posi-
tive.
bUse recommended only if baseline viral load is <100,000 copies/
mL except when initiated in combination with dolutegravir in
which case abacavir/lamivudine can be used at any baseline viral
load.
cTenofovir-DF/emtricitabine/elvitegravir/c fixed-dose combination
should not be initiated in individuals with creatinine clearance
<70 mL/min.
dUse recommended only if baseline viral load is <100,000 copies/mL.
NB. The viral load advice for abacavir/lamivudine and rilpivirine
applies only to initiating these agents in individuals with a detectable
viral load – when these agents are used as a switch option in the
context of viral load suppression the baseline viral load can be disre-
garded.
5.3 Which nucleoside reverse transcriptase inhibitor backbone
5.3.1 Recommendations
• We recommend therapy-na€ıve individuals start combination ART con-
taining tenofovir-DF and emtricitabine as the preferred NRTI backbone
(1A).
• We suggest abacavir and lamivudine is an acceptable alternative NRTI
backbone in therapy-na€ıve individuals. In those with a baseline viral
load >100,000 copies/mL, it should be used with caution if there are
clinical reasons to prefer over tenofovir-DF and emtricitabine (2A).
• The caution regarding baseline viral load does not apply if abacavir/
lamivudine is used with dolutegravir (2A).
• Abacavir must not be used in individuals who are HLA-B*57:01-positive
(1A).
5.4 Which third agent
5.4.1 Recommendations
• We recommend therapy-na€ıve individuals start combination ART con-
taining atazanavir/r, darunavir/r, dolutegravir, elvitegravir/c, raltegravir
or rilpivirine as the third agent (1A).
• We suggest that for therapy-na€ıve individuals, efavirenz is an accept-
able alternative third agent (1A).
5.5 Novel antiretroviral therapy strategies
5.5.1 Recommendation
• We recommend against the use of PI monotherapy as initial therapy
for treatment-na€ıve patients (1C).
5.5.2 Recommendation
• We suggest the use of darunavir/r-based dual ART regimen with ralte-
gravir in treatment-na€ıve patients with CD4 count >200 cells/µL and
viral load <100,000 copies/mL where there is need to avoid abacavir or
and tenofovir-DF (2A).
• We recommend against the use of PI-based dual ART with a single
NNRTI, NRTI or CCR5 receptor antagonist for treatment-na€ıve patients
(1B).
6.0 Supporting individuals on therapy
6.1 Adherence
6.1.1 Interventions to increase adherence to treatment
6.1.1.1 Recommendations
• We recommend adherence and potential barriers to it are assessed and
discussed with PLWH whenever ART is discussed, prescribed or dis-
pensed (GPP).
• We recommend adherence support should address both perceptual bar-
riers (e.g. beliefs and preferences) and/or practical barriers (e.g. limita-
tions in capacity and resources) to adherence (GPP).
• Individuals experiencing difficulties with adherence should be offered
additional support from staff within the MDT who have experience in
adherence support and/or from organisations offering peer support
(GPP).
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6.1.2 Should the choice of first-line antiretroviral therapy combination be
affected by risk of non-adherence?
6.1.2.1 Recommendation
• In individuals where there is clinical concern that doses may be missed
intermittently, there is insufficient evidence to recommend a PI/r over
NNRTI- or INI-based regimens. However, where there is a risk of fre-
quent prolonged treatment interruptions, PI/r-based regimens may be
associated with less frequent selection for drug resistance (2C).
6.2 Pharmacology
6.2.1 Drug interactions
6.2.1.1 Recommendations
• Drug histories should be taken at each clinic visit, and a full medica-
tion history (including herbals, recreational drugs and other non-pre-
scribed medications) should be undertaken at least annually (GPP).
• All potential adverse pharmacokinetic interactions between antiretrovi-
ral drugs and other concomitant medications should be checked before
administration (with tools such as www.hiv-druginteractions.org) (GPP).
• Wherever feasible, PLWH should be counselled about the risks of drug
interactions, and advised to use resources such as the Liverpool HIV
Drug Interactions App (iOS or Android) (GPP).
6.2.2 Therapeutic drug monitoring
6.2.2.1 Recommendation
• We recommend against the unselected use of therapeutic drug moni-
toring (TDM) (GPP).
• TDM may be of clinical value in specific populations (e.g. children,
pregnant women) or selected clinical scenarios (e.g. malabsorption,
drug interactions, suspected non-adherence to therapy) (2C).
6.2.3 Stopping therapy: pharmacological considerations
6.2.3.1 Recommendations
• We recommend individuals stopping ART containing an NNRTI in com-
bination with an NRTI backbone replace all drugs with a PI (darunavir/
r once daily) for 4 weeks (1C).
• We recommend individuals stopping a PI-containing regimen stop all
drugs simultaneously and no replacement is required (1C).
6.3.2 Switching antiretrovirals in combination antiretroviral therapy
6.3.2.1 Recommendations
• We recommend, in individuals on suppressive ART regimens, considera-
tion is given to differences in side-effect profile, drug–drug interac-
tions and drug-resistance patterns before switching any ARV
component (GPP).
• In individuals with previous NRTI resistance mutations, we recommend
against switching a PI/r to either an NNRTI or an INI as the third agent
(1B).
6.3.3 Protease inhibitor monotherapy
6.3.3.1 Recommendation
• We recommend against the use of PI monotherapy for routine ART
(1A).
• We recommend against the use of PI monotherapy for individuals
whose initial regimen has failed or who have established resistance to
one more antiretroviral drugs (1A).
6.3.4 Treatment with one boosted protease inhibitor and one NRTI
6.3.4.1 Recommendation
• We suggest that a boosted PI plus lamivudine as an alternative to
three-drug ART in individuals with viral suppression (2A).
6.4 Stopping therapy
6.4.1 Recommendation
• We recommend against treatment interruption or intermittent therapy
in individuals stable on a virally suppressive ART regimen (1A).
7.0 Managing virological failure
7.2 Blips, low-level viraemia and virological failure
7.2.1 Recommendations
In individuals on ART:
• A single VL 50–200 copies/mL preceded and followed by an unde-
tectable VL is usually not a cause for clinical concern (GPP).
• We recommend that a single VL >200 copies/mL is investigated further,
including a genotypic resistance test, as it is indicative of virological
failure (1C).
• We recommend that in the context of repeated viral blips, resistance
testing be attempted (1D).
7.3 Individuals with no or limited drug resistance
7.3.1 Recommendations
• We recommend for individuals experiencing virological failure on first-
line ART with WT virus at baseline and without emergent resistance
mutations at failure, switch to a PI/r-based combination ART regimen
is the preferred option (1C).
• We recommend individuals experiencing virological failure on first-line
ART with WT virus at baseline and limited emergent resistance muta-
tions (including two-class NRTI/NNRTI) at failure, switch to a new PI/r-
based regimen with the addition of at least one, preferably two, active
drugs (1C).
• We recommend individuals experiencing virological failure on first-line
PI/r plus two-NRTI-based regimens, with limited major protease muta-
tions, switch to a new active PI/r with the addition of at least one,
preferably two, active agents of which one has a novel mechanism of
action (1C).
• We recommend against switching a PI/r to an INI or NNRTI as the third
agent in individuals with historical or existing reverse transcriptase
mutations associated with NRTI resistance or past virological failure on
NRTIs (1B).
7.4 Individuals with multiple class virological failure with or without
extensive drug resistance
7.4.1 Recommendations
• We recommend individuals with persistent viraemia and with limited
options to construct a fully suppressive regimen are discussed/referred
for expert advice (or through virtual clinic referral) (GPP).
• We recommend individuals with extensive drug resistance are switched
to a new ART regimen containing at least two and preferably three
fully active agents with at least one active PI/r such as darunavir/r and
one agent with a novel mechanism (an INI, maraviroc or enfuvirtide)
with etravirine an option based on viral susceptibility (1C).
• We recommend individuals with extensive drug resistance including
reduced darunavir susceptibility receive dolutegravir as the INI (1C).
• We suggest that consideration on an individual basis should be given
to whether inclusion of NRTIs with reduced activity on genotypic test-
ing will provide additional antiviral activity if the regimen includes
three fully active drugs including a boosted PI (2C).
• We recommend all individuals receive intensive adherence support at
the start and at regular intervals to support them on their new ART
combination (GPP).
7.5 Individuals with limited or no therapeutic options when a fully viral
suppressive regimen cannot be constructed
7.5.1 Recommendations
• We recommend accessing newer agents through research trials,
expanded access and named individual programmes (GPP).
• We suggest that consideration on an individual basis should be given
to whether inclusion of NRTIs with reduced activity on genotypic test-
ing will provide additional antiviral activity – this may well be the case
where it is difficult to construct a regimen with three fully active
drugs including a boosted PI (see previous Section) (2C).
• We recommend against discontinuing or interrupting ART (1B).
• We recommend against adding a single, fully active ARV because of
the risk of further resistance (1D).
• We recommend against the use of maraviroc to increase the CD4 cell
count in the absence of CCR5 tropic virus (1C).
• We recommend that in the context of triple class failure and
raltegravir/elvitegravir selected integrase resistance, twice daily dolute-
gravir should be included as part of a new regimen where there is at
least one fully active agent in the background regimen (1C).
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8.0 Special populations
8.1 HIV and TB co-infection
8.1.1 When to start ART in TB/HIV co infection
8.1.1.1 Recommendations
• We recommend all patients with HIV TB co-infection start ART (1B)
• We recommend individuals with CD4 cell count <50 cells/µL start ART
as soon as TB treatment is tolerated and wherever possible within
2 weeks (1B).
• We recommend that for individuals with CD4 cell count ≥50 cells/µL,
ART can be deferred until between 8 and 12 weeks of TB treatment,
especially when there are difficulties with drug–drug interactions,
adherence and toxicities (1B). (Although the data suggest a cut-off of
50 cells/µL, because of the daily variability in CD4, a cut-off of 100
cells/µL may be more appropriate.)
8.1.2 What to start in TB/HIV co infection
8.1.2.1 Recommendations
• We recommend efavirenz in combination with tenofovir-DF and emtri-
citabine as first-line ART (1B) in TB/HIV coinfection
• We recommend that when rifampicin is used with efavirenz standard
doses of efavirenz are given whatever the body weight (1B)
• We suggest that raltegravir should be used with caution with rifampi-
cin (2C)
• We suggest dolutegravir is a possible alternative agent (for which there
is currently little evidence) but the dose should be increased to 50 mg
bd (2D)
• We recommend frequent viral load monitoring if INIs are used (1C)
• We recommend that rifampicin is not used with either NVP or a regi-
men containing ritonavir or cobicistat (1C)
• We recommend that where effective ART necessitates the use of riton-
avir or cobicistat, that rifabutin is used instead of rifampicin (1C)
8.2 Hepatitis B and C virus co-infection
8.2.1 When to start ART in HBV co-infection
Table 8.2.1 Summary recommendations for the treat-
ment of hepatitis B and C co-infection
HBV requiring
treatment*
HBV not
requiring
treatment
HCV with immediate
plan to start HCV
treatment*
HCV with no
immediate
plan to
start HCV
treatment
Start ART
promptly (1A)
(include
tenofovir-DF
and
emtricitabine)
Start ART (1A)
(include
tenofovir-DF
and
emtricitabine)
Start ART before
HCV treatment
commenced (1C);
acceptable to
defer if CD4 cell
count >500 cells/
µL. Discuss with
HIV and viral
hepatitis specialist
Start ART (1A)
*See BHIVA guidelines for the management of hepatitis
viruses in adults (www.bhiva.org/hepatitis-guideline-
s.aspx) for indications to treat hepatitis B and C.
8.2.2 Hepatitis B
8.2.2.1 When to start antiretroviral therapy in HBV co-infection
8.2.2.1.1 Recommendations
• We recommend individuals with HIV and hepatitis B virus (HBV) co-
infection are treated with fully suppressive ART inclusive of anti-HBV
active antivirals, regardless of CD4 cell count (1A).
• We recommend individuals with HIV and HBV co-infection who have
an HBV-DNA ≥2000 IU/mL and/or evidence of more than minimal
fibrosis (Metavir ≥F2) are treated with fully suppressive ART inclusive
of anti-HBV active antivirals promptly (1C)
8.2.2.2 What to start in HBV co-infection
8.2.2.2.1 What to start recommendations
• We recommend tenofovir-DF/emtricitabine as part of a fully suppres-
sive ART combination should be given to all individuals starting HIV
treatment (1C).
• We recommend neither lamivudine nor emtricitabine be used as the
sole active drug against HBV in ART due to the rapid emergence of
HBV resistant to these agents (1B).
• We recommend lamivudine/emtricitabine may be omitted from the
ART regimen and tenofovir-DF be given as the sole anti-HBV active
agent if there is clinical or genotypic evidence of lamivudine/emtric-
itabine-resistant HBV or HIV (1D).
8.2.3 Hepatitis C
8.2.3.1 When to start antiretroviral therapy in HCV co-infection
8.2.3.1.1 Recommendations
• We recommend all individuals with HIV and hepatitis C virus (HCV) co-
infection be assessed for HCV treatment (GPP).
• We recommend commencing ART regardless of CD4 cell count (1A).
• We recommend HCV be considered an additional factor supporting ART
in individuals with CD4 >500 cells/µL who are uncertain about com-
mencing ART (2C)
• We suggest treating HCV before commencing ART is an option if there
are concerns about drug–drug interactions or adherence (GPP)
8.3.2.2 What to start in HCV co-infection
8.3.2.2.1 Recommendations
• We recommend if individuals are commencing ART, and direct-acting
antivirals are not being considered, standard first-line ART should be
commenced (GPP).
• We recommend that when direct-acting antivirals are to be used, there
is careful consideration of possible drug–drug interactions (1C) and
current or archived HIV resistance. All drug interactions should be
checked with an expert source (e.g. www.hiv-druginteractions.org).
• We suggest that if abacavir is to be used with ribavirin, the ribavirin
should be weight-based dose-adjusted (2C)
8.3 HIV-related cancers
8.3.1 When to start ART
8.3.1.1 AIDS-defining malignancies
• We recommend that all patients with AIDS-defining malignancies
should start ART promptly (1B).
8.3.1.1.1 Kaposi sarcoma (KS)
• We recommend that ART should be started promptly in all individuals
diagnosed with KS (1B).
8.3.1.1.2 Non-Hodgkin lymphoma (NHL)
• We recommend that chemotherapy regimens should be combined with
ART therapy in Burkitt lymphoma and diffuse large B-cell lymphoma
(1B).
• We recommend that all individuals with primary effusion lymphoma
(PEL), plasmablastic lymphoma and primary central nervous system
lymphoma should be started on ART if not already on it (1C).
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8.3.1.1.3 Cervical cancer
• We suggest that women with CIN2/3 should commence ART promptly
(2B).
• We recommend that all women living with HIV who are to be treated
with chemo-radiotherapy (CRT) for cervical cancer CRT should start
ART promptly (1C) and opportunistic infection prophylaxis (1D).
8.3.1.2 Non-AIDS-defining malignancies
8.3.1.2.1 Anal cancer
• We recommend that all PLWH who are to be treated with chemo-
radiotherapy should start ART (1C) and opportunistic infection prophy-
laxis (1D).
8.3.1.2.2 Hodgkin lymphoma
• We recommend all PLWH and Hodgkin lymphoma should receive ART
during chemotherapy (1A).
8.3.1.2.3 Other non-AIDS-defining cancers
• We suggest all PLWH who require chemotherapy or radical radiother-
apy should receive concomitant ART and opportunistic infection pro-
phylaxis unless contraindicated (level of evidence 2C).
8.3.2 What to start
• We recommend that all potential interactions between ART, oppor-
tunistic infection prophylaxis and cancer therapy should be considered
(1C).
• We suggest that all individuals with non-AIDS-defining malignancies
who are due to start chemotherapy or radiotherapy should be started
on ART unless contraindicated (2C).
8.3.3 Opportunistic infection prophylaxis in HIV-associated malignancy
• We recommend that all individuals with AIDS-defining malignancies
should start ART immediately (1B).
• We suggest that all individuals with non-AIDS-defining malignancies
who are due to start chemotherapy or radiotherapy should be started
on ART immediately unless contraindicated (2C).
• We recommend herpes simplex virus (HSV) prophylaxis in PLWH with a
history of HSV infection who are starting chemotherapy to reduce the
incidence and severity of reactivations (1D).
• We recommend that individuals with antibodies against hepatitis B
core antigen (HBcAb) should be treated with prophylactic antivirals in
line with BHIVA hepatitis guidelines (1B).
8.3.4 Other considerations from the BHIVA guidelines for HIV-associated
malignancies
• We recommend that potential pharmacokinetic interactions between
antiretrovirals and systemic anticancer therapy are checked prior to
administration (with tools such as: www.hiv-druginteractions.org) (1C).
• We suggest avoiding ritonavir (or cobicistat)-boosted ART in HIV-posi-
tive individuals who are to receive cytotoxic chemotherapy agents that
are metabolised by the CYP450 enzyme system (2C).
• We suggest avoiding atazanavir in HIV-positive individuals who are to
receive irinotecan (2C).
• We suggest switching antiretroviral agents in HIV-positive patients
who are to receive cytotoxic chemotherapy agents to avoid severe
and/or overlapping toxicities (2C).
• Medicines reconciliation prior to chemotherapy to minimise potential
pharmacokinetic interactions and overlapping toxicity should be under-
taken by an experienced pharmacist (GPP).
8.4 HIV-associated neurocognitive impairment
8.4.2 When to start ART
8.4.2.1 Recommendation
• We recommend individuals with symptomatic HIV-associated neu-
rocognitive disorders start ART immediately, irrespective of CD4 cell
count (1C).
8.4.3 What to start with
8.4.3.1 Recommendations
• We recommend individuals with HIV-associated NC disorders start stan-
dard combination ART regimens (1C).
• We recommend avoiding efavirenz-containing regimens in individuals
with HIV-associated NC disorders (1C).
8.4.4 Continuing or worsening NC impairment despite ART
8.4.4.1 Recommendations
Best practice management should include (GPP):
• Reassessment for confounding conditions.
• Assessment of CSF HIV RNA and genotyping of CSF HIV RNA.
• In subjects with detectable CSF HIV RNA, modifications to antiretroviral
therapy should be based on paired plasma and CSF genotypic results.
8.5 Chronic kidney disease
8.5.1 When to start antiretroviral therapy
8.5.1.1 Recommendations
• We recommend individuals with HIV-associated nephropathy (HIVAN)
start ART immediately irrespective of CD4 cell count (1C).
• We recommend individuals with end-stage kidney disease who are suit-
able candidates for renal transplantation start ART immediately (1C).
8.5.2 What to start
8.5.2.1 Recommendations
• We recommend against the use of ARV drugs that are potentially
nephrotoxic in individuals with stages 3–5 CKD if acceptable alterna-
tive ARV agents are available (GPP).
• We recommend dose adjustment of renally cleared ARV drugs in indi-
viduals with reduced renal function (GPP).
8.5.3 Need to switch
8.5.3.1 Recommendations
• We recommend against continued use of tenofovir-DF and atazanavir
in individuals with worsening renal function who have developed or
are approaching CKD stages 3–5 if acceptable alternative ARV agents
are available (GPP).
8.6 Cardiovascular disease
8.6.2.1 Recommendation
• We suggest that the coronary heart disease (CHD) risk of HIV-positive
adults of white ethnicity is estimated as per the BHIVA monitoring
guidelines (www.bhiva.org/monitoring-guidelines.aspx) (2C).
8.6.4 What to start
8.6.4.1 Recommendations
In individuals with a high CVD risk:
• We recommend use of alternatives to fosamprenavir/r (1C) and lopina-
vir/r (1C)
• We suggest that atazanavir/r is the preferred PI (2C).
• We suggest avoiding abacavir (2C) and maraviroc if an acceptable
alternative is available.
• First-line ARV therapy with tenofovir-DF plus (emtricitabine or lamivu-
dine) with dolutegravir or raltegravir or rilpivirine (if viral load
<100,000 copies/mL) are preferred first line regimens (GPP).
• Adverse effects on lipid parameters should be considered when select-
ing ARVs (GPP).
8.6.5 Modification of CVD risk factors
8.6.5.1 Recommendations
In patients with a high CVD risk:
• We recommend that traditional modifiable risk factors should be min-
imised; smoking cessation is of critical importance (1A).
• We suggest that that this should include switching ARVs to those with
a more favourable metabolic profile but only where there is minimal
risk of treatment failure (2C).
8.7 Women
8.7.2 When to start
8.7.2.1 Recommendations
• We recommend therapy-na€ıve HIV-positive women who are not preg-
nant start ART (see Section 4.0) (1A).
8.7.3 What to start
8.7.3.1 Recommendations
• There are insufficient data to support specific recommendations for
HIV-positive non-pregnant women. We therefore recommend therapy-
na€ıve HIV-positive women start ART as per general guidelines (1A).
• We recommend both HIV-positive women of childbearing potential
and healthcare professionals who prescribe ART are conversant with
the benefits and risks of ARV agents for both the health of the HIV-
positive woman and for that of an unborn child (GPP).
• We recommend that potential pharmacokinetic interactions between
ARVs, hormonal contraceptive agents and hormone replacement ther-
apy are checked before administration (GPP).
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8.8 Mental health
8.8.1 Recommendations
• What to start: we recommend that efavirenz-containing regimens be
avoided in individuals with a current or past history of depression, psy-
chosis, suicidal ideation or attempted suicide, or at risk of self-harm
(1C).
• Switching therapy: we recommend that efavirenz-containing regimens
should be switched promptly to a viable alternative when PLWH pre-
sent with depression, psychosis, suicidal ideation or attempted suicide,
or self-harm (1C).
8.9 Adolescents
8.9.1 Recommendations for management of HIV, ART and sexual and
reproductive health specifically for perinatally acquired HIV
• Avoid standard-dose (600 mg) efavirenz-based regimens in any young
person <50 kg, with any history of mental health or psychological or
neurocognitive problems.
8.10 Bone disease and antiretroviral therapy
8.10.2 When to start antiretroviral therapy
8.10.2.1 Recommendation
• We recommend that general recommendations for the timing of ART
are followed in patients with, or at risk of osteoporosis (1D).
8.10.3 What to start
8.10.3.1 Recommendations
• We recommend against the use of tenofovir-DF disoproxil fumarate in
individuals aged >40 years with osteoporosis, a history of fragility frac-
ture, or a FRAX score of >20% (major osteoporotic fracture) if accept-
able alternative ARV agents are available (1B).
8.10.4 Switching treatment
8.10.4.1 Recommendations
• We recommend against continued use of tenofovir-DF in individuals
>40 years who are diagnosed with osteoporosis, have sustained a fragi-
lity fracture, or have a FRAX score of >20% (major osteoporotic frac-
ture) if acceptable alternative ARV agents are available (1C).
8.11 Considerations for later life
8.11.2 When to start ART
8.11.2.1 Recommendation
• We recommend standard criteria are used to determine when to com-
mence antiretroviral therapy in older PLWH (1C).
8.11.3 What to start
8.11.3.1 Recommendation:
• We recommend standard antiretroviral regimens are commenced in
older PLWH (1C).
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3.0 Involvement of people living with HIV in decision-making
3.1 Recommendations
• We recommend PLWH are given the opportunity to be
involved in making decisions about their treatment
(GPP).
• Provision of treatment-support resources should
include in-house, independent and community infor-
mation providers and peer-support resources (GPP).
3.2 Auditable outcomes
• Percentage of PLWH who confirm they have been
given the opportunity to be involved in making deci-
sions about their treatment.
• Percentage of PLWH who have been offered signpost-
ing or referral to peer support or treatment advocacy
services.
• Proportion of PLWH utilising peer support or treatment
advocacy services.
3.3 Rationale
PLWH should be given the opportunity to be involved in
making decisions about their treatment [1]. Studies show
that trust, a good-quality relationship and good commu-
nication skills between doctor and PLWH are associated
with better adherence and treatment outcomes in HIV
and in other disease areas [2–6].
Studies have shown that beliefs about the necessity,
efficacy and side effects of ART, the practicability of tak-
ing it, and ability to adhere to therapy, all affect adher-
ence [7–9].
Before prescribing ART (treatment initiation or switch-
ing), clinicians should assess the individual’s readiness to
take therapy, including:
• Understanding of HIV therapy, and perceptions of per-
sonal need for ART;
• Concerns about taking ART or specific ARV drugs,
including potential adverse effects;
• Concerns with possible adverse social consequences,
such as disclosure or interference with lifestyle;
• Confidence that they will be able to adhere to the med-
ication (self-efficacy);
• Psychological or neurocognitive issues that could
impact on adherence;
• Socio-economic factors that could impact on adher-
ence, including, but not limited to, poverty, housing,
immigration status or domestic violence;
• Pregnancy or parenting plans.
Community advocacy and peer support, including
clinic-based peer support, are helpful in supporting an
individual’s understanding and confidence around treat-
ments, and may also help increase readiness to start ther-
apy. Community organisations in the UK have been
instrumental in providing a range of information
resources for PLWH and peer-support services, including
published and web-based information materials, tele-
phone advice lines, treatment advocates and peer-support
groups, working in collaboration with healthcare profes-
sionals. They are an important and essential adjunct to
clinic-based services and are helpful in addressing the
issues discussed below. Peer support is particularly
important at diagnosis but there may be other crucial
times whe peer support in particularly important such as
starting/switching ART, disclosing to others or planning a
family.
A number of factors may affect adherence, adverse
effects and treatment outcomes, including social and
cultural beliefs. Depression is significantly associated
with low adherence [10,11] and some studies report an
independent association between depression and mortal-
ity in people with HIV [12]. Adherence can be improved
by treating depression [13], so all PLWH should be
screened for depression before starting therapy, using
simple screening tools such as the Arroll two question
quick screen [14]. HIV-positive individuals should also
be screened for anxiety and for cognitive impairment
using validated tools (see the BHIVA guidelines for
the routine investigation and monitoring of adult
HIV-1-infected individuals 2011; www.bhiva.org/Guide-
lines.aspx).
Current problematic alcohol and recreational drug use
are also associated with low adherence [15–17], although
a history of injecting drug use, even current use, does not
necessarily predict poor adherence [18]. PLWH should be
asked about alcohol and recreational drug use and
offered support to moderate or manage it if desired.
Conversely, adherence has been associated with posi-
tive experiences of quality of life such as having a mean-
ingful life, feeling comfortable and well cared for, using
time wisely, and taking time for important things [19].
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Self-management skills and courses that teach these to
PLWH have been associated with both improved adher-
ence and better clinical outcomes in a number of studies
[20–22]. It may be helpful to PLWH to inform them of
these and other psychological support options locally
available, in line with the BPS/BHIVA/MedFASH Stan-
dards for Psychological Support for Adults Living with
HIV [23].
An individual’s socio-economic status has a direct
effect on adherence. For instance, a US study found that
poverty had a direct effect on adherence, largely due to
food insufficiency [24]. A 2010 report on poverty in peo-
ple with HIV in the UK found that 1-in-6 people with
HIV was living in extreme poverty, in many cases due to
unsettled immigration status [25]. In addition, the ASTRA
study revealed that after adjustment for demographic fac-
tors, increasing financial hardship, non-employment,
non-homeownership, non-university education and lack
of supportive network were associated with higher risk of
virological rebound in ART-treated individuals [26]. Clin-
icians should be aware of the socio-economic status of
HIV-positive individuals and refer to social support where
necessary.
Clinicians should establish what level of involvement
the HIV-positive individual would like and tailor their
consultation style appropriately. They should also con-
sider how to make information accessible and under-
standable to PLWH (e.g. with pictures, symbols, large
print and different languages) [1], including addressing
linguistic and cultural issues. Youth is consistently asso-
ciated with lower adherence to ART, loss to follow-up
and other negative healthcare behaviours [27] and some
studies have found an independent association between
poorer adherence and attendance and female gender [28],
so information and consultation style should be age and
gender appropriate for the individual.
If there is a question about an individual’s capacity
to make an informed decision, this should be assessed
using the principles in the Mental Capacity Act 2005
[29].
PLWH presenting at the clinic may be at different
stages of readiness to take therapy [30] and clinicians’
first task is to assess their readiness, by means of open
(rather than closed) questions. However, if an HIV-posi-
tive individual presents in circumstances that necessitate
starting ART immediately, for example with an AIDS
diagnosis or very low CD4 cell count, then doctors should
prescribe ART and provide support for their adherence,
especially through the first few weeks. Recognising symp-
toms that individuals attribute to ART side effects might
avoid loss of adherence and deterioration of trust in the
patient–provider relationship [31,32].
A ‘perceptions and practicalities’ approach should be
used to tailor support to meet the needs of the individual,
to identify both the perceptual factors (such as beliefs
about ART) and practical factors (such as capacity and
resources) influencing adherence [1,8].
In terms of preparing PLWH for potentially lifelong
ART it is important to explain and discuss the rationale
for ART, potential adverse effects, why adherence is
essential and the implications of missed/stopped ART.
Clear and appropriate explanations of the mechanisms of
ART and how different drugs inhibit HIV replication may
help clarify the rationale for combination therapy and
why it is so important to take the drugs in the right way,
at the right time. A review of the individual’s social cir-
cumstances, support, occupation, social life, options to
store ART, ability to follow any necessary food require-
ments, understanding of drug–drug interactions and
where to seek advice are important. The impact of storing
or taking ART on potential disclosure to others should be
considered. Written information or signposting to online
resources should be offered, as should access to peer sup-
port. The preparation required for ART will vary from
one person to the next and the multidisciplinary team
and/or repeat visits should be utilised as indicated.
Supporting PLWH requires good communication not
just between clinician and the HIV-positive individual
but also between all healthcare staff involved with their
care, including those in their HIV services, their general
practitioner (GP) and any clinicians involved in manage-
ment of co-morbid conditions. PLWH should be offered
copies of letters about them sent to their GP and other
physicians. Disclosure of HIV status to the GP should be
considered best practice and should always be discussed.
However, an individual’s decision not to disclose their
status to their GP should be respected, subject to the clin-
ician’s duty to protect vulnerable individuals.
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4.0 When to start
4.1 Chronic infection
4.1.1 Recommendations
• We recommend people with HIV start ART (1A).
4.1.2 Auditable outcomes
• Proportion of diagnosed PLWH on ART.
• Proportion of PLWH not on ART where the rationale
for this, and a discussion of the benefits of ART, has
been documented at least annually.
4.1.3 Rationale
Until recently, BHIVA recommended that individuals with
chronic HIV infection should start ART before the CD4
count fell to below 350 cells/lL [1]. This recommendation
was based on evidence from cohort studies that demon-
strated an increased risk of disease progression in indi-
viduals who delayed ART until their CD4 count was
below 350 cells/lL and the absence of robust evidence
from RCTs in which the intervention, comparator and
populations were similar to our own setting [2–13].
Three trials have randomised people with a CD4 cell
count >350 cells/lL to start or to defer treatment. The
HIV Prevention Trials Network (HPTN) 052 trial [14]
randomised individuals to early (initiate ART at a CD4
cell count between 350 and 550 cells/lL) or deferred
(initiate ART at a CD4 cell count below 250 cells/lL)
ART. While the study reported a benefit to earlier ART
initiation, those in the deferred comparator arm started
treatment at a significantly lower CD4 cell count than
recommended in the UK since 2008 [15]. This study is
thus likely to overestimate the benefits of immediate
treatment compared with starting at <350 cells/lL. A
further study, the ANRS 12136 Temprano trial [16] pre-
sented results in early 2015. This study, conducted in
the Ivory Coast, randomised persons with a CD4 cell
count <800 cells/lL to immediate ART or to receipt of
ART adhering to WHO criteria for initiation of therapy
(these criteria changed several times over the course of
the trial). Again, while the trial results demonstrated a
clinical benefit associated with earlier ART initiation,
the median CD4 cell count at ART initiation in the
comparator arm is likely to be much lower than would
be considered clinically acceptable in the UK. Further-
more, the population considered in the trial (those in
the Ivory Coast with a high incidence of tuberculosis)
is substantially different to the UK setting.
More recently, preliminary results of the START study
have been presented and published [17]. This study
enrolled 4685 adults with CD4 cell counts above 500
cells/lL (median CD4 cell count 651 cells/lL) in 35 coun-
tries, and randomised them to start ART immediately or
to defer ART until the CD4 count fell below 350 cells/lL.
The risk of developing AIDS, a serious non-AIDS event or
of death (combined as the primary endpoint) was reduced
by 57% in those who were randomised to start earlier,
after a median follow-up period of 3 years. The results
were similar in high-income when compared to low- and
middle-income countries and driven mainly by a differ-
ence in rates of AIDS events, particularly TB and cancers.
Immediate ART was not associated with higher risk of
grade 4 events or unscheduled hospital admissions.
Data on virological efficacy, drug resistance and toxic-
ity, and the results of substudies (examining effects on
bone, neurological function, lung function and small
arterial elasticity) and quality of life outcomes have not
yet been reported. Nevertheless, these results demonstrate
a benefit of ART at CD4 counts of >500 cells/lL, and
suggest that if individuals are able to commit to taking
ART, it should be started, regardless of the CD4 count.
Considerations when preparing an individual to start ART
are addressed in Section 3.3. It is important to recognise
that despite the significant reduction in relative risk of dis-
ease progression associated with early ART, the absolute
risk of deferring ART was small. In this study, 4.1% of
individuals in the deferred arm vs. 1.5% in the immediate
treatment arm experienced a serious illness over 3 years of
follow-up. The absolute risk of deferring therapy should be
considered when making individual decisions.
4.1.4 References
1 Williams I, Churchill D, Anderson J et al. British HIV
Association guidelines for the treatment of HIV-1-positive
adults with antiretroviral therapy 2012 (Updated November
2013). HIV Med 2014; 15 (Suppl 1): 1–85.
2 Braithwaite RS, Roberts MS, Chang CC et al. Influence of
alternative thresholds for initiating HIV treatment on
quality-adjusted life expectancy: a decision model. Ann
Intern Med 2008; 148: 178–185.
3 Braithwaite RS, Roberts MS, Goetz MB et al. Do benefits of
earlier antiretroviral treatment initiation outweigh harms for
© 2016 British HIV Association HIV Medicine (2016), 17 (Suppl. 4), s2--s104
s20 BHIVA Writing Group
individuals at risk for poor adherence? Clin Infect Dis 2009;
48: 822–826.
4 Sterne JA, May M, Costagliola D et al. Timing of initiation
of antiretroviral therapy in AIDS-free HIV-1-infected
patients: a collaborative analysis of 18 HIV cohort studies.
Lancet 2009; 373: 1352–1363.
5 Cain LE, Logan R, Robins JM et al. When to initiate
combined antiretroviral therapy to reduce mortality and
AIDS-defining illness in HIV-infected persons in developed
countries: an observational study. Ann Intern Med 2011;
154: 509–515.
6 Jaen A, Esteve A, Miro JM et al. Determinants of HIV
progression and assessment of the optimal time to initiate
highly active antiretroviral therapy: PISCIS Cohort (Spain). J
Acquir Immune Defic Syndr 2008; 47: 212–220.
7 Kitahata MM, Gange SJ, Abraham AG et al. Effect of early
versus deferred antiretroviral therapy for HIV on survival. N
Engl J Med 2009; 360: 1815–1826.
8 Plettenberg A, Brockmeyer NH, Haastert B et al. Impact of
earlier HAART initiation on the immune status and clinical
course of treated patients on the basis of cohort data of the
German Competence Network for HIV/AIDS. Infection 2011;
39: 3–12.
9 Writing Committee for the Cascade Collaboration. Timing of
HAART initiation and clinical outcomes in human
immunodeficiency virus type 1 seroconverters. Arch Intern
Med 2011; 171: 1560–1569.
10 Cain LE, Robins JM, Lanoy E et al. When to start treatment?
A systematic approach to the comparison of dynamic
regimes using observational data. Int J Biostat 2010; 6
[Article 18].
11 Goldman DP, Juday T, Seekins D et al. Early HIV treatment
in the United States prevented nearly 13,500 infections per
year during 1996–2009. Health Aff (Millwood) 2014; 33:
362–369.
12 Olubajo B, Mitchell-Fearon K, Ogunmoroti O. A comparative
systematic review of the optimal CD4 cell count threshold
for HIV treatment initiation. Interdiscip Perspect Infect Dis
2014; 2014: 625670.
13 Piroth L, Fournel I, Mahy S et al. A decision tree to help
determine the best timing and antiretroviral strategy in
HIV-infected patients. Epidemiol Infect 2011; 139: 1835–
1844.
14 Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-
1 infection with early antiretroviral therapy. N Engl J Med
2011; 365: 493–505.
15 Gazzard BG, Anderson J, Babiker A et al. British HIV
Association Guidelines for the treatment of HIV-1-infected
adults with antiretroviral therapy 2008. HIV Med 2008; 9:
563–608.
16 Danel C, Gabillard D, Le Carrou J et al. Early ART and IPT
in HIV-infected African adults with high CD4 count
(Temprano Trial). Conference on Retroviruses and
Opportunistic Infections. February 2015. Seattle, WA, USA
[Abstract 115LB].
17 INSIGHT START Study Group. Initiation of antiretroviral
therapy in early asymptomatic HIV infection. N Engl J Med
2015; 373: 795–807.
4.2 Individuals presenting with AIDS or a major
infection
4.2.1 Recommendation
• We recommend that individuals presenting with an
AIDS-defining infection, or with a serious bacterial
infection and a CD4 cell count <200 cells/lL, start ART
within 2 weeks of initiation of specific antimicrobial
chemotherapy (1B).
4.2.2 Auditable outcome
• Proportion of HIV-positive individuals presenting with
an AIDS-defining infection or with a serious bacterial
infection and a CD4 cell count <200 cells/lL who are
started on ART within 2 weeks of initiation of specific
antimicrobial chemotherapy.
4.2.3 Rationale
This recommendation is largely based on the ACTG 5164
study that demonstrated fewer AIDS progressions/deaths
and improved cost-effectiveness when ART was com-
menced within 14 days (median 12 days; IQR 9–13 days)
compared with initiation after completion of treatment
for the acute infection (median 45 days; IQR 41–55 days)
[1,2]. Those with tuberculosis (TB) as the primary infec-
tion were excluded from this study, and the majority of
individuals enrolled had Pneumocystis pneumonia. The
patients were well enough to give informed consent and
to take oral medications, and therefore the findings may
not be generalisable to those who are severely unwell or
who require intensive care. Previous observational data
suggest a survival benefit for HIV-positive patients who
are started on ART while in the intensive care unit [3,4],
but the data are insufficient to make a recommendation
in this group [3,4].
There was no increase in the incidence of immune
reconstitution disorders or adverse events generally with
early ART initiation in ACTG 5164 [1,5]. However,
those with intracranial opportunistic infections may be
more prone to severe immune reconstitution disorders
with early ART initiation. Some data suggest that par-
ticular caution should be exercised with cryptococcal
meningitis: two studies from sub-Saharan Africa have
demonstrated an increased mortality with early ART
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initiation; however, both were in very different health-
care settings from the UK and one utilised antifungal
regimens that would not be preferred [6,7]. The COAT
study highlighted that those with an acellular CSF or
with decreased levels of consciousness were at higher
risk of death with early ART initiation [7]. It is impor-
tant to note that immune reconstitution disorders can
be difficult to diagnose and case definitions vary across
studies. Those presenting with TB and malignancies are
discussed in Section 8.
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4.3 Treatment of primary HIV infection
4.3.1 Recommendation
• We recommend all individuals with suspected or diag-
nosed PHI are reviewed promptly by an HIV specialist
and offered immediate ART (1B).
4.3.2 Auditable outcomes
• Proportion of individuals with PHI assessed by an HIV
specialist within 2 weeks.
• Proportion of individuals with PHI offered immediate
ART.
4.3.3 Rationale
Primary HIV infection (PHI) is defined as HIV infection
within a maximum of 6 months from the estimated time
of HIV transmission. It can be diagnosed based on labo-
ratory test results in the setting of a clinical sexual his-
tory [1]. In the setting of the recent results from the
START, TEMPRANO and HPTN052 trials, there is now no
longer equipoise when counselling all individuals diag-
nosed with HIV; these studies showed clinical benefit to
starting immediate ART over deferral [2–5].
In the context of PHI there are additional considera-
tions to take into account when considering best manage-
ment. PHI is a distinctive situation where often-
significant symptoms consistent with seroconversion
occur at a time of the stress of coming to terms with a
new HIV diagnosis. Individuals diagnosed with PHI with
low initial CD4 T cell counts [6,7], high plasma viral
loads (>100,000 copies HIV RNA) [8] and short test inter-
vals (diagnosis within 12 weeks of a previous negative
test) [9,10] have a more rapid rate of disease progression
than others without these features at PHI, and hence early
ART initiation should be prioritised.
ART should be started only when the individual feels
ready to do so. However, there are certain clinical presen-
tations of PHI where expedited ART initiation should be
recommended. We recommend starting ART as soon as
possible for patients presenting with PHI meeting any
one of the following criteria known to be associated with
morbidity or very rapid disease progression:
• Neurological involvement (1D);
• Any AIDS-defining illness (1A);
• CD4 cell count <350 cells/lL (1C);
• PHI diagnosed within 12 weeks of a previous negative
test (1C).
The pros and cons of early ART initiation with a view
to long-term therapy should be clearly and sensitively
presented to any individual diagnosed with PHI (Table
4.3.1). ART once started, should be considered as poten-
tially lifelong due to the increased all-cause mortality
observed from treatment interruption in the SMART study
[11], which was seen regardless of nadir CD4 cell count.
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Table 4.3.1 The pros and cons of starting ART in PHI
Pros of starting ART in PHI Cons of starting ART in PHI
Enhanced probability of
immunological recovery to normal
levels [12–18]
Ambivalence to ART at a time of
emotional challenges can risk poor
adherence and the development of
drug resistance
Individuals with recent HIV diagnosis
may feel comforted to know that
they are taking immediate control
of their infection with evidence to
support enhanced immunological
and virological benefits [19]
Individuals with recently diagnosed
PHI may be in a particularly
vulnerable psychological state, and
thus ill-prepared to commit to
starting long-term treatment.
Reduced risk of onward viral
transmission at a time of very
high viral load and consequent
high risk of transmission [19–24]
Reduction in morbidity and more
rapid disease progression
associated with high viraemia [8]
Recent data from the START,
TEMPRANO and HPTN052 trials
identify clinical benefit from
starting ART irrespective of CD4
count [3–5]
Earlier intervention within the first
12 weeks of diagnosis confers
enhanced immune recovery for
this group of individuals who
progress more rapidly if ART is
deferred [12–17]
Limitation of viral reservoir to
significantly below that seen when
treatment deferred [5]
The rationale for immediate ART initiation amongst
individuals diagnosed with PHI include:
• Preservation of immune function and CD4 T lympho-
cytes in terms of both total CD4 counts and the ratio
of CD4:CD8 T cells, which reflects immune activation,
inflammation and all-cause mortality that are other-
wise impaired by uncontrolled viral replication, and
are associated with survival in untreated individuals
[13–19].
• Reduction in morbidity associated with high viraemia
and profound CD4 cell depletion during acute infection
[7–11].
• Reduction in the enhanced risk of onward transmission
of HIV associated with PHI [21–26].
There is never likely to be a randomised controlled trial
in PHI comparing immediate vs. deferred ART that is
powered to a survival outcome, as such a study would
require decades to accrue endpoints. Hence recommenda-
tions of best management of PHI are based on surrogate
markers of mortality and CD4 cell count. Increasing evi-
dence has identified both rapid and enhanced recovery of
surrogate markers of the immune system [7–9] in terms
of CD4 cell count [10] and CD4:CD8 ratio [11,12] for
individuals initiating ART close to the time of HIV trans-
mission compared to deferred ART initiation. A recent
analysis demonstrated lower likelihood of achieving a
normal CD4 cell count if treatment initiation was delayed
more than 12 months after PHI; therefore, even outside
the circumstances where prompt ART is advised, starting
within 1 year of PHI diagnosis is advisable [18].
Immediate or expedited ART initiation for symptomatic
seroconversion and those with very high plasma viral
loads will additionally resolve clinical symptoms and
limit the enhanced risk of onward viral transmission [12–
18]. Furthermore, earlier ART initiation has been shown
to correspond with reduced measures of the latent pool of
infected cells (viral reservoir) [27–29], the current barrier
to HIV remission or cure [30,31]. We therefore recom-
mend an expedited pathway of care for individuals diag-
nosed with PHI to ensure a clear and informed discussion
of the pros and cons of immediate ART is provided to all
individuals to support them making the correct treatment
decision. An individual’s readiness to start ART should be
explored prior to commencing (see Section 3.3).
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4.4 Impact of treatment on prevention of onward
transmission
4.4.1 Recommendations
• We recommend that ART is offered to all PLWH for
the prevention of onward transmission (1A).
• We recommend the evidence that treatment with ART
substantially lowers the risk of transmission is dis-
cussed with all PLWH (GPP).
• An assessment of the risk of transmission to others
should be made at diagnosis and subsequent visits
(GPP).
4.4.2 Auditable outcome
• Record in medical notes of all individuals about the
discussion that treatment with ART lowers the risk of
HIV transmission and perform an assessment of the
current risk of transmission.
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The discussion should include the following:
• If the decision to start ART is being driven primarily
by transmission risk it should be the HIV-positive indi-
vidual’s choice and must not be due to pressure from
partners or others.
• The clinical benefits of ART at all CD4 cell counts
should be emphasised.
• Individuals should be reassured about the relatively
low risk of tolerability and toxicity issues with modern
ART, and the option to switch ART if problems occur.
• Condoms, both male and female, continue to be rec-
ommended as protection from other sexually transmit-
ted infections and unplanned pregnancy.
• There are risks associated with interrupting ART, and
once started, it should generally be continued.
• Much of the evidence that ART lowers the risk of
transmission mainly relates to vaginal sex. Recent data
also show that ART greatly reduces the risk of trans-
mission for anal sex, although the upper estimates for
risk for anal sex are higher, and more data are needed;
therefore, other prevention strategies, including con-
doms, should be discussed.
• High and consistent adherence to ART is required to
maintain viral suppression and minimise transmission
risk.
• Taking ART does not result in immediate complete
viral suppression; it usually takes several months to
achieve an undetectable viral load in blood.
4.4.3 Rationale
The potential effect of HIV treatment to reduce the risk of
onward sexual transmission should be discussed with all
PLWH as a part of safer sex messages in general. For
individuals with a high CD4 cell count, the impact of
treatment on the risk of transmission may be an addi-
tional factor to aid their decision-making. NHS England
approved the use of ART for prevention in July 2015 [1].
The initial evidence base for treatment to reduce trans-
mission was based on a number of cohort studies that
found that transmission between heterosexual couples
where the HIV-positive partner had an undetectable viral
load on treatment was very rare or did not occur [2–6].
This was followed by good evidence from one ran-
domised controlled trial (HPTN 052) [7] that showed ART
can markedly reduce (by 96%) the risk of transmission to
HIV-negative partners. This is supported by the secondary
outcomes of another trial [8] that also found a marked
reduction in transmission from partners taking ART (by
92%). It is important to note that 97% of the couples in
HPTN 052 were heterosexual and the Partners in Preven-
tion study was conducted entirely with heterosexual
couples. The evidence base thus relates mainly to the risk
of transmission for vaginal sex in heterosexual couples.
More recently, data from the PARTNER study have
demonstrated a protective effect of viral suppression in
serodifferent couples where the HIV-positive person is on
suppressive ART (viral load less than 200 copies/mL).
After 16,800 and 28,000 condomless sex acts in MSM
and heterosexual couples respectively, there were no
cases of HIV transmission when 86 would have been
expected based on previous incidence studies [9].
Condoms should still be recommended to protect from
other sexually transmitted infections, and to lower further
any residual risk of transmission.
PLWH should be informed that taking ART does not
result in immediate viral suppression. Most individuals
commencing ART achieve viral suppression by 3–
6 months; integrase inhibitors are characterised by more
rapid viral suppression with most individuals achieving
an undetectable viral load by 1–3 months [10–12]. PLWH
should also be informed about the possibility of virologi-
cal failure leading to transmission of HIV. Decisions on
condom use and safer sex should always be based on a
recent viral load test result and not on an assumption
that taking ART implies non-infectiousness.
Suppressive ART expands the choices available to sero-
different heterosexual people wishing to conceive. Sex
without condom use around the time of ovulation (timed
UPSI) carries very little if any risk provided the HIV-posi-
tive partner has a durably suppressed viral load. Pre-
exposure prophylaxis, although recommended in some
guidelines [13], is likely to add very little as risk reduc-
tion in this scenario. Details of the use of ART to prevent
mother-to-child transmission are covered in the BHIVA
guidelines for the management of HIV infection in preg-
nant women [14]. Sperm washing is not recommended in
the context of viral suppression [15].
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5.0 What to start
5.1 Summary of recommendations
• We recommend that therapy-na€ıve PLWH start ART
containing two nucleoside reverse transcriptase inhibi-
tors (NRTIs) plus one of the following: ritonavir-
boosted protease inhibitor (PI/r), non-nucleoside
reverse transcriptase inhibitor (NNRTI) or integrase
inhibitor (INI) (1A).
Table 5.1.1 Summary recommendations for choice of
ART
Preferred Alternative
NRTI backbone Tenofovir-DF and
emtricitabine
Abacavir and
lamivudinea,b
Third agent (alphabetical
order)
Atazanavir/r Efavirenz
Darunavir/r
Dolutegravir
Elvitegravir/cc
Raltegravir
Rilpivirined
/r: boosted with ritonavir; /c: boosted with cobicistat.
aAbacavir is contraindicated if an individual is HLA-
B*57:01 positive.
bUse recommended only if baseline viral load is <100,000
copies/mL except when initiated in combination with
dolutegravir in which case abacavir/lamivudine can be
used at any baseline viral load.
cTenofovir-DF/emtricitabine/elvitegravir/c fixed-dose
combination should not be initiated in individuals with
creatinine clearance <70 mL/min.
dUse recommended only if baseline viral load is <100,000
copies/mL.
NB: The viral load advice for abacavir/lamivudine and
rilpivirine applies only to initiating these agents in indi-
viduals with a detectable viral load – when these agents
are used as a switch option in the context of viral load
suppression the baseline viral load can be disregarded.
5.1.1 Summary of auditable outcomes
• Proportion of therapy-na€ıve individuals starting ART
containing preferred or alternative agents.
• Proportion of individuals with undetectable viral load
at 6 months and at 12 months after starting ART.
• Proportion of individuals who switch therapy in the
first 6 and 12 months.
5.2 Introduction
For the ‘which NRTI backbone’ and ‘which third agent’
questions, evidence profiles and summary of findings
tables were constructed to assess quality of evidence
across predefined treatment outcomes (Appendix 3). Evi-
dence from randomised controlled trials and systematic
reviews was identified from a literature search (Appen-
dix 2). Outcomes were scored and ranked (critical, impor-
tant, not important) by members of the writing group.
The following were ranked as critical outcomes: viral
suppression at week 48/96, proportion with virological
failure, proportion developing resistance, proportion dis-
continuing for adverse events, proportion with grade 3/4
adverse events.
Treatments were compared and differences in critical
outcomes assessed. Where there were differences, consen-
sus opinion was sought to determine whether the differ-
ence in size of effect was above the threshold for clinical
decision-making. If conflicting differences were detected,
the balance of outcomes was based on consensus opinion
of the writing group.
A treatment was defined as preferred or alternative to
indicate strong or conditional recommendations with
each decision based on the assessment of critical out-
comes and the balance of desirable and undesirable
effects in a general ART-na€ıve population. ‘Preferred’
indicates a strong recommendation that most clinicians
and PLWH would want to follow unless there is a clear
rationale not to do so. ‘Alternative’ indicates a condi-
tional recommendation and is an acceptable treatment
option for some PLWH and might be, in selected individ-
uals, the preferred option.
Factors including potential side effects, co-morbidities,
individual preference and drug interactions need to be
taken into account when selecting an ART regimen, and
may include both preferred and alternative treatment
options.
For guidance on assessment of PLWH before initiation of
ART and monitoring individuals on ART, the reader should
consult the BHIVA guidelines for the routine investigation
and monitoring of adult HIV-1-infected individuals
(www.bhiva.org/monitoring-guidelines.aspx).
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5.3 Which nucleoside reverse transcriptase inhibitor
backbone
5.3.1 Recommendations
• We recommend therapy-na€ıve individuals start combi-
nation ART containing tenofovir-DF and emtricitabine
as the preferred NRTI backbone (1A).
• We suggest abacavir and lamivudine is an acceptable
alternative NRTI backbone in therapy-na€ıve individu-
als. In those with a baseline viral load >100,000
copies/mL, it should be used with caution if there are
clinical reasons to prefer over tenofovir-DF and emtric-
itabine (2A).
The caution regarding baseline viral load does not
apply if abacavir/lamivudine is used with dolutegravir
(2A).
• Abacavir must not be used in individuals who are
HLA-B*57:01-positive (1A).
5.3.2 Rationale
The evidence and rationale for which NRTI backbone to
use for initial therapy has not changed since the last
iteration of the guidelines in 2012 [1]. Three ran-
domised controlled trials have compared tenofovir-DF/
emtricitabine with abacavir/lamivudine as the NRTI
backbone in combination with different third agents:
atazanavir/r or efavirenz [2–6], efavirenz [7–9] and lopi-
navir/r [10].
Assessment of virological efficacy as a critical outcome
was complicated by different definitions across the three
studies. By GRADE analysis (see Appendix 3), there was
no difference in rates of virological suppression at
48 weeks or 96 weeks but the analysis excluded the lar-
gest of the three trials (ACTG 5202) and the quality of
evidence for this outcome was assessed as low or very
low. Assessment of the risk of protocol-defined virologi-
cal failure at 48 weeks favoured tenofovir-DF/emtric-
itabine (relative risk [RR] 0.76, 95% confidence interval
[CI] 0.53–1.07), although the effect was not statistically
significant and heterogeneity in the analysis was rela-
tively high. Assessment of protocol-defined virological
failure at 96 weeks showed a significant difference
favouring tenofovir-DF/emtricitabine (RR 0.73, 95% CI
0.59–0.92). Data were only available from one study [2]
for this analysis; however, this was by far the largest of
the three trials and the quality of evidence assessment for
this outcome was rated as high. The difference in virolog-
ical failure was assessed to be large enough to be above
the clinical threshold for decision-making. The difference
equates to a number needed to treat for 1 year to prevent
one case of virological failure of approximately 20.
The results of ACTG 5202 [2–4] are complicated by
early withdrawal of those individuals receiving abacavir/
lamivudine with a baseline viral load >100,000 copies/mL
at the recommendation of the Data and Safety Monitor-
ing Board owing to significantly inferior performance. No
difference in virological efficacy between the tenofovir-
DF/emtricitabine and abacavir/lamivudine arms was seen
in those in the lower viral load stratum (baseline viral
load <100,000 copies/mL). The subsequent 96-week anal-
ysis, after discontinuation of those subjects in the higher
viral load stratum, may therefore underestimate the dif-
ference between the two backbones. HLA-B*57:01 screen-
ing was not routine in ACTG 5202 and potentially this
may have influenced some of the safety endpoints, but
appears not to have influenced the primary virological
outcome. In the higher viral load stratum the number of
study participants with suspected hypersensitivity reac-
tions was equal between both arms and virological failure
in these individuals was infrequent.
With regard to the assessment of the other critical and
important outcomes, no difference was shown between
tenofovir-DF/emtricitabine and abacavir/lamivudine. No
data were available to assess quality of life outcomes. For
grade 3/4 adverse events (all) and grade 3/4 alanine
transaminase/aspartate transaminase elevation there were
trends that favoured tenofovir-DF/emtricitabine (see
Appendix 3).
Although the rate of drug resistance was not different
between the NRTI backbones, the number developing
drug resistance was higher numerically in those receiving
abacavir/lamivudine, given the higher rate of virological
failure.
Bone mineral density outcomes significantly favoured
abacavir/lamivudine.
Given the favourable virological outcomes of tenofovir-
DF/emtricitabine compared with abacavir/lamivudine and
the lack of other significant differences in critical and
important adverse event outcomes, tenofovir-DF/emtric-
itabine is recommended as the preferred NRTI backbone
of choice. Abacavir/lamivudine is an acceptable alterna-
tive option in individuals with a baseline viral load
<100,000 copies/mL (other than in combination with
dolutegravir when abacavir/lamivudine can be initiated
regardless of baseline viral load), but must only be used
after ensuring HLA-B*57:01 is negative.
When selecting an NRTI backbone, factors such as
potential side effects, co-morbidities, individual prefer-
ence and cost should also be considered. Observational
studies have variably reported associations between aba-
cavir and cardiovascular disease (CVD) [11–14], and teno-
fovir-DF may cause renal disease [15]. These aspects are
discussed in more detail in Section 8. However, based on
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the balance of current evidence we suggest abacavir is
not used in individuals at high risk of CVD (see Sec-
tion 8.6 Cardiovascular disease) and tenofovir-DF is not
used in people with stage 3–5 chronic kidney disease
(CKD) or at high risk of progression of CKD (see Sec-
tion 8.5 Chronic kidney disease) if acceptable alternative
antiretroviral agents are available.
5.3.3 Not recommended
We believe there is no routine role for other NRTI back-
bones in the treatment of ART-na€ıve patients. Zidovu-
dine/lamivudine may be considered in certain specific
circumstances (e.g. pregnancy [16]) but should not be
given routinely due to the proven association with mito-
chondrial toxicity, particularly lipoatrophy, with zidovu-
dine. There is no place for the use of stavudine- or
didanosine-containing regimens as initial therapy, due to
the associations with significant mitochondrial and hep-
atic toxicities.
5.3.4 Lamivudine vs. emtricitabine
The nucleoside backbone tenofovir-DF/lamivudine has
not been well studied in randomised trials. This combina-
tion warrants further review of evidence as the lower
costs associated with generic medications may make this
an attractive combination in the future. There are a num-
ber of theoretical advantages in using emtricitabine
rather than lamivudine, including:
• Emtricitabine triphosphate (TP) has a longer intracellu-
lar half-life [17];
• Emtricitabine TP is incorporated more efficiently than
lamivudine TP into proviral deoxyribonucleic acid
(DNA) [18];
• Greater in vitro potency [19].
Extensive review of the literature between 2000 and
2015 identified seven studies in ART-na€ıve individuals
that included randomisation to a lamivudine- or emtric-
itabine-containing backbone. In two of these lamivudine
vs. emtricitabine was the only variable [20,21]. However,
neither of these studies has been published and therefore
have not been subject to formal peer review. One study,
performed in Zambia, randomised 332 subjects to fixed-
dose combinations of either tenofovir-DF/lamivudine/efa-
virenz or tenofovir-DF/emtricitabine/efavirenz. Virologi-
cal suppression rates at 48 weeks were similar (85.3% vs.
90.1%) but due to wide 97.5% confidence limits (28.1
to 18.4%), non-inferiority of the lamivudine-containing
regimen was not demonstrated. The other unpublished
study in ART-na€ıve individuals was a double-blind com-
parison of lamivudine or emtricitabine with stavudine
and either efavirenz or nevirapine with virological failure
defined as a viral load >400 copies/mL on consecutive
visits. The probability of virological failure was reported
as 10% with either agent, although a significantly lower
rate of M184V mutation development on failure was
reported in the emtricitabine-containing regimen [21]. A
significantly lower rate of M184V mutation development
on failure was reported in the emtricitabine-containing
regimen. Of the remaining five studies at least one other
component, additional to lamivudine or emtricitabine,
differed, therefore prohibiting direct comparison. Three
studies compared abacavir/lamivudine with tenofovir-DF/
emtricitabine [3,7,10], one compared zidovudine/lamivu-
dine with tenofovir-DF/emtricitabine [22], one compared
zidovudine/lamivudine/efavirenz vs. tenofovir-DF/emtric-
itabine efavirenz vs. didanosine/emtricitabine/atazanavir
[23]. A randomised comparison of 440 patients stable on
therapy with suppressed viral load substituting lamivu-
dine for emtricitabine showed no difference in virological
failure at 48 weeks [24]. However, this is of limited appli-
cability to the question of therapy in ART-na€ıve patients
since ‘stable switch’ studies are inherently biased in
selecting patients who are already doing well on treat-
ment. Of note, no trials using abacavir/emtricitabine as a
backbone have been performed.
A number of observational studies and retrospective
analyses of randomised controlled trials have sought to
find clinical correlates of the pharmacological differences
between lamivudine and emtricitabine. In general, these
studies focus on the development of resistance, as evi-
denced by the emergence of the M184I/V mutation on
treatment failure. Where data on resistance were avail-
able, none of the individual randomised controlled trial
trials showed significant differences between lamivudine-
and emtricitabine-containing arms. However, a pooled
analysis [25] of three trials of lamivudine or emtricitabine
with another NRTI plus efavirenz showed significantly
less emergent M184V on emtricitabine (odds ratio [OR]
0.32, P = 0.02) when considering the whole treated popu-
lation. However, the interpretation of this result is com-
plicated by the use, with lamivudine, of nucleoside
analogues that are no longer recommended due to toxic-
ity issues, making it difficult to confidently exclude dif-
ferences in adherence contributing to the development of
resistance. A sub-analysis in this same paper compared
the tenofovir-DF/lamivudine/efavirenz arm from one ran-
domised controlled trial with tenofovir-DF/emtricitabine/
efavirenz from another and again found a significantly
lower frequency of M184V/I [19]; this type of cross-trial
comparison must, however, be interpreted with caution.
A WHO appraisal on the interchangeability of lamivudine
and emtricitabine concluded that the clinical and virolog-
ical efficacy and safety of lamivudine and emtricitabine
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are comparable but the development of the M184V/I
mutation is associated to a greater extent with the use of
a lamivudine- rather than an emtricitabine-containing
regimen [26]. They also stated, however, that the clinical
and public health implications of this difference are not
clear.
Cohort studies investigating this same question are
subject to a number of confounders and have given
mixed results. In general, they have shown significantly
lower M184I/V development with the use of emtricitabine
[27–29] but most have not restricted the analysis to indi-
viduals starting their first treatment regimen and have
included a diverse range of other antiretroviral agents, so
the relevance to recommendations for first-line therapy is
open to question. A large UK CHIC analysis, including
5455 HIV-positive individuals, directly compared tenofo-
vir-DF/lamivudine with tenofovir-DF/emtricitabine and
found no significant difference in the emergence of
M184V/I. This study was not restricted to treatment-na€ıve
individuals [30]. On the other hand, a cohort study in the
Netherlands of 4740 individuals was restricted to those
starting first-line therapy with tenofovir-DF/lamivudine
or tenofovir-DF/emtricitabine together with an NNRTI
[31]. This study showed higher rates of virological failure
for the lamivudine-containing regimens (OR = 1.78,
P = 0.16 given with efavirenz) but did not adjust for year
of HAART initiation in the multivariable analysis. This is
important as lamivudine-containing regimens were
started in significantly earlier years than emtricitabine-
containing regimens and there has been a well-documen-
ted improvement in virological outcomes as the use of
HIV therapy has evolved; this and other unidentified con-
founders may limit the validity of the results [32].
It is clear that the evidence concerning this question is
mixed and of variable quality, leaving open the question
of whether lamivudine and emtricitabine are interchange-
able in first-line therapy. The paucity of sufficiently
high-quality evidence addressing this question means
that tenofovir-DF/lamivudine cannot be clearly recom-
mended as an alternative nucleoside backbone when ini-
tiating first-line therapy.
If cost pressures become such that co-formulation is no
longer a major driving factor in antiretroviral choice,
then it will be reasonable to revisit this recommendation.
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5.4 Which third agent
5.4.1 Recommendations
• We recommend therapy-na€ıve individuals start combi-
nation ART containing atazanavir/r, darunavir/r,
dolutegravir, elvitegravir/c, raltegravir or rilpivirine as
the third agent (1A).
• We suggest that for therapy-na€ıve individuals, efavir-
enz is an acceptable alternative third agent (1A).
5.4.2 Rationale
The BHIVA guidelines for the treatment of HIV-1-infected
adults with antiretroviral therapy 2008 [1] recommended
efavirenz as the preferred third agent in view of signifi-
cantly better virological outcomes compared with lopina-
vir/r [2], subsequently confirmed in a smaller study [3].
In the following version of the guidelines, the preferred
third agents were expanded to include more agents based
on performance against efavirenz (atazanavir/r [4–9];
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raltegravir [10–13]; elvitegravir/c [14]), lopinavir/r (ataza-
navir/r [15]; darunavir/r [16–18]) and atazanavir/r (elvite-
gravir/c [19]). Rilpivirine was added as an alternative
third agent based on comparison with efavirenz
[15,20,21].
Since the latest update to guidelines was published
[22], the integrase inhibitor dolutegravir and the fixed-
dose combination of abacavir/lamivudine/dolutegravir
(Triumeq) has received licensing approval. Additionally
there have also been a number of new randomised
controlled trials comparing third agents for initial
antiretroviral therapy. For the current guidelines, evi-
dence for agreed treatment outcomes for each potential
third agent was compared with preferred third agents
from the previous guidelines [22], either directly or
indirectly depending on the available evidence (Appen-
dix 3):
• Efavirenz vs. rilpivirine [14];
• Efavirenz vs. dolutegravir [19];
• Atazanavir/r vs. darunavir/r vs. raltegravir [16];
• Raltegravir vs. dolutegravir [18];
• Darunavir/r vs. dolutegravir [17].
5.4.3 Individual agents
5.4.3.1 Atazanavir/ritonavir
Atazanavir/r has been compared directly in randomised
controlled trials with efavirenz [7,23,24], raltegravir [16]
and darunavir/r [16,25].
In ACTG 5202, although rates of virological failure
were similar, there were significantly fewer cases of resis-
tance development on atazanavir/r compared with efavir-
enz (OR 0.24, 95% CI 0.14–0.41) at 138 weeks,
P <0.00001). Some adverse events favoured atazanavir/r
over efavirenz (see Appendix 3)
In ACTG 5257, the odds ratio for developing resistance
at virological failure on raltegravir compared with ataza-
navir/r was 2.04 (95% CI 0.91–4.57, P = 0.08) at
96 weeks. Although, for overall response, atazanavir/r
was outperformed by raltegravir (OR 2.04, 95% CI 1.30–
3.18, P = 0.002) at 96 weeks in favour of raltegravir, dri-
ven mainly by significant differences in adverse event
discontinuations (OR 0.07 favouring raltegravir at
96 weeks, 95% CI 0.03–0.15, P <0.0001), virological fail-
ure rates (% total population) were similar in the two
arms (OR 0.88, 95% CI 0.64–1.21, P = 0.43). Resistance
development was more common on raltegravir than ata-
zanavir/r when considering the proprortion of virological
failures with resistance (OR 2.57, 95% CI 1.08–6.08), but
when considering the proportion of the total trial popula-
tion developing resistance, this was not statistically sig-
nificant (OR 2.04, 95% CI 0.91–4.57).
Virological response to atazanavir/r was similar to dar-
unavir/r in ACTG 5257 and ATADAR at 96 and 48 weeks,
respectively. There were no significant differences in
virological failure or resistance development rates in
either study (reported only at week 24 for ATADAR).
Compared to darunavir/r, individuals randomised to
receive atazanavir/r in ACTG 5257 were significantly
more likely to discontinue due to adverse events (OR 0.30
favouring darunavir/r, 95% CI 0.20–0.46, P <0.00001).
Although discontinuation for adverse events is a critical
outcome, there was no difference in discontinuations for
the specific non-critical outcomes considered (Appendix 3)
and around half of discontinuations from atazanavir/r
were for hyperbilirubinaemia/jaundice. On this basis it
was felt that the difference between atazanavir/r and its
comparators was not clinically significant and that ataza-
navir/r should remain a preferred third agent for initial
therapy. However, jaundice is a potentially distressing
and stigmatising event and PLWH who do not want to
start atazanavir or wish to switch from atazanavir for this
reason should have this decision respected. The require-
ment for pharmacokinetic boosting necessitates caution
with respect to drug–drug interactions.
5.4.3.2 Darunavir/ritonavir
Comparison between darunavir/r and atazanavir/r is
described in Section 5.4.3.1. For the comparison between
darunavir/r and raltegravir in the three-arm ACTG 5257
study [16], overall response was significantly higher for
raltegravir (OR 1.83, 95% CI 1.16–2.89 at 96 weeks in
favour of raltegravir, P = 0.009). The corresponding pro-
portion of patients with an undetectable HIV-1 RNA at
96 weeks by intention-to-treat analysis was 88.3% for
atazanavir/r, 93.9% for raltegravir, and 89.4% for daru-
navir/r. Although there were more virological failures on
darunavir/r (OR 0.69 favouring raltegravir, 95% CI 0.51–
0.94, P = 0.02), individuals on raltegravir were more
likely to develop resistance (OR 4.59, 95% CI 1.54–13.65,
P = 0.006) favouring darunavir/r for percentage of the
total population with resistance. There were fewer discon-
tinuations for toxicity in the raltegravir arm (8/603 vs.
32/601 in the darunavir/r arm, OR 0.24, 95% CI 0.11–
0.52); however, for the critical outcomes of grade 3 or 4
clinical or laboratory adverse events, grade 3 or 4 head-
ache and grade 3 or 4 diarrhoea there were no significant
differences. Darunavir/r was also compared with dolute-
gravir in the Flamingo study, and is discussed in Sec-
tion 5.4.3.3. The requirement for pharmacokinetic
boosting necessitates caution with respect to drug–drug
interactions.
5.4.3.3 Dolutegravir
Dolutegravir has gained marketing authorisation and
NHS England approval since the last guidelines update.
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There are three key randomised controlled trials that
investigate dolutegravir for first-line therapy:
• SPRING-2 [18]: double-blind randomised controlled
trial of tenofovir-DF/emtricitabine or abacavir/lamivu-
dine plus raltegravir vs. tenofovir-DF/emtricitabine or
abacavir/lamivudine plus dolutegravir.
• SINGLE [19]: double-blind randomised controlled trial
trial of tenofovir-DF/emtricitabine/efavirenz (fixed-
dose combination) vs. abacavir/lamivudine plus dolute-
gravir.
• FLAMINGO [17]: open label randomised controlled trial
trial tenofovir-DF/emtricitabine or abacavir/lamivudine
plus darunavir/r vs. tenofovir-DF/emtricitabine or aba-
cavir/lamivudine plus dolutegravir.
In SPRING-2, dolutegravir was non-inferior to ralte-
gravir at weeks 48 and 96 [18]. When analysed by base-
line viral load (participants were stratified by baseline
viral load at randomisation) there was no significant dif-
ference in virological response at baseline viral load
>100,000 copies/mL at 48 weeks (OR for success on
dolutegravir = 1.57, 95% CI 0.83–2.97, P = 0.17) but by
week 96 there was a significant difference favouring
dolutegravir (OR for success on dolutegravir = 2.10, 95%
CI 1.17–3.75, P = 0.01). Overall virological failure rates
at 48 and 96 weeks were not significantly different; and
there was no significant difference for baseline viral load
<100,000 copies/mL at 48 or 96 weeks, or for baseline
viral load >100,000 copies/mL at 48 weeks. SPRING-2
was not powered for a stratified viral load comparison.
Rates of virological failure and resistance development
were similar and no differences in other critical or impor-
tant outcomes were demonstrated.
In SINGLE [19], abacavir/lamivudine/dolutegravir
demonstrated superior virological efficacy to tenofovir-
DF/emtricitabine/efavirenz, driven by significantly more
discontinuations due to adverse events in the tenofovir-
DF/emtricitabine/efavirenz arm (OR for discontinuation
for adverse events = 0.22 favouring abacavir/lamivudine/
dolutegravir, 95% CI 0.11–0.45, P <0.001). There was no
impact of baseline viral load on respsonse rates in
SINGLE.
Dolutegravir also demonstrated superior overall effi-
cacy compared with darunavir/r in FLAMINGO (OR for
success at 48 weeks = 1.08, 95% CI 1.01–1.17,
P = 0.03) [17]. There was no difference in rates of viro-
logical failure and no instance of drug resistance in
either arm. No differences were detected for other criti-
cal outcomes, although for important outcomes, there
were significantly more clinical serious adverse events
in the dolutegravir arm (OR 2.00, 95% CI 1.05–3.80,
P = 0.03).
The consensus of the Writing Group was that, despite
the superiority of dolutegravir in this study, the open-
label trial design and lack of difference for other critical
outcomes, meant darunavir/r should remain a preferred
third agent.
5.4.3.4 Elvitegravir/cobicistat
Elvitegravir/c was a preferred option in the last update
and remains so, based on demonstration of non-inferior-
ity to efavirenz and atazanavir/r. In GS-102 [26], elvite-
gravir/c was non-inferior to efavirenz at weeks 48 and 96
in terms of virological success, virological failure and
proportion of people who developed resistance; rates of
NRTI and third-agent resistance development in individu-
als with virological failure were similar. For example, by
week 96, 9/17 persons with virological failure on elvite-
gravir/c developed integrase resistance compared with 9/
23 with virological failure on efavirenz. There were no
differences in adverse event discontinuations or rate of
grade 3/4 adverse event outcomes, with data lacking for
some of the non-critical safety outcomes considered by
the writing group. Elvitegravir/c has the advantage of
simple dosing as a fixed-dose combination with tenofo-
vir-DF/emtricitabine; the requirement for pharmacoki-
netic boosting necessitates caution with respect to drug–
drug interactions.
When compared with atazanavir/r in GS-103 [27],
elvitegravir/c was again non-inferior with respect to viro-
logical success and virological failure rates at weeks 48
and 96. There were no cases of NRTI- or PI-resistance
development at weeks 48 and 96 in the atazanavir/r arm
compared with five and six cases in the elvitegravir/c
arm, respectively. By week 144, there were eight cumula-
tive cases of resistance in the elvitegravir/c arm com-
pared with two in the atazanavir/r (both isolated M184I/
V) [28]. Discontinuations for adverse events were similar
and the only important outcome that differed was a sig-
nificantly higher rate of grade 3/4 laboratory events in
the atazanavir/r arm (OR 0.07 favouring elvitegravir/c,
95% CI 0.05–0.11, P <0.0001 at week 48). Again, as this
was driven predominantly by hyperbilirubinaemia in the
atazanavir/r arm, and the consensus of the writing group
was that this difference was not clinically important.
Cobicistat is an inhibitor of renal tubular creatinine
secretion; exposure to cobicistat results in small increases
in serum creatinine and modest reductions (10–15 mL/
min) in creatinine clearance [29]. Renal toxicity with
elvitegravir/cobicistat/tenofovir-DF/emtricitabine is infre-
quent (0.8–2%) in patients with baseline creatinine clear-
ance at least 70 mL/min [26,27]. The use of elvitegravir/
cobicistat/tenofovir-DF/emtricitabine is not recommended
for patients with creatinine clearance less than 70 mL/
min [30].
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5.4.3.5 Raltegravir
Raltegravir was compared to atazanavir/r, darunavir/r
and dolutegravir in studies outlined in Sections 5.4.3.1,
5.4.3.2 and 5.4.3.3, respectively. In ACTG 5257 virologi-
cal failure with resistance occurred in 3.0% of study par-
ticipants assigned to raltegravir (two of whom developed
intermediate-level resistance to dolutegravir) and in 1.5%
or fewer of those in either boosted PI group [16]. Ralte-
gravir was non-inferior to efavirenz in STARTMRK with
similar outcomes for virological response, virological fail-
ure and resistance rates at weeks 48 [12] and 96 [11]. The
study was unblinded after week 144 and at later points of
follow-up (up to week 240) raltegravir demonstrated
superior efficacy to efavirenz driven by more discontinu-
ations due to adverse-events in the efavirenz arm [31].
There was a trend to more discontinuations for adverse
events on efavirenz at weeks 48 and 96 (OR 0.52 and
0.51 favouring raltegravir, respectively) and by week 240,
this difference reached statistical significance. Unlike
other preferred third agents for first-line use, the licensed
dose of raltegravir is taken twice daily.
5.4.3.6 Rilpivirine
Rilpivirine has been compared directly with efavirenz in
three large randomised controlled trial trials: ECHO [32],
THRIVE (both double-blind, placebo-controlled, multi-pill
studies) [15] and StAR (open-label single-pill fixed-dose
combination comparison of tenofovir-DF/emtricitabine/
efavirenz and tenofovir-DF/emtricitabine/rilpivirine) [14].
There were no differences in overall virological success at
weeks 48 or 96 in the three studies. However, there were
significant differences in drug resistance and virological
failure, both in favour of efavirenz. For critical safety
outcomes there was a difference in the proportion discon-
tinuing for adverse events in favour of rilpivirine. Pooled
analyses by the investigators of the two randomised con-
trolled trial trials showed the risk of virological failure
with rilpivirine was highest in participants with a base-
line viral load >100,000 copies/mL [15] and when analy-
sis is restricted to individuals with a baseline viral load
less than 100,000 copies/mL, virological response to rilpi-
virine was non-inferior to efavirenz. A 96-week analysis
of the same studies, restricted to individuals with baseline
viral load less than 100,000 copies/mL, demonstrated
virological response rates of 84% on rilpivirine and 80%
on efavirenz (95% CI 1.7 to 9.7%) and virological fail-
ure rates of 8% and 6%, respectively (P = 0.46) [32].
Based on the superior virological success on rilpivirine
compared to efavirenz when used within its licensed indi-
cation (i.e. at baseline viral load less than 100,000 copies/
mL) we believe it should be moved from alternative to
preferred third agent status. It is important to note that
there are very few data regarding the administration of
rilpivirine with an abacavir/lamivudine NRTI backbone.
In addition rilpivirine must be administered with food
(Appendix 4) and has significant interactions with acid-
reducing agents; proton pump inhibitors are contra-
indicated.
5.4.3.7 Efavirenz
Efavirenz has long been a preferred agent for initial HIV
therapy and has been a ‘gold standard’ comparator for
several clinical trials investigating first-line treatment.
However, dolutegravir demonstrated superiority to efavir-
enz in SINGLE [19], as has rilpivirine in subgroup analy-
ses [33], and raltegravir with longer-term follow-up of
STARTMRK [31]. The difference between efavirenz and
comparators is driven by a higher rate of discontinuation
for adverse events on efavirenz-based regimens, mainly
due to its potential for significant central nervous system
(CNS) toxicity. Since the last update of the guidelines, a
meta-analysis of ACTG studies demonstrated a higher risk
of suicidality in those randomised to efavirenz-containing
regimens [34]. Individuals with significant past or current
mental health issues may be excluded from clinical trial
populations so the ACTG analysis could potentially
underestimate the impact of efavirenz in higher-risk
PLWH. Although, subsequently, an observational cohort
study did not demonstrate an association between efavir-
enz use and suicidality [35] this was a non-randomised,
retrospective analysis. Individuals with a history of psy-
chiatric disorders appear to be at a greater risk of serious
psychiatric adverse events [36] and for PLWH with a cur-
rent or previous history of psychiatric disorders, includ-
ing depression, anxiety and suicidal ideation, caution
should be exercised in prescribing efavirenz and strong
consideration given to using an alternative third agent.
Secondarily, although not considered an important out-
come for the purpose of these guidelines, efavirenz is
associated with an adverse impact on lipids compared to
newer agents. Since there are several effective and well-
tolerated alternative third agent options available, it is
the view of the writing group that efavirenz should be
downgraded from preferred to alternative option for ini-
tial therapy. The writing group recognises that the major-
ity of individuals who start efavirenz-based therapy
tolerate it reasonably well, so it remains a reasonable
alternative. For patients stable on efavirenz-based ART,
we recommend a review of tolerability, including sleep
and mood, at all visits.
5.4.3.8 Previous alternative third agents
Unlike previous versions of the guidelines, lopinavir/r,
fosamprenavir/r and nevirapine are no longer listed as
alternative options. Efavirenz was superior to lopinavir/r
for critical virological outcomes in ACTG 5142 [2]; lopi-
navir/r and fosamprenavir/r perform similarly [37] and
© 2016 British HIV Association HIV Medicine (2016), 17 (Suppl. 4), s2--s104
s34 BHIVA Writing Group
are associated with higher rates of gastrointestinal and
metabolic toxicities than preferred PI/r options [38]. Lopi-
navir/r may be an important option for some individuals
such as those with PI resistance mutations and a con-
traindication for darunavir/r. Nevirapine was non-inferior
to atazanavir/r for critical virological outcomes in ARTEN
[39] but with the availability of alternative NNRTIs and
alternative classes, we feel that the small risk of serious
hepatic or cutaneous toxicity is no longer acceptable.
Individuals who are stable on nevirapine should, how-
ever, be reassured as to the long-term efficacy and safety
of this option.
5.4.3.9 Cobicistat
Cobicistat is an inhibitor of CYP3A isozymes [40] and,
similarly to ritonavir, is used as a pharmacokinetic
enhancer of other antiretroviral drugs. It is a component
in the fixed-dose combination pill Stribild (elvitegravir/
cobicistat/emtricitabine/tenofovir-DF). Cobicistat as a sin-
gle drug has also been licensed as a pharmacokinetic
enhancer of atazanavir and darunavir.
The efficacy and safety of cobicistat-boosted atazanavir
has been evaluated in comparison with ritonavir-boosted
atazanavir, in a Phase 3, non-inferiority, randomised,
double-blind study in treatment-na€ıve individuals [41,42].
Atazanavir with cobicistat was shown to be non-inferior
to atazanavir with ritonavir in terms of viral suppression.
Discontinuation rates due to adverse events were similar,
and no major tolerability issues were reported.
The evidence supporting the use of cobicistat to boost
darunavir is more limited. Cobicistat enhances darunavir
plasma levels to a similar degree as ritonavir, with a sim-
ilar pharmacokinetic profile [43] and in a single-arm
study had acceptable efficacy and safety profiles [44].
Cobicistat affects tubular secretion of creatinine, by
inhibiting renal cation transporters. This results in small
increases in serum creatinine and decreases in estimated
creatinine clearance. However, it does not cause impair-
ment of renal function as actual glomerular filtration rate
is not affected [45].
5.4.3.9 Summary
When selecting a third agent from either the preferred or
alternative options, factors such as potential side-effects,
dosing requirements, dosing convenience, individual pref-
erence, co-morbidities, drug interactions and cost should
be considered.
In summary, efavirenz should no longer remain a pre-
ferred third agent and should now be considered an alter-
native. Because of similar critical treatment outcomes,
atazanavir/r, darunavir/r, dolutegravir elvitegravir/c, ral-
tegravir and rilpivirine are all recommended as preferred
third agents (with the caveat that rilpivirine is only
recommended within its licence in individuals with a
baseline viral load less than 100,000 copies/mL).
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5.5 Novel antiretroviral therapy strategies
5.5.1 Recommendation
• We recommend against the use of PI monotherapy as
initial therapy for treatment-na€ıve patients (1C).
5.5.1.1 Rationale
Data on use of PI monotherapy as initial ART are limited.
In one randomised controlled trial comparing lopinavir/r
vs. lopinavir/r plus zidovudine and lamivudine, the use of
PI monotherapy as initial ART was associated with lower
rates of virological suppression at 48 weeks and with the
emergence of PI mutations [1]. There were no significant
differences in tolerability. For this reason, PI monother-
apy is not recommended as initial ART. However, as with
other novel strategies there may be specific circumstances
where a rationale for its use may be made.
5.5.1.2 Reference
1 Delfraissy JF, Flandre P, Delaugerre C et al. Lopinavir/
ritonavir monotherapy or plus zidovudine and lamivudine
in antiretroviral-naive HIV-infected patients. AIDS 2008;
22: 385–393.
5.5.2 Recommendation
• We suggest the use of darunavir/r-based dual ART reg-
imen with raltegravir in treatment-na€ıve patients with
CD4 count >200 cells/lL and viral load <100,000
copies/mL where there is need to avoid abacavir and
tenofovir-DF (2A).
• We recommend against the use of PI-based dual ART
with a single NNRTI, NRTI or CCR5 receptor antagonist
for treatment-na€ıve patients (1B).
5.5.2.1 Rationale
A number of studies have assessed the use of PI-based
dual ART as initial therapy in treatment-na€ıve patients.
The combination of an NNRTI with a PI/r has been
shown to have similar virological efficacy compared with
triple-combination regimens in one study [1]. There were
no significant differences in time to either virological or
regimen failure with a combination of lopinavir/r and
efavirenz compared with either two NRTIs and efavirenz
or two NRTIs and lopinavir/r although the NRTI-sparing
arm underperformed in individuals with high baseline
viral load (greater than 100,000 copies/mL). There was,
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however, an increased rate of drug resistance in the
NRTI-sparing arm, with the emergence of more NNRTI-
associated resistance mutations than the comparator
arms. An increased rate of grade 3/4 toxicities was
observed, predominantly low-density lipoprotein choles-
terol and triglyceride elevations.
Two randomised controlled trial trials have evaluated a
dual-therapy regimen containing one NRTI with a PI/r
compared to standard therapy of a PI/r and two NNRTIs.
The GARDEL study demonstrated non-inferiority of the
dual regimen of lopinavir/r plus lamivudine compared to
lopinavir/r, lamivudine or emtricitabine plus a third NRTI
in virological efficacy at 48 weeks [2] irrespective of
baseline viral load. A post hoc analysis also showed no
difference in virological efficacy with respect to the
choice of dual NRTI backbone and pre-treatment CD4 cell
count (<200 cells/lL) [3]. A study comparing tenofovir-
DF and lopinavir/r to two NRTIs and lopinavir/r failed to
demonstrate non-inferiority of the dual-therapy arm
compared with a standard triple-therapy combination but
numbers were small and the response rates were numeri-
cally similar at 51% and 53%, respectively [4]. As lopina-
vir/r is no longer among the first-recommended PIs, the
dual combination with lamivudine, as used in GARDEL
study, has not been considered as an alternative first-line
regimen.
The efficacy of dual therapy with the CCR5-receptor
antagonist maraviroc in combination with a PI/r has been
assessed in a number of studies [5–8] but only one [8]
was powered to demonstrate non-inferiority. This study
compared maraviroc/darunavir/ritonavir to tenofovir DF/
emtricitabine/darunavir/r, and showed lower virological
efficacy of the dual therapy arm at 48 weeks.
The efficacy of the raltegravir plus a PI/r has been
compared with standard triple therapy in several studies
[9–13] The NEAT-001/ANRS-143 [10] demonstrated non-
inferiority of raltegravir compared to tenofovir-DF/
emtricitabine when combined with darunavir/r at
96 weeks. However, the dual-therapy arm was associated
with higher rates of virological failure and with treat-
ment-emergent integrase resistance (5/28 patients) in
those with baseline CD4 cell count <200 cells/lL or viral
load >100,000 copies/mL. Similarly, a single-arm study
investigating raltegravir in combination also with daru-
navir/r, showed increased risk of virological failure with
emergent integrase resistance with baseline viral load
>100,000 copies/mL compared with those with a baseline
viral load <100,000 copies/mL [13]. There was no differ-
ence in safety between both arms.
The PROGRESS study demonstrated similar virological
efficacy of raltegravir plus lopinavir/r compared to teno-
fovir-DF/emtricitabine and lopinavir/r, although the study
was relatively small [11,12]. Overall there is evidence to
support the use of a PI/r, preferably darunavir/r plus ral-
tegravir, in selected patient populations.
The use of raltegravir with unboosted atazanavir is not
recommended due to development of integrase resistance
in 4/6 of those who met the criteria for resistance testing
[9].
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6.0 Supporting individuals on therapy
6.1 Adherence
6.1.1 Interventions to increase adherence to treatment
6.1.1.1 Recommendations
• We recommend adherence and potential barriers to it
are assessed and discussed with PLWH whenever ART
is discussed, prescribed or dispensed (GPP).
• We recommend adherence support should address both
perceptual barriers (e.g. beliefs and preferences) and/or
practical barriers (e.g. limitations in capacity and
resources) to adherence (GPP).
• Individuals experiencing difficulties with adherence
should be offered additional support from staff within
the MDT who have experience in adherence support
and/or from organisations offering peer support (GPP).
6.1.1.2 Auditable outcomes
• Record in medical notes discussion and assessment of
adherence and potential barriers, both before starting a
new ART regimen and while on ART.
• Record in medical notes the provision or offer of
adherence support.
6.1.1.3 Rationale
Low adherence to ART is associated with drug resis-
tance, progression to AIDS [1] and death [2–4]. Given
the multiple adverse consequences of treatment failure
(risk of disease progression, increase in complexity and
costs of treatment, and risk of HIV transmission) engag-
ing PLWH in treatment decisions and the monitoring
and support of adherence are of paramount importance
[5] (see Section 3.0). Investing time to prepare an indi-
vidual for starting ART is important and utilising mem-
bers of the MDT who have experience in adherence
support, such as specialist nurses and pharmacists,
should be considered for all individuals starting ART,
reporting adherence concerns or who have experienced
virological failure.
Non-adherence is best understood as a variable beha-
viour with intentional and unintentional causes. Most
people taking medication are non-adherent some of the
time. Unintentional non-adherence is linked to limitations
in capacity or resources that reduce the ability to adhere
to the treatment as intended. Intentional non-adherence
is the product of a decision informed by beliefs, emotions
and preferences [6].
BHIVA recommendations on the monitoring of adher-
ence to ART are available (www.bhiva.org/monitoring-
guidelines.aspx). The National Institute for Health and
Care Excellence (NICE) has published detailed guidance
on the assessment and support of adherence to medica-
tion in chronic diseases; key recommendations for
adherence support are shown in Box 6.1 [7].
For PLWH it may help to normalise ambivalence and
conversations about suboptimal adherence by reassuring
the person that many others have doubts and concerns
about ART. A person’s motivation to start and continue
medication is influenced by their judgement of their per-
sonal need for medication (necessity beliefs), relative to
their concerns about potential adverse effects. Delayed
uptake and non-adherence are associated with doubts
about personal need for ART and concerns about taking
it [8,9]. PLWH may not raise adherence concerns so
should be encouraged to do so, and provided with feed-
back, at each visit.
Interventions to support adherence should be tailored
to address specific relevant perceptual and practical barri-
ers. A three-step ‘perceptions and practicalities approach’
[9] may be helpful:
• Identify and address any doubts about personal need
for ART;
• Identify and address specific concerns about taking
ART;
• Identify and address practical barriers to adherence.
Strategies to improve adherence should be tailored to
the patient’s needs, and can include the following.
• Elicit understanding of, and educate on, HIV and
adherence in a way that is appropriate for the patient
[10–12]. Similarly, review clinical outcomes with the
patient in a way that is understandable
• Provide a rationale for treatment that is tailored to the
individual [6,13].
• Assess misinformation about adherence [14,15].
• Clinicians should not contest miraculous healing
beliefs [14,16] but rather offer the compatible belief
that medication and God can work together to bring
health.
• Limit ART complexity and explore patient’s lifestyle
and work hours to select the most appropriate regimen
[17].
• Many patients find it difficult to remember to take
medication on time [17]. Suggestions such as using a
phone or watch alarm [18], or linking an established
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Box 6.1 Summary of NICE guidance on adherence support [7]
Assessment
Recognise that non-adherence is common and that most patients are non-adherent sometimes. Routinely assess
adherence in a non-judgemental way whenever you prescribe, dispense and review medicines. The purpose of assess-
ing adherence is not to monitor patients but rather to find out whether patients need more information and support.
Make it easier for them to report non-adherence by:
• Asking the question in a way that does not apportion blame
o explaining why you are asking the question
o mentioning a specific time period such as ‘in the past week’
o asking about medicine-taking behaviours such as reducing the dose, stopping and starting medicines.
 If a patient is not taking their medicines, discuss with them whether this is because of beliefs and concerns or
problems about the medicines (intentional non-adherence) or because of practical problems (unintentional non-
adherence).
 Find out what form of support the patient would prefer to increase their adherence to medicines.
Intervention
Patients may need support to help them make the most effective use of their medicines (e.g. further information and
discussion, or practical changes to the type of medicine or the regimen). Any interventions should address the con-
cerns and needs of individual patients. Tailor any intervention to increase adherence to the specific difficulties with
adherence the patient is experiencing.
Address any beliefs and concerns that patients have that result in reduced adherence.
Interventions might include:
• Suggesting that patients record their medicine taking
• Encouraging patients to monitor their condition
• Simplifying the dosing regimen
• Using alternative packaging for the medicine
• Using a multi-compartment medicines system.
Side effects can be a problem for some patients. If this is the case you should:
• Discuss how the patient would like to deal with side effects
• Discuss the benefits, side effects and long term effects with the patient to allow them to make an informed choice
• Consider adjusting the dosage
• Consider switching to another medicine with a different risk of side effects
• Consider what other strategies might be used (for example, timing of medicines).
© 2016 British HIV Association HIV Medicine (2016), 17 (Suppl. 4), s2--s104
BHIVA guidelines for the treatment of HIV-1 positive adults with ART s41
daily behaviour with taking medication – for example,
taking ART with a morning cup of tea may help.
• Suggest techniques to make swallowing ART easier,
such as taking it with yoghurt to mask the taste.
• Suggest techniques to limit the risk of involuntary dis-
closure. HIV-related stigma can compromise adherence
to ART [17,19], and not taking medication in front of
others can be protective [14,20]. Clinicians can offer
alternative reasons as to why someone might need to
take medication at a particular time to decrease con-
cern about disclosure (e.g. taking birth control/mi-
graine/blood pressure medication).
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6.1.2 Should the choice of first-line antiretroviral
therapy combination be affected by risk of non-adherence?
6.1.2.1 Recommendation
• In individuals where there is clinical concern that
doses may be missed intermittently, there is insuffi-
cient evidence to recommend a PI/r over NNRTI- or
INI-based regimens. However, where there is a risk of
frequent prolonged treatment interruptions, PI/r-based
regimens may be associated with less frequent selec-
tion for drug resistance (2C).
6.1.2.2 Rationale
Clinicians are poor at both predicting future adherence to
ART in naïve subjects [1] and at detecting non-adherence
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during ART [2,3]. However, in a case where a clinician or
HIV-positive individual has concerns about future adher-
ence, should this influence the choice of first-line ther-
apy?
The consequences of low adherence depend on drug
pharmacokinetics, potency, fitness of resistant strains and
genetic barrier to resistance [4]. Hence, both the level and
pattern of non-adherence must be considered.
Large randomised controlled trials of first-line therapy
may not be able to inform this choice as subjects likely
to be non-adherent may be excluded from such trials. On
the other hand, observational studies often select PLWH
already established on ART [5,6] where the observed
effects of non-adherence on treatment outcome are likely
to differ from those in individuals starting ART de novo.
This selection bias may exclude those who have either
experienced early virological failure, disease progression
(or even death) or have defaulted from care. In addition,
most studies either pre-date the use of boosted-PI regi-
mens in first-line therapy [5,7] or include large numbers
of people on unboosted PI regimens.
Three different outcomes may be considered: virologi-
cal suppression, selection of drug resistance and effect of
pattern of non-adherence.
6.1.2.2.1 Effect of adherence on viral suppression
There are no data from randomised controlled trials that
directly address this question. Among subjects reporting
<95% adherence in a randomised controlled trial compar-
ing lopinavir/r with once-daily darunavir/r, virological
failure was more likely in the lopinavir/r than the daru-
navir/r arm; there were no differences between the two
arms when analysing individuals reporting >95% adher-
ence [8].
Among individuals who were virologically suppressed
initially, adherence <95% was associated with an
increased risk of failure [6], and very low adherence
(<50%) results in virological rebound irrespective of regi-
men [6,9,10]. However, virological suppression has been
observed with only moderate adherence (50–75%) among
individuals on NNRTIs [6,9,10] and virological failure has
been reported to be significantly more likely on
unboosted PI-based regimens where adherence was <95%
[6]. However, this finding may have been confounded by
the once-daily dosing in the efavirenz group. A further
study [11] examined only individuals with undetectable
viraemia and found no difference in rates of virological
rebound for those on PI/r vs. NNRTIs.
6.1.2.2.2 Effect of adherence on selection of drug resis-
tance
The effect of level of non-adherence on selection of drug
resistance varies by class. This was first described for
unboosted PI regimens where moderate-to-high
adherence was associated with increased risk of resistance
[12]. The incidence of resistance in studies of boosted-PI
regimens is low [8,13–17] but is observed with adherence
just below 80–95% [5,18]. In contrast, for first-generation
NNRTIs the selection for resistance has been associated
with very low average adherence (<50%) [19,20].
6.1.2.2.3 Effect of pattern of non-adherence
The pattern of non-adherence may also be important. A
number of small observational studies have examined
short intermittent treatment interruptions (2–7 days) in
individuals with prolonged virological suppression. For
efavirenz, cycles of 2 days off per week appeared no
more likely to result in treatment failure than continuous
therapy, as long as the treatment interruption was not
prolonged [21,22]. However, cycles of 7- or 28-day treat-
ment interruption resulted in failure of efavirenz and
selection of resistance [23,24]. For PI/r, one study found
that average adherence, rather than duration of treatment
interruption, was associated with virological response
[25].
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6.1.3 Dosing frequency
An overview of systematic reviews of consumer-oriented
medication interventions found that simplified dosing
regimens improved adherence in the majority of studies
in several reviews [1]. A review of adherence interven-
tions for antiretroviral therapy included 19 studies (6312
adult individuals). Average adherence was modestly
higher with once-daily regimens than twice-daily regi-
mens (weighted mean difference = 2.55%, 95% CI 1.23–
3.87, P = 0.0002) but virological suppression was similar.
Both adherence and viral suppression decreased over
time, but adherence decreased less with once-daily than
twice-daily dosing. Lower pill burden was associated with
both better adherence and virological suppression [2].
NICE [3] reviewed several randomised controlled trials of
interventions to reduce dose frequency and found that
adherence may increase with once-daily dosing but not
in all studies. Once-daily dosing is a reasonable interven-
tion to reduce unintentional non-adherence to ART but
no correpsonding impact on viral suppression has been
observed.
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6.1.4 Fixed-dose combinations
In examining whether fixed-dose combination formula-
tions (FDCs) of drugs improve adherence or treatment
outcome, only studies comparing the same drugs with the
same dose frequency given as combination or separate
pills were considered. No meta-analyses have been pub-
lished on this subject for ART. A meta-analysis of nine
randomised controlled trials and cohort studies in a range
of diseases found the use of FDCs was associated with a
significant reduction in the risk of non-adherence but in
the single HIV randomised controlled trial included no
significant difference in treatment failure between groups
receiving FDC vs. non-FDC was observed [1]. Gupta et al.
[2] reported a meta-analysis of cohort studies and found
that use of FDCs for anti-hypertensives was associated
with increased adherence but with no improvement on
the control of blood pressure.
A retrospective study of a pharmacy database found no
benefit in persistence on first-line ART for any FDC over
separate agents [3]. In the ECHO/THRIVE studies, a lower
virological response rate in individuals with baseline viral
load 100,000–500,000 copies/mL was observed for rilpi-
virine- versus efavirenz-based regimens when dosed as
separate agents [4]; this was not repeated when formu-
lated as FDCs in the preliminary 48-week results from the
STaR study [5]. Although the use of FDCs may have dri-
ven this apparent improvement in performance of rilpi-
virine, it may also have arisen due to the simpler once-
daily regimens in STaR, other methodological differences
or by chance.
A further advantage of FDCs is that they prevent indi-
viduals from preferentially adhering less closely to one
component of a regimen than others. A minority of par-
ticipants in one study did report such ‘differential’ adher-
ence, but this was not associated with outcome for
currently used first-line strategies [6]. This was also
reported in an Italian observational study; however, the
difference was small and may have been confounded by
other factors [7].
An observational study of outcomes following a switch
from Atripla to multi-tablet regimens including swapping
emtricitabine for lamivudine provides some evidence that
this may not result in an increase in virological failures
[8]. In view of the higher-quality evidence in support of
FDCs and the implications and costs of treatment failure,
there is insufficient evidence to support this strategy at
present.
A recent meta-analysis of nine randomised-controlled
antiretroviral trials analysed the impact of FDCs on
adherence and treatment outcomes [9]. All nine trials
were switch studies, regimen components differed
between the FDC and non-FDC arms and five of the
trials, investigating the impact of FDC backbone, were
from several years ago. Four of the trials compared
switching to a single-tablet regimen with continuing the
existing multi-tablet regimen and there was no difference
in virological failure rate; by switch = failure analysis
there was a significant difference favouring single tablets.
In summary, FDCs support adherence to treatment, and
this may well reduce the risk of virological failure. How-
ever, the size of this effect is yet to be defined. This needs
to be balanced against the potentially far lower cost of
generically available antiretroviral agents as separate or
combined preparations of the same drugs.
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6.1.5 Single-tablet regimens
There are currently four single-tablet regimens (STRs)
available. Atripla (tenofovir-DF/emtricitabine/efavirenz)
was the first STR approved for use in adults and in chil-
dren at least 12 years old who weighed at least 40 kg [1].
The second available STR, which also contained an
NNRTI, was Eviplera (tenofovir/emtricitabine/rilpivirine).
Tenofovir-DF/emtricitabine/rilpivirine is licensed for the
treatment of adults, who have no known mutations asso-
ciated with resistance to NNRTIs, tenofovir-DF or emtric-
itabine, and have a viral load ≤100,000 HIV-1 RNA
copies/mL [2]. More recently, STRs containing an INSTI
have become available. These are Stribild (tenofovir-DF/
emtricitabine/elvitegravir/c) [3] and Triumeq (abacavir/
lamivudine/dolutegravir) [4]. Triumeq is the first STR
containing an abacavir/lamivudine backbone and testing
for HLA-B*57:01 is recommended before use. If the indi-
vidual is HBV co-infected, then additional drug treatment
should be considered.
Potential advantages of using STRs are improved
adherence, reduced selective adherence, patient prefer-
ence and improvement in quality of life [5,6] although a
recent analysis of individuals switching to STRs did not
demonstrate significant changes in quality of life [7].
Randomised studies demonstrating these advantages are
scarce, and among cohort and observation studies results
are varied. One meta-analysis of four randomised switch
STR trials has been presented but none of these trials
compared the same drugs head to head [7]. In this meta-
analysis there was no significant difference for virologi-
cal failure, discontinuations due to adverse events or
switch = failure endpoint. Only two of the trials assessed
quality of life and found no difference between STR and
control [7].
Disadvantages of STRs include cost, limited choice of
regimens and the inability to dose-adjust for weight,
renal impairment or drug–drug interactions. Also HLA-
B*57:01 testing and hepatitis B status must be considered
for abacavir-containing STRs. Transmitted resistance will
limit the possible use of STRs.
A cohort study from Denmark reported that switching
from an STR to a generic triple-tablet regimen resulted in
maintained efficacy, was safe and lower in cost [8]. A ret-
rospective look at switching from FDCs to separate com-
ponents in the Balearic Islands found lower
pharmaceutical cost but higher overall healthcare cost in
the first year following the change [9].
STRs have not been compared to the same drugs in
multiple-pill regimens in randomised clinical trials. In the
switch studies there was no proven benefit, despite the
large cost difference. Although there are potential
advantages of using STR there are currently no cost-
effectiveness data looking at STRs versus generic medica-
tions.
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6.2 Pharmacology
More than for any other infection, individuals receiving
ART require their doctor to have a clear understanding of
the basic principles of pharmacology to ensure effective
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and appropriate prescribing. This is especially the case in
four therapeutic areas.
6.2.1 Drug interactions
6.2.1.1 Recommendations
• Drug histories should be taken at each clinic visit, and
a full medication history (including herbals, recre-
ational drugs and other non-prescribed medications)
should be undertaken at least annually (GPP).
• All potential adverse pharmacokinetic interactions
between antiretroviral drugs and other concomitant
medications should be checked before administration
(with tools such as www.hiv-druginteractions.org)
(GPP).
• Wherever feasible, PLWH should be counselled about
the risks of drug interactions, and advised to use
resources such as the Liverpool HIV Drug Interactions
App (iOS or Android) (GPP).
6.2.1.2 Auditable measure
• Full medication history at least annually.
• Record in medical notes of potential adverse pharma-
cokinetic interactions between ARV drugs and other
concomitant medications.
6.2.1.3 Rationale
The importance of eliciting a complete medication history
in order to manage potential drug interactions in patients
cannot be overemphasised. Drug–drug interactions may
involve positive or negative interactions between ARV
agents or between these and drugs used to treat other
coexistent conditions. A detailed list is beyond the remit
of these guidelines but clinically important interactions
to consider when co-administering with ARV drugs
include interactions with the following drugs: methadone,
oral contraceptives, anti-epileptics, antidepressants, lipid-
lowering agents, acid-reducing agents, certain antimicro-
bials (e.g. clarithromycin, minocycline and fluconazole),
some anti-arrhythmics, TB therapy, anti-cancer drugs,
immunosuppressants, phosphodiesterase inhibitors and
anti-hepatitis C virus (HCV) therapies. Most of these
interactions can be managed safely (i.e. with/without
dosage modification, together with enhanced clinical vig-
ilance) but in some cases (e.g. rifampicin and PIs, proton
pump inhibitors and atazanavir, inhaled fluticasone and
ritonavir/cobicistat) the nature of the interaction is such
that co-administration must be avoided and alternatives
sought.
Importantly, education on the risks of drug interac-
tions, including over-the-counter or recreational drugs,
should be undertaken and PLWH should be encouraged
to check with pharmacies or their healthcare professionals
before commencing any new drugs, including those pre-
scribed in primary care.
Large surveys report that about one-in-three-to-four
PLWH receiving ART is at risk of a clinically significant
drug interaction [1–7]. This suggests that safe manage-
ment of HIV drug interactions is only possible if medica-
tion recording is complete, and if physicians are aware of
the possibility that an interaction might exist. Incomplete
or inaccurate medication recording has resulted from
self-medication, between hospital and community health
services [8] and within hospital settings particularly when
multiple teams are involved, or when medical records are
fragmented (e.g. with separate HIV case notes) [9].
More worryingly, one survey in the UK reported that
even when medication recording is complete, physicians
were only able to identify correctly one-third of clinically
significant interactions involving HIV drugs [2]. In addi-
tion to HIV specialist and local drug information pharma-
cists, the University of Liverpool’s comprehensive drug
interaction website (www.hiv-druginteractions.org) is an
excellent and highly recommended resource for informa-
tion relating to potential drug interactions. Additional
information resources also include the electronic medici-
nes compendium (www.medicines.org.uk/emc) and medi-
cal information departments of pharmaceutical
companies.
Communication with GPs and other medical specialties
involved in care is fundamental in minimising the risk of
adverse drug–drug interactions. All clinic letters should
carry as a standard header or footer advice to check for
interactions, and links to resources, such as www.hiv-
druginteractions.org, to address the potential for drug
interactions.
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6.2.2 Therapeutic drug monitoring
6.2.2.1 Recommendation
• We recommend against the unselected use of therapeu-
tic drug monitoring (GPP).
• Therapeutic drug monitoring may be of clinical value
in specific populations (e.g. children, pregnant women)
or selected clinical scenarios (e.g. malabsorption, drug
interactions, suspected non-adherence to therapy) (2C).
6.2.2.2 Rationale
Therapeutic drug monitoring (TDM) has been shown to be
valuable in optimising the management of certain indi-
viduals; however, the general utility of this test in those
receiving ART has been poorly assessed. With the marked
improvement in efficacy and tolerability of modern ARV
regimens, the role of TDM in clinical management has
also evolved. A Cochrane review of randomised con-
trolled trials [1] suggested little value when used unselec-
tively. However, TDM may aid the management of
vulnerable populations or complex clinical situations.
• Monitoring adherence. While detection of drug at ther-
apeutic or even high plasma concentrations does not
exclude low adherence, absence of measurable drug, or
else very low levels of drug, strongly suggest lack of
medication intake, particularly in the absence of evi-
dence of significant malabsorption. Here, TDM should
rarely be interpreted in isolation, but rather integrated
with virological rebound, particularly in the absence of
any resistance mutations and other features in the his-
tory that suggest risk for low treatment adherence.
• Optimising treatment in vulnerable PLWH. In vulnera-
ble PLWH (e.g. children, pregnant women [2] and indi-
viduals with extremes of body mass index) or in
specific clinical situations (e.g. liver and renal impair-
ment, treatment failure, drug interactions both foreseen
and unanticipated, malabsorption, suspected non-
adherence and unlicensed once-daily dosing regimens).
In these scenarios, the aim is to optimise dosing based
either on known efficacy or toxicity cut-offs, or else to
achieve the range of plasma concentrations encoun-
tered in individuals without these factors, who have
been recruited to pharmacokinetic studies at licensed
treatment doses that are known to be both safe and
efficacious.
• Managing drug interactions (see above). Where the HIV
drug has the potential to be adversely affected by
another drug, and the combination is unavoidable,
TDM may be used either to manage that interaction, or
else discount a significant interaction in a particular
individual.
• Other situations. Knowledge of plasma drug concentra-
tions may be clinically useful when evaluating whether
there is scope for treatment simplification, or else con-
firming or refuting impaired drug absorption as a rea-
son for virological failure.
More detailed recommendations for the use of TDM are
available in the BHIVA guidelines for the routine investi-
gation and monitoring of adult HIV-1-infected individuals
(www.bhiva.org/monitoring-guidelines.aspx). As for all
other investigations, it is essential that TDM is under-
taken correctly, especially with regard to timing (under-
taken when steady state has been achieved). A consensus
has been achieved for defining targets [3] for many
ARVs. With many newer agents, evidence for a defined
minimum target for efficacy is either weak or lacking,
and evidence for an upper toxicity cut-off for most ARVs
is lacking.
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6.2.3 Stopping therapy: pharmacological considerations
6.2.3.1 Recommendations
• We recommend individuals stopping ART containing
an NNRTI in combination with an NRTI backbone
replace all drugs with a PI (darunavir/r once daily) for
4 weeks (1C).
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• We recommend individuals stopping a PI-containing
regimen stop all drugs simultaneously and no replace-
ment is required (1C).
6.2.3.2 Auditable outcome
• Proportion of individuals with an undetectable viral
load on ART who, on stopping a regimen containing
an NNRTI in combination with an NRTI backbone, are
switched to PI/r for 4 weeks.
6.2.3.3 Rationale
In general, treatment interruptions are not recommended
for most individuals. Whatever the reason for stopping
ART (e.g. drug toxicity, intercurrent illness, after preg-
nancy or individual choice), pharmacological issues must
be considered for a clinician to give guidance. The half-
life of each drug included in the regimen is critical. There
is the potential for monotherapy or dual therapy if ARV
drugs with different half-lives are stopped simultane-
ously.
NNRTI and NRTI resistance mutations have been
detected following discontinuation of previously suppres-
sive regimens [1,2] and may have the potential to affect
the likelihood of viral resuppression on restarting an
NNRTI- based ART regimen.
There are limited data on which to base recommenda-
tions for how to protect against development of resis-
tance in the period immediately following treatment
cessation. Several discontinuation strategies have been
proposed [3], and choice is influenced by clinical consid-
erations, individual wishes and pharmacological princi-
ples. Options include: (i) simultaneously stopping all
drugs in a regimen containing drugs with similar half-
lives; (ii) a staggered stop, discontinuing the drug with
the longest half-life first in a regimen containing drugs
with short and long half-lives; or (iii) replacing all drugs
with a drug with a short half-life and high genetic barrier
to resistance (i.e. a PI). There is no randomised compar-
ison of these three strategies. However, in one study a
lower number of emergent resistance mutations were seen
in those switching to a PI compared with those undertak-
ing a simultaneous or staggered stop [2]. Therapeutic
plasma concentrations of efavirenz can also be detected
up to 3 weeks after stopping the drug in some people and
thus a staggered stop of 1 week may potentially be inad-
equate to prevent emergence of NNRTI mutations [4]. The
optimal duration of replacement with a PI is not known,
but 4 weeks is probably advisable.
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6.2.4 Switching therapy: pharmacological considerations
6.2.4.1 Recommendations
There are no high-quality data on how to switch away
from efavirenz to an alternative ‘third’ agent. Based on
pharmacological principles, there is little rationale for
any strategy other than straightforward substitution when
switching to a PI/r or raltegravir. Pharmacokinetic studies
show that straightforward substitution with etravirine, ril-
pivirine, dolutegravir and elvitegravir/c may result in
slightly lower concentrations of either drug for a short
period following switching, but limited virological data
suggest that risk of virological failure with this strategy
is low. Different strategies for switching to nevirapine
have been proposed, but no comparative data are avail-
able to guide the choice of strategy. Limited data suggest
that the dose of maraviroc should be doubled in the week
following switching (unless given together with a PI/r).
If switching away from efavirenz is undertaken when
viral load is likely to still be detectable (e.g. because of
CNS intolerance within the first few weeks of starting
efavirenz), substitution with a PI/r in preference to a
within-class switch is advised.
6.2.4.2 Rationale
Switching a component of an ART regimen is frequently
considered in PLWH to manage drug side effects or
address adherence issues. ARVs that either induce or
inhibit drug-metabolising enzymes have the potential to
affect the plasma concentrations of the new agent. This
applies in particular to switching away from NNRTIs.
Induction of drug metabolising enzymes by efavirenz is
likely to persist for a period beyond drug cessation. Con-
sideration should also be given of whether or not viral
load is maximally suppressed when planning how to
switch away from efavirenz to an alternative agent.
Broadly, strategies for switching from efavirenz to an
alternative ‘third’ agent may be summarised as follows.
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6.2.4.2.1 Efavirenz to nevirapine
A pharmacokinetic study performed in HIV-positive indi-
viduals suggested that individuals changing from efavir-
enz to nevirapine should commence on 200 mg twice a
day to ensure therapeutic plasma concentrations and
potentially avoid selection of resistance to nevirapine [1].
However, no one in the nevirapine lead-in group experi-
enced virological failure in the 3-month follow-up per-
iod. Switching without dose escalation is in direct
contrast to the information in the Viramune summary of
product characteristics, which advises administration of a
nevirapine lead-in dose (200 mg once daily for 2 weeks)
when starting nevirapine [2], as this has been shown to
decrease the frequency of rash.
In ART-experienced individuals who are virologically
suppressed with an undetectable plasma HIV RNA level
(<50 copies/mL), the risk of hypersensitivity and/or hepa-
totoxicity on switching to nevirapine is not increased in
those with higher CD4 cell counts (above the gender-spe-
cific CD4 cell count thresholds) [3]. In ART-experienced
individuals with detectable plasma HIV RNA levels, a
switch to nevirapine is not advised.
Furthermore, the need to minimise any window for
developing resistance is greatest in those who discontinue
efavirenz early on when virological suppression has not
yet been achieved. The latter scenario is made more com-
plex when enzyme induction has not yet been fully
achieved, and if doubt exists, alternatives to switch to
should be considered.
6.2.4.2.2 Efavirenz to etravirine
In individuals with undetectable viral loads, switching
from efavirenz to etravirine, standard doses of etravirine
can be commenced [4]. To date, no data are available on
what strategy to adopt in those with active viral
replication.
6.2.4.2.3 Efavirenz to rilpivirine
Concentrations of rilpivirine are lowered by previous efa-
virenz administration. However, 28 days after the switch,
they returned to levels comparable with those when rilpi-
virine was administered without previous efavirenz treat-
ment, except for a 25% lower Cmin. Therefore, for
individuals with undetectable viral loads switching from
efavirenz to rilpivirine, standard doses of rilpivirine can
be commenced [5]. To date, no data are available on
what strategy to adopt in individuals with active viral
replication.
6.2.4.2.4 Efavirenz to a ritonavir-boosted protease
inhibitor
Because of the strong inhibitory effect of ritonavir on
CYP450 3A4, a modification of the PI/r dose is unlikely
to be needed when switching from efavirenz to PI/r. For-
mal pharmacokinetic data are unavailable. TDM data on
atazanavir/r showed that after stopping efavirenz, ataza-
navir concentrations were above the suggested minimum
effective concentration in all studied subjects [6].
6.2.4.2.5 Efavirenz to raltegravir
Although formal pharmacokinetic data are not available,
switching efavirenz to raltegravir should not lead to clin-
ically significant consequences, as co-administration of
efavirenz with raltegravir led to a 21% decrease in ralte-
gravir Cmin and the degree of this reduction is unlikely to
be clinically meaningful [7].
6.2.4.2.6 Efavirenz to maraviroc
A formal pharmacokinetic study in HIV-positive individ-
uals showed that the induction effect of efavirenz neces-
sitated an increase in maraviroc dose to 600 mg twice
daily for 1 week following the switch [8]. Maraviroc
300 mg twice daily (standard dose) seems to be safe after
this period. Although there is an absence of data, when
switching from efavirenz to maraviroc plus a PI/r, it is
likely that a dose of 150 mg twice daily is safe from the
first day after the switch. Whether it is advisable to use
maraviroc 150 mg once daily in this context or for how
long a twice-daily dose should be used after the switch
remains unknown.
6.2.4.2.7 Efavirenz to elvitegravir/cobicistat
Concentrations of elvitegravir are lowered by previous
efavirenz administration: elvitegravir AUC/Ctrough were
37%/67% and 29%/55% lower 1 and 2 weeks post-
switch, respectively, but still above the protein binding-
adjusted 95% inhibitory concentration (45 ng/mL). There-
fore, for individuals with undetectable viral loads switch-
ing from efavirenz to elvitegravir/c, standard doses of
elvitegravir/c can be commenced [9]. Pharmacodynamic
data from a Phase 3b switch study in HIV-positive sub-
jects are also available [10]. To date, no data are available
on what strategy to adopt in individuals with active viral
replication.
6.2.4.2.8 Efavirenz to dolutegravir
Mathematical modelling suggests that dolutegravir con-
centrations achieved target minimum effective concentra-
tions by 3 days following efavirenz discontinuation
(6 days in efavirenz poor metabolisers). Importantly, there
was no time point where both the efavirenz and dolute-
gravir concentrations were predicted to be sub-therapeu-
tic [11]. On that basis, straightforward (with no dose
adjustment) substitution of efavirenz with dolutegravir is
recommended.
6.2.4.2.9 Nevirapine to rilpivirine
A study switching 32 individuals with an undetetcbale
viral load from tenofovir-DF/emtricitabine + nevirapine
to tenofovir-DF/emtricitabine/rilpivirine fixed-dose com-
bination showed that all individuals maintained viral
suppression. Mean rilpivirine Ctrough was above Ctrough
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measured in Phase 3 studies by week 1 and the majority
of individuals (27/32) had undetectable plasma nevirapine
concentrations by week 2 [12]. Therefore, for individuals
with undetectable viral loads switching from nevirapine
to rilpivirine, standard doses of rilpivirine can be com-
menced. To date, no data are available on what strategy
to adopt in individuals with active viral replication.
6.2.4.2.10 Nevirapine to dolutegravir
Concentrations of dolutegravir have been shown to be
moderately decreased (n = 10) by previous nevirapine
administration in PLWH with an undetectable viral load:
dolutegravir AUC was lowered by 19% and Ctrough by
34% [13] These changes are unlikely to be clinically sig-
nificant as dolutegravir concentrations are maintained
well above the protein binding-adjusted 90% inhibitory
concentration (64 ng/mL) during and right after stopping
nevirapine administration. Therefore, for individuals with
undetectable viral loads switching from nevirapine to ril-
pivirine, standard doses of rilpivirine can be commenced.
6.2.4.3 References
1 Winston A, Pozniak A, Smith N et al. Dose escalation or
immediate full dose when switching from efavirenz to
nevirapine-based highly active antiretroviral therapy in
HIV-1-infected individuals? AIDS 2004; 18: 572–574.
2 Boehringer Ingelheim. Viramune Summary of Product
Characteristics. 2011.
3 Kesselring AM, Wit FW, Sabin CA et al. Risk factors for
treatment-limiting toxicities in patients starting nevirapine-
containing antiretroviral therapy. AIDS 2009; 23: 1689–
1699.
4 Waters L, Fisher M, Winston A et al. A phase IV,
double-blind, multicentre, randomized, placebo-controlled,
pilot study to assess the feasibility of switching
individuals receiving efavirenz with continuing central
nervous system adverse events to etravirine. AIDS 2011;
25: 65–71.
5 Crauwels H, Vingerhoets J, Ryan R et al. Pharmacokinetic
parameters of once-daily TMC278 following administration
of EFV in healthy volunteers. Conference on Retroviruses
and Opportunistic Infections. February 2011. Boston, MA,
USA. [Abstract 630].
6 Maitland D, Boffito M, Back D et al. Therapeutic drug
monitoring (TDM) of atazanavir (ATV) during the first
4 weeks of therapy after switching from efavirenz (EFV)
containing regimen. 7th International Congress on Drug
Therapy in HIV Infection. November 2004. Glasgow,
Scotland [Abstract 293].
7 Iwamoto M, Wenning LA, Petry AS et al. Minimal effects of
ritonavir and efavirenz on the pharmacokinetics of
raltegravir. Antimicrob Agents Chemother 2008; 52: 4338–
4343.
8 Waters L, Jackson A, Else L et al. Switching safely:
pharmacokinetics, efficacy and safety of switching efavirenz
to maraviroc twice daily in patients on suppressive
antiretroviral therapy. Antivir Ther 2015; 20: 157–163.
9 Cohen C, Elion R, Ruane P et al. Switch from efavirenz/
emtricitabine/tenofovir DF to elvitegravir/cobicistat/
emtricitabine/tenofovir DF: efficacy and pharmacokinetics.
53rd ICAAC. September 2013. Denver, CO, USA [Abstract H-
658].
10 Pozniak A, Markowitz M, Mills A et al. Switching to
coformulated elvitegravir, cobicistat, emtricitabine, and
tenofovir versus continuation of non-nucleoside reverse
transcriptase inhibitor with emtricitabine and tenofovir in
virologically suppressed adults with HIV (STRATEGY-
NNRTI): 48 week results of a randomised, open-label, phase
3b non-inferiority trial. Lancet Infect Dis 2014; 14: 590–
599.
11 Generaux G, Song I, Bowers G, Piscitelli S. A mechanistic
SimCYP simulation evaluating dolutegravir and efavirenz
pharmacokinetics following a switch from once-daily
efavirenz to once-daily dolutegravir. 15th International
Workshop on Clinical Pharmacology of HIV and Hepatitis
Therapy. May 2014. Washington DC, USA [Abstract P_36].
12 Allavena C, Dailly E, Reliquet V et al. Switching from
tenofovir/emtricitabine and nevirapine to a tenofovir/
emtricitabine/rilpivirine single-tablet regimen in
virologically suppressed, HIV-1-infected subjects. J
Antimicrob Chemother 2014; 69: 2804–2808.
13 Dailly E, Allavena C, Gregoire M et al. Influence of
nevirapine administration on the pharmacokinetics of
dolutegravir in patients infected with HIV-1. J Antimicrob
Chemother 2015.
6.3 Switching antiretroviral therapy in virological
suppression
6.3.1 Introduction
In individuals on fully virally suppressive regimens,
switching individual components of the ART combination
regimen is frequently considered for several reasons,
including: management of ARV drug toxicity or intoler-
ance, desire for once-daily dosing and reduced pill bur-
den, management of potential drug–drug interactions,
individual preference and cost [1]. Guidance on the man-
agement of drug toxicity of individual ARVs is not
within the scope of these guidelines. Guidance on inter-
ventions to support adherence, including once-daily dos-
ing and fixed-dose combinations is addressed in
Section 6.1 (Adherence) and pharmacological considera-
tions on switching ARVs is discussed in Section 6.2.4.
Switching individual components of an ART regimen
may well improve adherence and tolerability, but should
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not be at the cost of virological efficacy. The following
guidance concerns the impact on virological efficacy of
either switching the third agent or the NRTI backbone in
a combination ART regimen or simplifying to boosted PI
monotherapy. Evidence from a systematic literature
review (Appendix 2) was evaluated as well as the impact
on critical treatment outcomes of the different switching
strategies assessed. Critical outcomes included virological
suppression at 48 weeks, virological failure and discon-
tinuation from grade 3/4 events. Of note, when switching
in the context of viral suppression, rilpivirine and aba-
cavir/lamivudine can be used regardless of pre-treatment
viral load.
6.3.2 Switching antiretrovirals in combination
antiretroviral therapy
6.3.2.1 Recommendations
• We recommend, in individuals on suppressive ART
regimens, consideration is given to differences in side-
effect profile, drug–drug interactions and drug-resis-
tance patterns before switching any ARV component
(GPP).
• In individuals with previous NRTI resistance mutations,
we recommend against switching a PI/r to either an
NNRTI or an INI as the third agent (1B).
6.3.2.2 Auditable outcome
• Number of individuals with an undetectable viral load
on current regimen and documented previous NRTI
resistance who have switched a PI/r to either an NNRTI
or INI as the third agent.
6.3.2.3 Rationale
Within-class switches are usually undertaken to improve
ARV tolerability or to address potential adverse effects.
The available evidence for current recommended third
agents is limited but switching PI/r or NNRTIs in virolog-
ically suppressed individuals has, in a small number of
studies, not been associated with loss of virological effi-
cacy [2–4]. Consideration should, however, be given to
differences in side-effect profiles, drug–drug interactions,
pill burden and food effect (see Appendix 4). When
switching between different PIs, a previous history of
major PI mutations may potentially have an adverse
effect on the virological efficacy of the new PI/r.
6.3.2.3.1 Within class
For NRTIs, recent studies have mainly evaluated switch-
ing from a thymidine analogue to either tenofovir-DF or
abacavir to manage lipoatrophy, or have investigated
switching to one of two available NRTI fixed-dose combi-
nations (FDC; tenofovir-DF and emtricitabine or abacavir
and lamivudine). If screening for HLA-B*57:01 positivity
is undertaken before the switch to abacavir, then similar
virological efficacy is seen in subjects switched to
abacavir/lamivudine FDC compared with a switch to
tenofovir-DF/emtricitabine FDC [5]. Switching from aba-
cavir/emtricitabine FDC to tenofovir-DF/emtricitabine
FDC was also found to maintain viral suppression and is
safe [6]. However, switching to simplify to a triple nucle-
oside regimen is not recommended [7]. For PIs, recent
studies have evaluated both within-class switching and
simplification to an unboosted regimen [8–12]. These
changes have been to reduce bilirubin, lipids or bone and
renal biomarkers. For NNRTIs, etravirine and rilpivirine
have been evaluated in an intraclass switch [4,13,14]. All
study participants maintained virological control and
there were no adverse events. With the exception of a
small, single arm tenofovir-DF/emtricitabine plus ralte-
gravir to Stribild switch study (50 subjects, all of whom
maintained virological suppression with minimal impact
on renal and lipid markers) [15], there are no integrase
inhibitor within-class switch studies. In general, in the
absence of previous resistance mutations, switching
within class should result in maintaining virological sup-
pression.
6.3.2.3.2 Switch from PI
Several randomised controlled trials have assessed
switching between classes (PI to NNRTI or INI, NNRTI to
INI) in individuals who are virologically suppressed. A
meta-analysis of six trials showed non-inferiority in
maintenance of virological suppression when switching
from a PI (both ritonavir boosted and unboosted) to nevi-
rapine compared with continuing the PI, but was associ-
ated with more discontinuations due to liver toxicity [16].
Previous treatment failure on an NRTI-containing regi-
men has been associated with an increased risk of viro-
logical failure when switching from a PI- to an NNRTI-
based regimen [17]. A cohort analysis showed similar
rates of virological failure at 12 months in PLWH switch-
ing from a first-line PI/r to either efavirenz or nevirapine
compared with continuing on the PI/r [18]. If switching
to nevirapine, consideration should be given to the risk
of hypersensitivity reactions and hepatotoxicity. Similar
rates have been reported in virologically suppressed com-
pared with ART-na€ıve individuals stratified for CD4 cell
count and gender [19,20]. Only one randomised con-
trolled trial has assessed the switch from PI to once-daily
etravirine in people with HIV RNA suppression [21] and
no participants presented with virological failure through
to 48 weeks. Switching in virological suppression to rilpi-
virine from PI-maintained suppression was safe and, with
or without K103N, had a high response rate [22–24]. For
individuals without previous NRTI or NNRTI resistance
mutations switching from a PI/r to any of the current
licensed NNRTIs is likely to maintain virological efficacy
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and choice of NNRTI will depend on side-effect profile,
tolerability and individual preference.
Switching from a PI/r to the INI, raltegravir, in virolog-
ically suppressed individuals has been evaluated in three
randomised controlled trials. Two studies have shown
that previous history of NRTI resistance mutations
increases the risk of subsequent virological failure on
switching compared with continuing on a PI/r [25,26].
This association was not seen in a third trial [6]. How-
ever, it is not surprising that switching from an ARV with
a high genetic barrier to one with a low genetic barrier to
resistance may potentially increase the risk of virological
failure if the activity of the NRTI backbone has been
compromised by previous NRTI resistance. One ran-
domised controlled trial assessed switching from PI to
elvitegravir/c in people with viral suppression (excluding
individuals with a history of virological failure or resis-
tance to tenofovir-DF or emtricitabine), finding suppres-
sion is maintained and regimen is well tolerated [27].
6.3.2.3.3 Switch from NNRTI
Switching from an NNRTI to an alternative third agent
(elvitegravir/c or raltegravir [28,29]) in virologically sup-
pressed patients has been assessed. Raltegravir was
assessed for patient preference and was found to be
acceptable. NNRTI switch to elvitegravir/c maintained
viral suppression and was well tolerated. If switching
from an NNRTI, consideration must be given to previous
treatment history and potential pharmacokinetic interac-
tions. The latter is discussed in more detail in Sec-
tion 6.2.4.
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6.3.3 Protease inhibitor monotherapy
6.3.3.1 Recommendations
• We recommend against the use of PI monotherapy for
routine ART (1A).
• We recommend against the use of PI monotherapy for
individuals whose initial regimen has failed or who
have established resistance to one more antiretroviral
drugs (1A).
6.3.3.2 Auditable outcome
• Proportion of individuals on PI/r monotherapy as ART
maintenance strategy and record of rationale.
6.3.3.3 Rationale
For the assessment and evaluation of evidence, GRADE
tables were constructed (Appendix 3). Virological sup-
pression, drug resistance and serious adverse events were
defined as critical outcomes. From the systematic litera-
ture review (Appendix 2), twelve randomised trials and
two meta-analyses were identified, investigating the use
of either lopinavir/r or darunavir/r in stable, virologically
suppressed PLWH without active hepatitis B co-infection
[1–14]. Assessment of virological suppression showed sig-
nificantly fewer on PI monotherapy maintained virologi-
cal suppression compared with those continuing on
standard combination ART (RR 0.95, 95% CI 0.9–0.99),
although the difference was small. Viral load rebound is
usually at low level, and is easily reversed by reintroduc-
tion of NRTIs [10]. There were no differences in the fre-
quency of emergence of viral resistance, or of serious
adverse events. The long-term consequences of this viral
rebound and resuppression were assessed in the PIVOT
trial where primary endpoint was loss of future drug
options and secondary endpoints included clinical events
[15]. PI monotherapy was non-inferior (inferiority margin
10%) on the primary end point of impact on future treat-
ment options [15]. One potential concern is the develop-
ment of CNS disease in people on PI monotherapy
[7,14,15]; however, PIVOT did not identify any difference
in neurocognitive scoring over 5 years [15]. Overall, there
is no significant clinical benefit of PI monotherapy
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compared with standard combination ART and the added
disadvantage of a lower rate of viral suppression with PI
monotherapy. For this reason PI monotherapy should not
be used in unselected populations for maintaining viro-
logical suppression where standard ART is an acceptable
alternative. There may be potential benefits of PI
monotherapy, in terms of drug resistance, long-term drug
toxicity and cost [16,17]. We recognise that PI monother-
apy may well be an acceptable option in some specific
populations and has been found to be safe, well tolerated
and cost-effective [15]. Clinicians might consider PI
monotherapy in individuals who are unable to tolerate
NRTIs due to toxicities or as a short-term measure to
manage or bridge complex clinical scenarios (e.g. stop-
ping certain NNRTI-containing regimens or managing
toxicity overdose or acute illness). Where PI monotherapy
is considered, darunavir/r (dosed once or twice daily) or
lopinavir/r (dosed twice daily) should be used but with
reintroduction of NRTIs if there is loss of virological con-
trol. Atazanavir/r monotherapy is not recommended
because it has been associated with higher rates of viro-
logical failure [18,19]. PI monotherapy is not recom-
mended in individuals with active hepatitis B co-
infection.
6.3.3.3.1 PI monotherapy as second line after first-line
treatment failure
Three randomised controlled trials looked at PI monother-
apy as second-line therapy compared to triple-ART in
treatment failure, all in an African setting. In all three tri-
als the PI monotherapy arm had significantly more par-
ticipants with virological failure than the triple ART or
other arms in the trials [20–22].
This strategy therefore is not recommended.
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6.3.4 Treatment with one boosted protease inhibitor and
one NRTI
6.3.4.1 Recommendation
• We suggest that a boosted PI plus lamivudine as an
alternative to three-drug ART in individuals with viral
suppression (2A)
6.3.4.2 Rationale
Two studies have compared the use of boosted atazanavir
or lopinavir with lamivudine versus a conventional three-
drug regimen in patients with a suppressed viral load [1,2].
In both studies, the efficacy of dual therapy was non-infer-
ior to conventional therapy after 48 weeks of follow up. In
patients who have a suppressed viral load on a conven-
tional regimen, but who have drug toxicity associated with
abacavir or tenofovir-DF, dual therapy is thus a reasonable
option. This approach has not been compared formally
with protease inhibitor monotherapy, however.
6.3.4.4 References
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6.4 Stopping therapy
6.4.1 Recommendation
• We recommend against treatment interruption or inter-
mittent therapy in individuals stable on a virally sup-
pressive ART regimen (1A).
6.4.2 Auditable outcomes
• Proportion of individuals not on ART having previ-
ously been on ART.
• Documentation of reasons for stopping in those who
stopped.
6.4.3 Rationale
Several randomised controlled trials have investigated the
efficacy of CD4 cell count-guided intermittent therapy as
a potential strategy to reduce long-term risk of drug toxi-
city and drug resistance [1–4]. In the largest of these,
subjects were randomly allocated to either CD4 cell
count-guided intermittent therapy (stopping ART once
CD4 cell count >350 cells/lL, restarting when CD4 cell
count falls to 250 cells/lL) compared with a continuous
ART [4]. The trial showed intermittent therapy was asso-
ciated with a significantly higher rate of opportunistic
disease and all-cause mortality and a higher rate of major
cardiovascular, renal or hepatic disease. The effect was
seen at all CD4 cell count levels. The study showed for
the first time that continuous ART with virological sup-
pression is associated with a reduction in the risk of non-
AIDS co-morbidities and all-cause mortality as well as
HIV disease progression. For this reason, treatment inter-
ruption or intermittent therapy is not recommended.
Once ART has been started in a patient with HIV infec-
tion, it should be continued. An interruption of 1–2 days
can usually be managed and is unlikely to be associated
with adverse outcomes. Longer or frequent interruptions
of ART should only be considered in exceptional circum-
stances. These may include:
• Severe drug toxicity (e.g. hepatotoxicity).
• Severe psychological distress.
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Guidance on pharmacokinetic considerations when
stopping ART is contained in Section 6.2.3.
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7.0 Managing virological failure
7.1 Introduction
For detailed guidance on HIV viral load (VL), resistance
and genotypic tropism testing, the reader should consult
BHIVA guidelines for the routine investigation and moni-
toring of adult HIV-1-infected individuals [1] (www.bhi-
va.org/Monitoring.aspx).
The following recommendations concern the manage-
ment of PLWH experiencing virological failure on ART.
Populations at the time of virological failure will include
those with no or limited HIV drug resistance, those with
more extensive resistance or historical virological failure
on NRTIs, NNRTIs, and/or PIs and those with limited treat-
ment options, including failure of an integrase inhibitor
or X4 tropic virus. For the assessment and evaluation of
evidence, priority questions were agreed and outcomes
were ranked as critical, important and not important by
members of the writing group. For individuals with no or
limited HIV drug resistance the following were ranked as
critical outcomes: viral suppression to <50 copies/mL at
48 weeks, development of resistance, and discontinuation
for clinical and laboratory adverse events. For individuals
with three-class failure/few therapeutic options: clinical
progression, median CD4 cell count change at 48 weeks,
and development of new resistance were ranked as critical
outcomes. Treatments were compared where data were
available and differences in outcomes assessed. For this
update of the guidelines, the benefit of including NRTIs in
the context of virological failure/resistance was examined.
Details of the search strategy and literature review are
contained in Appendix 2.
In the UK, the virological failure rate on first-line
NNRTI-based regimens is 18% with approximately 4%
failing in the first year [2]. The options for switch depend
on the most recent and past ARV treatments as well as
current and archived resistance results. As baseline geno-
typic testing of reverse transcriptase and protease (not
integrase at the time of writing) is now performed rou-
tinely and is recommended practice, detection of resis-
tance at virological failure is rarely a result of
transmitted drug resistance and failure to adapt first-line
treatment [3,4].
The general principles for the management of individu-
als experiencing virological failure are outlined in Boxes
7.1 and 7.2 as GPPs. Details of typical patterns of HIV
drug resistance found in individuals with a history of or
presenting with virological failure are outlined in
Box 7.3.
7.1.1 Summary of auditable measures
• Record in medical notes of resistance result at baseline
(HIV diagnosis) or at ART initiation (if former not
available) and at first VL >200 copies/mL after prior
virological suppression (or less if genotyping success-
ful) and/or before switch.
• Record in medical notes of adherence assessment and
tolerability/toxicity to ART in individuals experiencing
virological failure or repeated viral blips.
Box 7.1 Best practice for the management of
individuals with suspected or confirmed virological
failure
• Factors affecting adherence and drug exposure,
including tolerability/toxicity issues, drug–drug
interactions/food interactions, ARV potency, signifi-
cant renal/liver disease and mental health/drug
dependency problems are evaluated.
• Resistance testing is performed while on failing
therapy or within 2–4 weeks of discontinuation.
• Past ART and resistance tests are reviewed for
archived mutations.
• Tropism testing is performed if maraviroc is being
considered.
• Intensification with a single additional active ARV
is not recommended.
• Once virological failure is confirmed and preferably
after a resistance-test result is available, the regi-
men is changed as soon as possible to avoid accu-
mulation of resistance mutations.
The choice of the new ART regimen will primarily
depend on the results of resistance testing, prior treat-
ment history and the individual’s preference. Addi-
tional considerations include the results of tropism
and HLA-B*5701 testing, drug–drug interactions/food
interactions, co-morbidities and future therapy
options. The goal of the new combination is to re-
establish a VL <50 copies/mL.
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• Proportion of individuals experiencing virological fail-
ure on current ART regimen.
• Proportion of individuals experiencing virological failure
switched to a new suppressive regimen within 6 months.
• Proportion of individuals on ART with previously doc-
umented HIV drug resistance with VL <50 copies/mL.
• Record of individuals with three-class virological fail-
ure with or without three-class resistance referred/dis-
cussed in multidisciplinary team with expert advice.
7.2 Blips, low-level viraemia and virological failure
Definitions (in the context of continued ART without
changes):
• Virological suppression: achieving and maintaining a
VL level <50 copies/mL.
• Virological failure: incomplete virological response
after commencing treatment or evidence of confirmed
virological rebound to >200 copies/mL.
• Incomplete virological response: two consecutive VL
>200 copies/mL after 24 weeks without ever achieving
VL <50 copies/mL. Consideration of the baseline VL
and regimen should be made as some regimens will
take longer than others to suppress HIV RNA levels. In
individuals with a high baseline viral load (e.g.
>100,000 copies/mL) it may take longer for viral load
to fall below the limit of detection; in contrast, indi-
viduals treated with an integrase inhibitor are more
likely to experience more rapid reduction in viral load.
• Virological rebound: failure to maintain a VL below
the limit of detection (ordinarily <40–50 copies/mL) on
two or more consecutive occasions.
• Low-level viraemia: a persistent VL between 50 and
200 copies/mL.
• Virological blip: after virological suppression, a single
VL between 50 and 200 copies/mL followed by an
undetectable result.
7.2.1 Recommendations
In individuals on ART:
• A single VL 50–200 copies/mL preceded and followed
by an undetectable VL is usually not a cause for clini-
cal concern (GPP). It should necessitate clinical vigi-
lance, adherence reinforcement, check for possible
interactions, and repeat testing within 2–6 weeks
depending on ARV regimen.
• We recommend that a single VL >200 copies/mL is
investigated further, including a rapid re-test +/- geno-
typic resistance test, as it may be indicative of virolog-
ical failure (1C).
• We recommend that in the context of low-level virae-
mia or repeated viral blips, resistance testing be
attempted (1D).
Box 7.2 Best practice for the management of
individuals with three-class virological failure
• In individuals with ongoing viraemia and with few
options to construct a fully suppressive regimen,
referral for specialist advice and/or discussion in a
multidisciplinary team ‘virtual’ clinic is imperative.
• In those with significant resistance, include at least
two and preferably three fully active agents with at
least one active PI/r (preferably darunavir/r) and
one agent with a novel mechanism of action
(preferably integrase inhibitor, CCR5 antagonist or
fusion inhibitor).
• Treatment interruption is not recommended.
Box 7.3 Typical resistance patterns on virological
failure
• No resistance (wild-type virus)
• Lamivudine/emtricitabine resistance (M184V/I) fol-
lowing any first-line therapy, including tenofovir-
DF/emtricitabine or abacavir/lamivudine.
• NNRTI resistance (e.g. K103N, Y181C/I/V or E138K)
and/or lamivudine/emtricitabine resistance (follow-
ing first-line therapy with an NNRTI-based regimen,
including tenofovir-DF/emtricitabine or abacavir/
lamivudine).
• INI resistance (e.g. Y143C/R, Q148R/H or N155H)
and/or lamivudine/emtricitabine resistance (follow-
ing first-line therapy with raltegravir or elvite-
gravir-based regimens, including tenofovir-DF/
emtricitabine or abacavir/lamivudine).
• Extended reverse transcriptase resistance (e.g.
K65R/L74V or thymidine analogue mutations) (fol-
lowing suboptimal regimens/individuals with more
extensive NRTI-based drug history associated with
virological failure).
• Three-class resistance (usually NRTI, NNRTI and PI)
(following multiple failing regimens).
• Limited or no therapeutic options (following multi-
ple failing regimens, including integrase and R5
inhibitors).
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7.2.2 Rationale
7.2.2.1 Blips
Optimal HIV control is ordinarily reflected by complete
virological suppression with an undetectable VL. A viro-
logical blip is variably defined but for the purposes of
these guidelines the definition that has been adopted is a
detectable VL between 50 and 200 copies/mL, which is
preceded by and followed by an undetectable result with-
out any change of therapy. Blips are frequent, tend to
cluster between 50 and 200 copies/mL, (median magni-
tude 79 copies/mL in one study with range between 51–
201 copies/mL) and, when real and not due to laboratory
variability, are short-lived (median 2.5 days, range 2–
11.5 days) [5–7]. Many individuals have at least one blip
at some time [8] and most studies have found no rela-
tionship between isolated blips and adverse outcomes
such as virological failure or emergent resistance [5,9,10].
However some studies have reported an association
between blips and future virological failure [6,11].
There is correlation between level of first detectable
viral load and subsequent virological rebound [8,12]. One
retrospective study of over 3000 individuals found viro-
logical failure (defined as consecutive HIV-1 VL >50
copies/mL measured at least 30 days apart, or any
VL>1000 copies/mL) in 26%; 14% of rebounds were pre-
ceded by transient HIV-1 VL of 50–999 copies/mL but
critically, only transient HIV VL >500 copies/mL corre-
lated with rebound in multivariable analyses [12]. This
concurs with other studies (see Section 7.2.2.2).
VL assay variation and laboratory processing artefacts
account for many blips (i.e. no ‘true’ increase in viral
replication), which partly explains why blips do not
appear to compromise long-term outcomes [9,13,14].
Most individuals with short-lived increases in HIV VL to
<200 copies/mL can be reassured that such events are rel-
atively common and unlikely to presage failure. However,
those with sustained low-level increases in VL (see
7.2.2.2) run a higher risk of virological failure. In keeping
with the DHSS guidance [15], these guidelines [16] define
virological failure as a confirmed viral load >200 copies/
mL, a threshold that eliminates most cases of viral load
blips.
A detectable viral load should prompt a review of
adherence (and reiteration of the importance of full
adherence), as well as looking for any tolerability/toxicity
issues, drug–drug interactions/food interactions, and evi-
dence of archived resistance. A VL result of 50–200
copies/mL preceded and followed by an undetectable VL
should not be a cause of clinical concern. In the context
of repeated blips or persistent low-level viraemia, geno-
typic resistance testing is recommended [11,17].
7.2.2.2 Low-level viraemia
Low-level viraemia (LLV) is observed in up to 8% of indi-
viduals [18] and, when compared to viral suppression to
<50 copies/mL, is associated with an increased risk of
virological failure and resistance [6,19,20]. The likelihood
of re-suppression after LLV is greater for lower magni-
tudes of viraemia [21]. Indeed it is uncertain whether LLV
<200 copies/mL always confers independent risks as vir-
aemia at this level may on occasions reflect assay varia-
tion. LLV is associated with resistance (37% in one study
[20]) that may be associated with LLV magnitude; in one
analysis, maximum VL was higher in those who devel-
oped resistance (368 vs. 143 copies/mL, P = 0.008). In
cohort studies [19] and clinical trials [20], individuals on
PI/r-based ART are more likely to experience detectable
viraemia than those on NNRTI. Many individuals with
LLV have low or undetectable plasma drug levels on
untimed samples underscoring the importance of assess-
ing adherence [22]; we do not however recommend rou-
tine therapeutic drug monitoring in this context (see
Section 6.2.2). LLV is also associated with immune acti-
vation [10]. Low-level antigenic exposure differentially
affects T cell activation and HIV-specific T cell response.
Resistance testing should be considered, where feasible,
in all cases of LLV (viraemia between 50 and 200 copies/
mL) on treatment. Where resistance is detected, regimens
should be modified appropriately. In the absence of clear
data, the writing group believes persistent LLV on a low-
genetic barrier regimen (including NNRTI-based or INI-
based therapy), even in the absence of detectable resis-
tance, warrants prompt regimen change [23,24].
Further evaluation should follow as for that set out in
Box 7.1.
Increasingly, viral load assays have quantification cut-
offs lower than 50 copies/mL. Thus, individuals may have
persistent viraemia >20 or >40 copies/mL but <50 copies/
mL, depending on the assay used. Rates of this ‘very low-
level’ viraemia (VLLV) are as yet unclear. Several studies
have evaluated the risk of virological rebound >50
copies/mL in individuals with detectable viraemia below
50 copies/mL. Results are conflicting [25–27]. In one
study, subjects were stratified based on the Abbott Real-
Time Assay into VL 40–49 copies/mL, <40 copies/mL
with RNA detected, and <40 copies/mL with no RNA
detected [26]. They found that compared to individuals
with VL <40 copies/mL and no detected RNA, having vir-
aemia of 40–49 copies/mL increased the risk of rebound
to >50 copies/mL by 4.67-fold while having detectable
RNA at <40 copies/mL increased the risk by 1.97-fold.
The risk of rebound to >400 copies/mL was increased by
6.91-fold and 2.88-fold, respectively. Other studies have
reported increased risk of rebound to >50, >200, >400
copies/mL but importantly, not >1000 copies/mL or
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higher [28]. The majority of the rebounds >200 copies/mL
were blips and resistance rarely emerged [28], making the
significance of these events unclear.
In the absence of clear data, the writing group believes
that, having assessed factors outlined in Box 7.1, no
treatment modification is required for individuals with
detectable viraemia below 50 copies/mL.
7.2.2.3 Virological failure
In the UK, among drug-experienced individuals who
experience virological failure approximately 70% have
no major resistance mutations on genotypic resistance
testing [29]. Confirmation of virological failure at any
stage should lead to the practice set out in Box 7.1.
7.3 Individuals with no or limited drug resistance
7.3.1 Recommendations
• We recommend for individuals experiencing virological
failure on first-line ART with wild-type virus at base-
line and without emergent resistance mutations at fail-
ure, switch to a PI/r-based combination ART regimen
is the preferred option (1C).
• We recommend individuals experiencing virological
failure on first-line ART with wild-type virus at base-
line and limited emergent resistance mutations (includ-
ing two-class NRTI/NNRTI) at failure, switch to a new
PI/r-based regimen with the addition of at least one,
preferably two, active drugs (1C).
• We recommend individuals experiencing virological
failure on first-line PI/r plus two-NRTI-based regimens,
with limited major protease mutations, switch to a new
active PI/r with the addition of at least one, preferably
two, active agents of which one has a novel mecha-
nism of action (1C).
• We recommend against switching a PI/r to an INI or
NNRTI as the third agent in individuals with historical
or existing reverse transcriptase mutations associated
with NRTI resistance or past virological failure on
NRTIs (1B).
7.3.2 Rationale
7.3.2.1 First-line treatment failure with no resistance
Seventy per cent of individuals have wild-type virus
despite failure of therapy [30–36]. Failure is usually attri-
butable to poor treatment adherence with drug levels that
are both insufficient to maintain VL suppression and
inadequate to select out viral mutations associated with
drug resistance detectable on standard tests. Factors
affecting adherence such as tolerability/toxicity issues,
regimen convenience, drug–food interactions and mental
health/drug dependency problems should be fully
evaluated and where possible corrected before initiation
of the new regimen. Additional adherence support should
be considered and careful discussion with the individual
take place. Therapeutic drug monitoring may be of bene-
fit in individuals to confirm low/absent therapeutic drug
levels and to enable targeted discussion.
A priority question to address was whether individuals
whose NNRTI-based ART had failed without detectable
resistance should receive a PI/r-based regimen.
The absence of detectable resistance mutations does
not exclude the presence of mutations in minor virus
populations, especially with the NNRTIs [9,10,37]. This
may increase the likelihood of subsequent failure if the
same first-line drugs, or drugs in the same class, are pre-
scribed [38,39]. Nevertheless, testing for minority resis-
tance is a specialist test and expert interpretation by a
virologist is essential. There is no indication for routine
minority-species testing for individuals with wild-type
virus and failed therapy.
We recommend that, following the development of
virological failure, or persistent low-level viraemia, on
either an NNRTI or INI-based ART regimen with two
NRTIs and when no resistance mutations are detected, a
switch to a PI/r-based regimen is optimal. This should
lead to virological suppression, and is least likely to
select emergent resistance. Restarting the previous failing
regimen is an alternative option, especially where poor
adherence has been identified as the likely cause and has
been addressed. However, the subject should be moni-
tored carefully and repeat VL performed after approxi-
mately 4 weeks. If there is inadequate virological
response, resistance testing should be performed to detect
any archived resistance. Switching to another NNRTI-, an
INI- or maraviroc- (where CCR5 tropism has been con-
firmed) based ART regimen is the final option but has to
be individualised, including history of virological failure,
and whether further switches in the combination are
occurring. In deciding which option, knowledge as to the
likely cause of virological failure especially the details of
poor adherence are important. In an NNRTI/2NRTI regi-
men, when all three agents have been stopped, the
chances of NNRTI resistance are 12–16% depending on
whether there is a simultaneous or staggered interruption
[40,41]
7.3.2.2 First-line treatment failure with non-nucleoside
reverse transcriptase inhibitor resistance
Up to two-thirds of PLWH with virological failure on an
NNRTI/2NRTI ART combination harbour viruses with
NNRTI and half NRTI mutations at 48 weeks [33–36,42]:
with increasing time, there will be accumulation of resis-
tance mutations that may compromise second-line regi-
mens [43]. The finding of associated NRTI resistance is
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more frequent in those on a thymidine analogue (TA)
backbone than on a non-TA one. Although potential
options for second-line therapy after failure on an
NNRTI-containing regimen include an integrase inhibitor
(raltegravir, elvitegravir or dolutegravir), etravirine or
maraviroc as the third agent, evidence supports the use
of a PI/r. A switch to any PI/r-based regimen should lead
to virological suppression and is unlikely to lead to fur-
ther emergent resistance and should be considered when-
ever possible. Where NRTI resistance has been
documented or likely, the addition of new active NRTIs
or another ARV(s) should be considered in combination
with a boosted PI. The exception to this is when M184V
is present alone, when recycling of NRTIs may be feasi-
ble. Combining raltegravir with a boosted-PI has been
found to be as efficacious as a boosted PI/r regimen with
at least two new or recycled NRTIs [44–46].
There are no direct comparisons of the boosted PIs in
second-line treatment after first-line failure on an
NNRTI-based regimen and choice should be individu-
alised. Sequencing from an efavirenz- or nevirapine-
based regimen to etravirine is not recommended [47]
unless switching to a new combination including a
boosted PI. Switching to an INI (raltegravir, elvitegravir
or dolutegravir) or maraviroc with two active NRTIs is an
option but is also not recommended if there are historical
or existingreverse transcriptase mutations/previous NRTI
virological failure [48].
7.3.2.3 First-line treatment failure on a ritonavir-boosted
protease inhibitor-based two nucleoside reverse
transcriptase inhibitor regimen with or without protease
inhibitor resistance
Less than 1% of individuals with virological failure har-
bour viruses with primary PI mutations and 10–20% NRTI
mutations at 48 weeks, with 75% having wild-type virus
[30,33–35,49,50]. For those whose regimens fail with lim-
ited or no resistance and where adherence is a concern,
remaining on the same regimen may be a reasonable
approach but with close monitoring and adherence sup-
port. However, the individual should be monitored care-
fully and repeat VL performed after approximately
4 weeks. If there is inadequate virological response, resis-
tance testing should be performed to detect any additional
archived resistance. There are currently limited data
regarding the efficacy of switching to another PI/r, NNRTI,
INI or maraviroc-based regimen and again the decision
should individualised. However, switching to an INI, mar-
aviroc or an NNRTI for a person with historical or existing
reverse transcriptase mutations is not recommended
because of an increased risk of virological failure and fur-
ther emergence of resistance [48]. By contrast, because of
the high genetic barrier of PI/r, sequencing to a regimen
that includes a new PI/r is unlikely to lead to further
emergent resistance and is recommended. Where PI/r
mutations exist, darunavir/r is the preferred agent (unless
resistance is likely) and inclusion of an INI, etravirine or
maraviroc (if R5 tropic virus) as one of the additional
drugs should be considered. Where darunavir/r is not suit-
able, depending on susceptibility, alternative PIs such as
tipranavir/r and lopinavir/r may be considered.
7.3.2.4 First-line treatment failure with integrase
inhibitor-based resistance
In studies of na€ıve subjects developing virological failure
on raltegravir or elvitegravir regimens, up to one-half
have been found to harbour viruses with primary inte-
grase mutations and 25% NRTI mutations at 48 weeks:
approximately half have wild-type virus [32,42,49,51]. By
contrast, no resistance has been seen in studies in treat-
ment-na€ıve individuals with dolutegravir/2NRTI-based
regimens [52–54]. Again, there are no data supporting a
switch to PI/r, NNRTI or maraviroc but sequencing to a
new regimen that includes a PI/r is unlikely to lead to
further emergent resistance and is recommended. Simi-
larly, although data from the VIKING-3 study in individ-
uals with pre-existing integrase mutations after failure on
raltegravir or elvitegravir in the context of three-class
resistance and with optimisation of the background regi-
men has shown over half achieve a VL <50 copies/mL
[55], there are no data to support sequencing to dolute-
gravir after first-line failure. Switching to an NNRTI or
maraviroc with two active NRTIs is an option but is also
not recommended in a person with historical or existing
reverse transcriptase mutations or previous NRTI virologi-
cal failure. Individuals experiencing virological failure on
raltegravir or elvitegravir should switch to a new regimen
as soon as possible to reduce the risk of accumulating
resistance mutations that may affect susceptibility to
dolutegravir where success of response has been linked to
the profile and number of resistance mutations.
7.4 Individuals with multiple class virological failure
with or without extensive drug resistance
7.4.1 Recommendations
• We recommend individuals with persistent viraemia
and with limited options to construct a fully suppres-
sive regimen are discussed/referred for expert advice
(or through virtual clinic referral) (GPP).
• We recommend individuals with extensive drug resis-
tance are switched to a new ART regimen containing
at least two and preferably three fully active agents
with at least one active PI/r such as darunavir/r and
one agent with a novel mechanism (an INI, maraviroc
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or enfuvirtide) with etravirine an option based on viral
susceptibility (1C).
• We recommend individuals with extensive drug resis-
tance including reduced darunavir susceptibility
receive dolutegravir as the INI (1C).
• We suggest that consideration on an individual basis
should be given to whether inclusion of NRTIs with
reduced activity on genotypic testing will provide
additional antiviral activity if the regimen includes
three fully active drugs including a boosted PI (2C).
• We recommend all individuals receive intensive adher-
ence support at the start and at regular intervals to
support them on their new ART combination (GPP).
7.4.2 Rationale
The risk of extended three-class resistance, defined as the
absence of any fully active NRTI, NNRTI, or PI, was only
2% among drug-experienced individuals in Western Eur-
ope in 2008 [56]. Ongoing treatment non-adherence
drives further virological failure and addressing this and
supporting strategies to improve adherence are important
considerations before the introduction of any new regi-
men. Until the last 5 years, limited treatment options
have been available for people with HIV who have had
virological failure with the three original classes of HIV
ARV drugs for which many have developed triple-class
resistance. Most of these individuals have received prior
suboptimal ARV treatment, often from the pre-ART era,
or have adhered poorly to multiple regimens and have
accumulated resistance. However, with the introduction
of second-generation inhibitors of reverse transcriptase
and protease that have enhanced activity against resistant
virus as well as agents active through novel sites of
action, the potential for virological control akin to that
achieved in a treatment-na€ıve person has now become a
probability [57,58].
Consequent to more active ARVs and improved strate-
gies of management, there has been substantial improve-
ment in the proportion of people who had virological
response after triple-class virological failure between
2000 and 2009 [59]. However, despite improvements in
treatments, viral load cannot be suppressed in some indi-
viduals. In most, this is a result of poor adherence but
some individuals do have extended drug resistance with
minimal treatment options and achieving viral suppres-
sion becomes increasingly difficult.
The drugs currently being used in triple-class failure
are the boosted PIs (predominantly twice-daily darunavir/
r but also on occasions tipranavir/r), the INIs raltegravir
and dolutegravir, the CCR5 chemokine receptor antago-
nist maraviroc, the NNRTI etravirine, and the fusion inhi-
bitor enfuvirtide. The available data for darunavir/r,
tipranavir/r, raltegravir, elvitegravir, dolutegravir, etravir-
ine and enfuvirtide show that they are most effective
when used with other active drugs to which the virus is
susceptible based on resistance testing and antiviral expe-
rience [60–68]. When used as the only effective agent,
the likelihood of achieving virological suppression is sig-
nificantly reduced and the development of emergent
resistance to the drug greater, and a future opportunity
for constructing an effective regimen is often lost.
In a meta-analysis of 10 trials (excluding dolutegravir)
of subjects with triple-class virological failure and viro-
logical resistance where the study drug was added to
optimised background therapy and compared with pla-
cebo, associations were demonstrated with increased viro-
logical suppression (pooled OR 2.97) and larger CD4 cell
count increases for the active agent [69]. Optimised back-
ground therapy genotypic sensitivity scores (GSSs) were
also associated with larger differences in virological sup-
pression and CD4 cell count increase between the two
groups. In a further non-inferiority study, elvitegravir
was found to be non-inferior to raltegravir when accom-
panied by a boosted PI and a third agent [61].
A non-inferiority trial comparing dolutegravir with ral-
tegravir as the comparator examined those with triple-
class experience but who were na€ıve to integrase inhibi-
tors and had at least two-class resistance and at least one
fully active drug as optimised background therapy [70].
Overall, once-daily dolutegravir was superior to ralte-
gravir at 48 weeks in achieving a VL <50 copies/mL.
However, there was no benefit in individuals who had
not received darunavir/r or had no primary darunavir
mutations.
This supports the use of at least two and preferably
three of these agents in the new regimen and with this
strategy, the goal of an undetectable VL is achievable in
most adherent individuals with multi-regimen failure.
A priority question addressed in this group was around
the net contribution of recycling NRTIs in the context of
virological failure and existing or potential reverse tran-
scriptase mutations. In two studies examining individuals
previously na€ıve to ART for whom an NNRTI/2NRTI regi-
men subsequently failed [44,45], a boosted PI/r regimen
with at least two new or recycled NRTIs was no less effi-
cacious than an NRTI-sparing regimen combining ralte-
gravir with a boosted-PI. Even in the presence of limited
or no predicted activity on the basis of genotypic assay,
NRTIs retained substantial virological activity equivalent
to that of raltegravir without evidence of increased toxic-
ity and therefore may allow the introduction of drugs
known to be active to be deferred. However, NRTI inclu-
sion was demonstrated to achieve improved virological
control over PI/r monotherapy out to 96 weeks [45].
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Once virological suppression has been achieved, the
advantage of retaining NRTIs where partial or complete
resistance is demonstrated is uncertain. A small ran-
domised open study of 90 virologically suppressed indi-
viduals evaluated the safety of withdrawing NRTIs
compared to a control arm of maintaining them in the
context of partial NRTI activity and the presence of at
least two fully active remaining drugs in the regimen. No
significant difference in virological failure between the
arms was observed out to 48 weeks although there were
three cases of virological failure in the simplification arm
and none in the NRTI control arm [71].
A fourth study examined individuals who had triple-
class failure and/or resistance when randomisation to the
new regimen was based on treatment history, tropism
testing and resistance profiles including a choice of NRTIs
[72]. Following randomisation, the subjects then received
the chosen regimen with or without the NRTIs. The
results demonstrated omitting NRTIs was non-inferior to
their inclusion. Of note, subjects in this study received an
average of three active drugs and therefore the lack of
NRTI benefit is not altogether surprising.
A further uncertainty has been whether maintaining
lamivudine/emtricitabine provides clinical benefit
through the replication deficit provided by the M184V
mutation combined with the residual antiviral activity of
lamivudine/emtricitabine [73,74]. Studies using lamivu-
dine monotherapy for individuals developing therapy
failure have shown that those harbouring M184V who
continue on lamivudine maintain lower VLs, have smaller
declines in CD4 cell counts, and rarely develop new
reverse transcriptase mutations [75–77]. In addition, the
presence of M184V mutation enhances in vitro suscepti-
bility to tenofovir-DF and this translates into a significant
HIV RNA response in clinical trials of tenofovir-DF inten-
sification [78,79]. Insufficient data exists to guide recom-
mendations as to whether there are clinical benefits of
trying to maintain M184V by continuing lamivudine/
emtricitabine when switching to new combination ART. It
is the belief of the writing group that any decision should
be individualised.
For those drugs with a novel mode of action (integrase
and fusion inhibitors, and CCR5 antagonists), the absence
of previous exposure indicates susceptibility, although
maraviroc is only active against CCR5-tropic virus. For
darunavir, tipranavir and etravirine, the number and type
of mutations inform the degree to which these drugs are
active [80–82]. The potential for drug–drug interactions is
also important. Etravirine can be paired with darunavir/r
(but not tipranavir/r or dolutegravir) and maraviroc dos-
ing is variable depending on the other drugs in the new
regimen; however, raltegravir and enfuvirtide require no
alteration.
Some individuals can have a successfully suppressive
fully active three-drug regimen constructed without a PI/
r [83]. Nevertheless, where feasible, a PI/r such as daru-
navir/r should be included because of its protective effect
on emergent resistance to the other drugs in the regimen.
Darunavir/r can be given as 800 mg/100 mg once daily
in treatment-experienced individuals without darunavir
resistance-associated mutations [84]. Enfuvirtide is an
option despite the inconvenience of subcutaneous injec-
tion and injection-site reactions. With the availability of
the newer agents, dual PI/r are not recommended [85].
The same principles regarding reviewing adherence,
tolerability/toxicity issues, drug–drug interactions/food
interactions, and mental health/drug dependency prob-
lems apply. Additional adherence support is important in
these individuals as the reason triple-class failure has
occurred often relates to past poor adherence. Addition-
ally, the pill burden is increased and careful discussion
should take place.
7.5 Individuals with limited or no therapeutic options
when a fully viral suppressive regimen cannot be
constructed
7.5.1 Recommendations
• We recommend accessing newer agents through
research trials, expanded access and named individual
programmes (GPP).
• We suggest that consideration, on an individual basis,
should be given to whether inclusion of NRTIs with
reduced activity on genotypic testing will provide
additional antiviral activity – this may well be the case
where it is difficult to construct a regimen with three
fully active drugs including a boosted PI (see Sec-
tion 7.4) (2C).
• We recommend against discontinuing or interrupting
ART (1B).
• We recommend against adding a single, fully active
ARV because of the risk of further resistance (1D).
• We recommend against the use of maraviroc to
increase the CD4 cell count when there is evidence for
X4 or dual tropic virus (1C).
• We recommend that in the context of triple-class fail-
ure and raltegravir/elvitegravir selected integrase resis-
tance, twice-daily dolutegravir should be included as
part of a new regimen where there is at least one fully
active agent in the background regimen (1C).
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7.5.2 Rationale
This situation usually occurs following attempts to
achieve virological suppression for individuals with tri-
ple-class failure with the newer agents, and often indi-
cates adherence issues have not been addressed
successfully or sequential addition of the newer agents
has occurred without incomplete viral suppression and
selection of resistance to the new drug.
There is evidence from cohort studies that continuing
therapy, even in the presence of viraemia and the absence
of CD4 T cell count increases, reduces the risk of disease
progression [86,87] whereas interruption may lead to a
rapid fall in CD4 cell count and a rise in VL [88,89].
Other studies suggest continued immunological and clini-
cal benefits if the HIV RNA level is maintained <10,000–
20,000 copies/mL [90]. Hence, if the CD4 cell count is
well maintained (>200 cells/lL), there is an argument to
continue the failing regimen and not change treatment
until investigational agents are available that can be put
together with drugs, which may have only partial activity
at best, to increase the likelihood of constructing virolog-
ically suppressive and durable regimen options. However,
the potential benefit must be balanced with the ongoing
risk of accumulating additional resistance mutations and
the regimen should be maintained only for the shortest
period possible [91,92].
In general, adding a single, fully active ARV to a
failing regimen is not recommended because of the risk
of rapid development of resistance. However, in indi-
viduals with a high likelihood of clinical progression
(e.g. CD4 cell count <100 cells/lL) and limited drug
options, adding a single drug may reduce the risk of
immediate clinical progression, because even transient
decreases in HIV RNA and/or transient increases in
CD4 cell counts have been associated with clinical ben-
efits [93].
Several studies and an early meta-analysis suggested
that CCR5 receptor antagonists were associated with sig-
nificant gains in CD4 cell counts even in the presence of
C-X-C chemokine receptor type 4 tropic virus. However,
a meta-analysis refuted this finding (P = 0.22) when
comparing with other new drugs [69].
VIKING-3 [55] was a study of individuals who had
received either raltegravir or elvitegravir and had inte-
grase resistance with the majority having additional tri-
ple-class resistance, and where there was at least one fully
active agent to use in the optimised background regimen.
Dolutegravir 50 mg twice daily was added to the failing
regimen and by day 8 and at the time of switching to an
optimised background regimen, the mean drop in VL was
log10 1.43. By week 24, 69% had achieved a VL <50
copies/mL. Response was associated with dolutegravir
susceptibility and was most reduced in those with Q148
with at least two additional resistance mutations.
Where feasible, PLWH should be given the opportunity
to enrol in research studies or expanded access pro-
grammes evaluating investigational new drugs. Drug
availability is difficult to predict, but many second-and
third-generation drugs and are in Phase IIb/III studies
(e.g. maturation inhibitors [94]) and others with novel
sites of action (e.g. CD4 receptor antagonists, etc.) are in
earlier phases of development. Drugs developed for, and
used in, other settings such as pegylated interferon that
have been incidentally demonstrated to decrease VL
should not be used without discussion with experienced
HIV physicians in a multidisciplinary team because data
are either too limited or contradictory.
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8.0 Special populations
8.1 HIV and TB co-infection
This guidance provides a brief summary of the key state-
ments and recommendations regarding prescribing ART
in HIV-positive individuals co-infected with TB. It is
based on the BHIVA guidelines for the treatment of TB/
HIV coinfection 2011 [1], which should be consulted for
further information. The full version of the guidelines is
available on the BHIVA website (www.bhiva.org/TB-HIV-
coinfection-guidelines.aspx).
8.1.1 When to start ART in TB/HIV co infection
8.1.1.1 Recommendations
• We recommend all patients with HIV TB co-infection
start ART (1B).
• We recommend individuals with CD4 cell count <50
cells/lL start ART as soon as TB treatment is tolerated
and wherever possible within 2 weeks (1B).
• We recommend that for individuals with CD4 cell
counts ≥50 cells/lL, ART can be deferred until between
8 and 12 weeks of TB treatment, especially when there
are difficulties with drug–drug interactions, adherence
and toxicities (1B). (Although the data suggest a cut-off
of 50 cells/lL, because of the daily variability in CD4
cell count, a cut-off of 100 cells/lL may be more
appropriate.)
8.1.1.2 Auditable outcome
• Proportion of individuals with CD4 cell count <100
cells/lL started on ART within 2 weeks of starting TB
therapy.
8.1.1.3 Rationale
In TB/HIV co-infection, cohort and randomised trial data
show that the short-term risk of developing further AIDS-
defining events and death is higher if ART is delayed
until after the first 8 weeks of TB therapy has been com-
pleted. In those with a CD4 cell count less than 50 cells/
lL, compared to those with greater than 200 cells/lL,
outcomes were best when ART was started as soon as
practicable and within 2 weeks of initiation of TB therapy
[2–5]. As there is marked intra-individual variability in
CD4 cell count [6], particularly amongst individuals with
low counts, a threshold of 100 cells/lL may be more
practicable. In one study of HIV-associated TB meningitis,
no difference in mortality was shown when starting ART
early or late [7] but we recommend the guidance above
be followed in this situation and consider monitoring of
cerebrospinal fluid (CSF) pressure.
Commencement of ART in individuals with low CD4
cell counts and TB is associated with a large pill burden
and higher rates of toxicity, drug interactions and
immune reconstitution disorders. These issues can be
reduced in individuals with CD4 cell counts of more than
100 cells/lL who can safely delay starting ART until
8 weeks of TB treatment have been completed. Individu-
als with HIV and a CD4 cell count >350 cells/lL have a
low risk of HIV disease progression or death during the
subsequent 6 months of TB treatment, depending on age
and viral load. There are limited data in this subgroup
and another option is for ART to be withheld until the
short-course of TB treatment is completed but with regu-
lar monitoring of CD4 cell count.
8.1.2 What to start in TB/HIV co infection
8.1.2.1 Recommendations
• We recommend efavirenz in combination with tenofo-
vir-DF and emtricitabine as first-line ART (1B) in TB/
HIV co-infection.
• We recommend that when rifampicin is used with efa-
virenz, standard doses of efavirenz are given whatever
the body weight [8] (1B).
• We suggest that raltegravir can be used as an alterna-
tive to efavirenz but should be used with caution (2C).
• We suggest dolutegravir is a possible alternative agent
to raltegravir (for which there is currently little evi-
dence) but the dose should be increased to 50 mg twice
daily (2D).
• We recommend frequent viral load monitoring if INIs
are used (1C).
• We recommend that rifampicin is not used with either
nevirapine or a regimen containing ritonavir or
cobicistat (1C).
• We recommend that where effective ART necessitates
the use of ritonavir or cobicistat, that rifabutin is used
instead of rifampicin (1C).
8.1.2.2 Auditable outcome
• Proportion of patients with active TB on anti-TB ther-
apy started on ART containing efavirenz.
8.1.2.3 Rationale
HIV-related TB should be treated with a regimen includ-
ing a rifamycin for the full course of TB treatment, unless
there is rifamycin resistance or intolerance. Rifamycins
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frequently interact with ARV medications and can be
associated with similar toxicities, notably rash and hep-
atitis. Efavirenz is the preferred third agent for ART dur-
ing TB treatment because of its efficacy in randomised
controlled trials [9].
No weight adjustment of efavirenz dose is required as
a randomised controlled trial has shown that the standard
adult efavirenz dose (600 mg daily) together with two
NRTIs is well tolerated and was efficacious in achieving
complete viral suppression among adults on concomitant
rifampicin-based TB treatment independent of weight [8].
Integrase inhibitors such as raltegravir and dolutegravir
should be prescribed with caution with concomitant
rifampicin as it decreases serum levels of raltegravir by
40–61% and trough levels are still low after doubling the
dose of raltegravir [10]. A Phase 2 trial of standard
(400 mg twice daily) and double dose (800 mg twice
daily) raltegravir has showed acceptable virological out-
comes [11]. Pharmacokinetic data suggest that dolute-
gravir can be used with rifampicin but the dolutegravir
needs to be administered at 50 mg twice daily [12].
When co-administered with rifampicin, concentrations
of standard-dose PIs, with or without ritonavir or cobicis-
tat, are decreased below therapeutic targets, and so can-
not be recommended [13–16]. Changing the dosing of the
PI/r has resulted in increased rates of hepatotoxicity [16–
18]. Elvitegravir cannot be administered with rifampicin
as it requires boosting.
Rifabutin has little effect on the concentrations of PI/r
but rifabutin concentrations are altered when the PI is
taken together with ritonavir or cobicistat. Current rec-
ommendations are to reduce the dose and/or frequency
of rifabutin. Atazanavir/r can be prescribed with rifabu-
tin at a dose of 150 mg thrice weekly. As darunavir/r
also acts as an inducer, rifabutin 150 mg once daily can
be given to reduce the theoretical risk of rifamycin resis-
tance due to a risk of sub-therapeutic rifabutin concen-
trations; this may, however, be associated with increased
side effects [19–21]. Recent data suggest rifabutin at
150 mg/day maintains adequate levels with lopinavir/r
[22]. Therapeutic drug monitoring may be useful in
guiding doses.
Raltegravir and dolutegravir can be used with full-dose
daily rifabutin without any dosage adjustment but there
are few clinical data to support this strategy.
There are few clinical data to support the use of newer
NNRTIs and CCR5 receptor antagonists with rifampicin or
rifabutin. We recommend that physicians who are consid-
ering using these drugs review pharmacokinetic and other
data summarised in the current BHIVA guidelines for
treatment of TB/HIV co-infection [1]. As new anti-tuber-
culous agents become available, drug–drug interactions
and the potential for overlapping toxicities should be
considered when selecting ART.
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8.2 Hepatitis B and C virus co-infection
8.2.1 When to start ART?
Table 8.2.1 Summary recommendations for the treatment
of hepatitis B and C co-infection
HBV requiring
treatment*
HBV not
requiring
treatment
HCV with immediate
plan to start HCV
treatment*
HCV with no
immediate
plan to
start HCV
treatment
Start ART
promptly (1A)
(include
tenofovir-DF
and
emtricitabine)
Start ART (1A)
(include
tenofovir-DF
and
emtricitabine)
Start ART before
HCV treatment
commenced (1C);
acceptable to
defer if CD4 cell
count >500 cells/
µL. Discuss with
HIV and viral
hepatitis specialist
Start ART (1A)
*See BHIVA guidelines for the management of hepatitis
viruses in adults infected with HIV 2013 [1] for indica-
tions to treat hepatitis B and C
8.2.2 Hepatitis B
8.2.2.1 When to start antiretroviral therapy in HBV co-
infection
8.2.2.1.1 Recommendations
• We recommend individuals with HIV and hepatitis B
virus (HBV) co-infection are treated with fully suppres-
sive ART inclusive of anti-HBV active antivirals,
regardless of CD4 cell count (1A).
• We recommend individuals with HIV and HBV co-
infection who have an HBV-DNA ≥2000 IU/mL and/or
evidence of more than minimal fibrosis (Metavir ≥F2)
are treated with fully suppressive ART inclusive of
anti-HBV active antivirals promptly (1C).
8.2.2.1.2 Rationale
Because of the negative effect of immune depletion on
HBV disease progression, the availability of single drugs
with high-level dual HBV and HIV antiviral activity, and
the increased risk of liver-related deaths in individuals
with CD4 cell counts ≥500 cells/lL, co-infected individu-
als with active HBV disease (HBV viral load ≥2000 IU/mL
or Metavir F2 or above) and those with CD4 cell counts
below 500 cells/lL should start ART inclusive of anti-
HBV active antivirals without delay. Individuals with CD4
cell counts ≥500 cells/lL and HBV DNA of <2000 IU/mL,
minimal or no evidence of liver inflammation or fibrosis,
and a repeatedly normal ALT should start ART, regardless
of CD4 cell count, when they are ready to do so. Anyone
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who chooses to defer treatment should be monitored not
less than 6-monthly with HBV DNA and ALT and at least
annually for evidence of fibrosis.
For more information on starting treatment for HBV
please refer to the BHIVA guidelines for the management
of hepatitis viruses in adults infected with HIV [1].
8.2.2.2 What to start in HBV co-infection
8.2.2.2.1 What to start recommendations
• We recommend tenofovir-DF/emtricitabine as part of a
fully suppressive ART combination should be given to
all individuals starting HIV treatment (1C).
• We recommend neither lamivudine nor emtricitabine
be used as the sole active drug against HBV in ART
due to the rapid emergence of HBV resistant to these
agents (1B).
• We recommend lamivudine/emtricitabine may be omit-
ted from the ART regimen and tenofovir-DF be given
as the sole anti-HBV active agent if there is clinical or
genotypic evidence of lamivudine/emtricitabine-resis-
tant HBV or HIV (1D).
8.2.2.2.2 Rationale
Tenofovir-DF, emtricitabine and lamivudine are agents
that have good antiviral activity against both HIV and
HBV. The efficacy of these drugs against HBV has been
assessed in randomised trials extending out to 5 years in
mono-infected patients [1]. They are recommended
agents in these guidelines for the treatment of HIV-1
infection.
All HBV co-infected individuals should commence a
regimen containing tenofovir-DF and emtricitabine.
Hepatitis B treatment options for patients declining ART
are discussed elsewhere [1].
If an individual becomes intolerant or is unable to
commence a tenofovir-DF-containing regimen, entecavir
should be used if it is active. Because entecavir demon-
strates modest anti-HIV activity and can select for HIV
resistance, it should only be used in addition to a fully
suppressive combination ART regimen. No individual co-
infected with HBV should receive a regimen containing
lamivudine or emtricitabine monotherapy as its use may
result in the selection of the YMDD mutation. Tenofovir-
DF resistance has not been clearly described and resis-
tance is unlikely to provide an explanation for most cases
of suboptimal responses to tenofovir-DF. In combination
with lamivudine or emtricitabine, it has been demon-
strated to be effective at suppressing HBV DNA, inducing
HBeAg seroconversion, and reducing the risk of HBV
breakthrough [1].
Where there is primary non-response or partial
response to HBV-active antivirals, or where there is
virological breakthrough, assessment of drug adherence
and HBV resistance testing should be undertaken. Co-
infected individuals who need to start a new ART regi-
men for reasons such as ART virological failure should
ensure that effective anti-HBV therapy is continued in
addition to their new ART regimen. Abrupt withdrawal of
effective treatment may lead to a flare in HBV replication
with liver damage. This may be particularly severe in
patients with cirrhosis.
8.2.3 Hepatitis C
8.2.3.1 When to start antiretroviral therapy in HCV co-
infection
8.2.3.1.1 Recommendations
• We recommend all individuals with HIV and hepatitis
C virus (HCV) co-infection be assessed for HCV treat-
ment (GPP).
• We recommend commencing ART regardless of CD4
cell count (1A).
• We recommend HCV be considered an additional factor
supporting ART in individuals with CD4 > 500 cells/lL
who are uncertain about commencing ART (2C).
• We suggest treating HCV before commencing ART is
an option if there are concerns about drug–drug inter-
actions or adherence (GPP).
8.2.3.1.2 Rationale
HIV has an impact on HCV infection. Individuals with
HCV co-infection have higher HCV viral loads, faster
rates of fibrosis progression and an increased risk of cir-
rhosis compared to those with HCV alone. End-stage liver
disease, hepatocellular carcinoma (HCC) and liver-related
death occur more frequently, at an earlier age, and within
a shorter time period with the risk of liver-related mortal-
ity and HCC increasing as the CD4 cell count declines.
The efficacy of pegylated interferon (PEG-IFN) lessens as
the CD4 cell count declines (PEG-IFN-free regimens seem
to not be affected by HIV markers) and although ART
slows the progression of liver disease it is still likely to
be faster than in HCV mono-infection.
For these reasons, individuals with HIV and HCV infec-
tion with CD4 cell counts <500 cells/lL should start ART;
this should be immediate irrespective of whether HCV
treatment is planned or not. For those with CD4 cell
counts between 350 and 500 cells/lL, initiation of anti-
HCV treatment should be delayed until after start of ART
unless there is an urgent indication for anti-HCV treat-
ment when ART should be commenced as soon as the
patient has been stabilised on HCV therapy.
Individuals with a CD4 cell count greater than 500
cells/lL who defer HCV therapy should be given the
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option to commence ART. If they opt to defer, they
should be monitored closely for HIV or hepatitis C disease
progression, including at least an annual assessment of
liver fibrosis.
8.3.2.2 What to start in HCV co-infection
8.3.2.2.1 Recommendations
• We recommend if individuals are commencing ART,
and direct-acting antivirals are not being consid-
ered, standard first-line ART should be commenced
(GPP).
• We recommend that when direct-acting antivirals are
to be used, there is careful consideration of possible
drug–drug interactions (1C) and current or archived
HIV resistance. All drug interactions should be checked
with an expert source (e.g. www.hiv-druginteraction-
s.org).
• We suggest that if abacavir is to be used with ribavirin,
the ribavirin should be weight-based dose-adjusted
(2C).
8.2.4 Reference
1 Wilkins E, Nelson M, Agarwal K et al. British HIV
Association guidelines for the management of hepatitis
viruses in adults infected with HIV 2013. HIV Med 2013; 14
(Suppl 4): 1–71.
8.3 HIV-related cancers
Please see the BHIVA guidelines for HIV-associated
malignancies 2014 [1] for further details
(www.bhiva.org/malignancy-guidelines.aspx).
8.3.1 When to start ART?
8.3.1.1 AIDS-defining malignancies
Kaposi sarcoma, high-grade B-cell non-Hodgkin lym-
phoma and invasive cervical cancer are all AIDS-defining
illnesses and are thus indications to commence ART
regardless of CD4 cell count or HIV viral load.
• We recommend that all patients with AIDS-defining
malignancies should start ART promptly (1B).
8.3.1.1.1 Kaposi sarcoma (KS)
• We recommend that ART should be started promptly in
all individuals diagnosed with KS (1B).
8.3.1.1.2 Non-Hodgkin lymphoma (NHL)
• We recommend that chemotherapy regimens should be
combined with ART therapy in Burkitt lymphoma and
diffuse large B-cell lymphoma (1B).
• We recommend that all individuals with primary effu-
sion lymphoma (PEL), plasmablastic lymphoma and
primary central nervous system lymphoma should be
started on ART if not already on it (1C).
8.3.1.1.3 Cervical cancer
Women with HIV and cervical intra-epithelial neoplasia
(CIN) 2/3 treated by excisional procedures have a signifi-
cantly higher treatment failure rate than HIV-negative
women. A number of studies show such relapse is less
frequent in the presence of ART, higher CD4 cell counts
or undetectable viral load.
• We suggest that women with CIN2/3 should commence
ART promptly (2B).
• We recommend that all women living with HIV who
are to be treated with chemo-radiotherapy (CRT) for
cervical cancer should start ART promptly (1C).
8.3.1.2 Non-AIDS-defining malignancies
8.3.1.2.1 Anal cancer
• We recommend that all PLWH who are to be treated
with chemo-radiotherapy should start ART (1C).
8.3.1.2.2 Hodgkin lymphoma
• We recommend all PLWH and Hodgkin lymphoma
should receive ART during chemotherapy (1A).
8.3.1.2.3 Other non-AIDS-defining cancers
• We suggest all PLWH who require chemotherapy or
radical radiotherapy should receive concomitant ART
unless contraindicated (level of evidence 2C).
8.3.2 What to start
• We recommend that all potential interactions between
ART, opportunistic infection prophylaxis and cancer
therapy should be considered (1C).
• We suggest that all individuals with non-AIDS-defin-
ing malignancies who are due to start chemotherapy or
radiotherapy should be started on ART unless con-
traindicated (2C).
8.3.3 Opportunistic infection prophylaxis in HIV-
associated malignancy
• We recommend that all individuals with AIDS-defining
malignancies should start ART immediately (1B).
• We suggest that all individuals with non-AIDS-defin-
ing malignancies who are due to start chemotherapy or
radiotherapy should be started on ART immediately
unless contraindicated (2C).
• We recommend that individuals with antibodies
against hepatitis B core antigen (HBcAb) should be
treated with prophylactic antivirals in line with BHIVA
hepatitis guidelines (1B).
8.3.4 Other considerations from the BHIVA guidelines
for HIV-associated malignancies [1]
• We recommend that potential pharmacokinetic interac-
tions between antiretrovirals and systemic anticancer
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therapy are checked prior to administration (with tools
such as: www.hiv-druginteractions.org) (1C).
Significant pharmacokinetic and pharmacodynamic
interactions have been reported between antiretroviral
drugs and systemic anticancer therapies. The mechanisms
of the pharmacokinetic interactions include the inhibition
and induction by antiretroviral agents of enzymes, espe-
cially the cytochrome P450 family and UGT (uridine
diphospho-glucuronosyl transferase) isoenzymes,
involved in the catabolism and activation of cytotoxic
chemotherapy agents. In addition, competition for renal
clearance, intracellular phosphorylation and abacavir
(ATP binding cassette) transporters, has been hypothe-
sised to contribute to these drug interactions [2]. Simi-
larly, pharmacodynamic interactions, in particular
overlapping toxicities between antiretrovirals and sys-
temic anticancer therapy suggest that some drug combi-
nations should be avoided in patients with HIV associated
cancers. Much of the guidance on the use of individual
antiretroviral agents with systemic anticancer therapy
comes from reviews of potential drug interactions rather
than from clinical studies [2–4]. The pharmacokinetic
interactions between antiretrovirals and systemic anti-
cancer therapy are not confined to cytotoxic chemother-
apy agents and extensive interactions with newer
targeted therapies such as imatinib, erlotinib, sorafanib,
bortezomib and temsirolimus have been described [4].
• We suggest avoiding ritonavir (or cobicistat)-boosted
ART in HIV-positive individuals who are to receive
cytotoxic chemotherapy agents that are metabolised by
the CYP450 enzyme system (2C).
In general, clinically important pharmacokinetic drug
interactions with systemic anticancer therapies are most
common with ritonavir-boosted protease inhibitor-based
ART and most clinicians avoid these combinations where
possible. For example, in a cohort study, the rates of sev-
ere infections and severe neutropenia following
chemotherapy for AIDS-related NHL were significantly
higher amongst individuals receiving concomitant PI
(mainly ritonavir boosted) than in those on NNRTI-based
ART regimens, although there was no difference in sur-
vival between the groups [5]. Furthermore, case reports of
clinically significant life-threatening interactions between
ritonavir-boosted-based ART and docetaxel [6], irinotecan
[7], vinblastine [8] have been published.
• We suggest avoiding atazanavir in HIV-positive indi-
viduals who are to receive irinotecan (2C).
The camptothecin cytotoxic agent, irinotecan, is exten-
sively metabolised by UGT1A1 isoenzymes that are
inhibited by atazanavir [9]. In people with Gilbert’s syn-
drome, who have a congenital deficiency of UGT1A1,
irinotecan administration has led to life-threatening toxi-
city [10].
• We suggest switching antiretroviral agents in HIV-
positive patients who are to receive cytotoxic
chemotherapy agents to avoid severe and/or overlap-
ping toxicities (2C).
• Medicines reconciliation prior to chemotherapy to min-
imise potential pharmacokinetic interactions and over-
lapping toxicity should be undertaken by an
experienced pharmacist (GPP).
Both antiretroviral agents and systemic anticancer
therapies have substantial toxicity and where these over-
lap it is likely that the risk of toxicity is greater. For
example zidovudine commonly causes myelosuppression
and anaemia [11], which are also frequent side effects of
cytotoxic chemotherapy and so these should not be co-
prescribed where possible. Similarly, stavudine, didano-
sine and zalcitabine cause peripheral neuropathy [12], a
common toxicity of taxanes and vinca alkaloids, so co-
prescribing should be avoided.
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8.4 HIV-associated neurocognitive impairment
8.4.1. Introduction
With the widespread use of effective combination
antiretroviral therapy, the incidence of severe HIV-asso-
ciated cerebral disease has declined dramatically [1];
however, more subtle forms of brain disease, known as
HIV-associated neurocognitive (NC) disorders are reported
to remain prevalent [2]. This NC deficit may present with
a wide spectrum of clinical symptoms and typically
includes patterns involving ineffective learning and diffi-
culties in decision making or executive function, rather
than pure difficulties in formulating new memory (the
cortical defect typical of Alzheimer’s disease [3]).
Given the changing picture of this disease, a research
nomenclature system has proposed classifying subjects
with abnormal neuropsychological testing results in to
three categories based on symptoms, measured via the
activities of daily living (ADL) scale [2]. Subjects with
abnormal neuropsychiatric testing results, who are other-
wise asymptomatic are classified as having HIV-
associated asymptomatic neurocognitive impairment
(ANI); those who are mildly symptomatic are classified as
having HIV-associated mild neurocognitive disorder
(MND); and those who are severely symptomatic are clas-
sified as having HIV-associated dementia (HAD). The
clinical relevance of ANI, namely asymptomatic subjects
with abnormal results on neuropsychological testing,
remains unclear. Although the presence of ANI has been
linked to progression of symptomatic cognitive impair-
ment in one longitudinal study [4], the presence of other
co-morbidities was also higher in individuals progressing
to symptomatic cognitive impairment. These guidelines
will focus only on symptomatic subjects.
Reports describing rates of NC impairment vary with
some groups describing up to 50% of HIV-positive sub-
jects meeting the above criteria [5]. However, such reports
should be interpreted with caution as asymptomatic sub-
jects are often included and not all reports correct for
effective antiretroviral use. More selective cohorts includ-
ing only aviraemic and symptomatic subjects suggest the
prevalence of MND to be between 6 and 19% [6,7].
Risk factors for the development of NC disorders are
poorly understood and are likely to be multifactorial
including both HIV disease factors [8] and concomitant
diseases [9]. Although it is possible that the choice of
combination antiretroviral therapy subjects receive may
influence NC function, this is a controversial area without
definitive evidence. The following recommendations
apply to individuals with symptomatic HIV-associated NC
disorders.
8.4.2 When to start ART
8.4.2.1 Recommendation
• We recommend individuals with symptomatic
HIV-associated neurocognitive disorders start ART
immediately, irrespective of CD4 cell count (1C).
8.4.2.2 Rationale
Current evidence suggests NC function improves after
commencing antiretroviral therapy for the first time [10]
in both cognitively symptomatic [11] and asymptomatic
[12] subjects. However, these studies have been under-
taken in individuals with other indications to commence
antiretroviral therapy, in general with CD4 cell counts
<350 cells/lL. For subjects with higher CD4 cell counts,
the ongoing neurology substudy in the START study will
prospectively assess NC function in HIV-positive subjects
commencing antiretroviral therapy at an earlier stage of
HIV disease.
In the absence of scientific data, in cognitively symp-
tomatic subjects with higher CD4 cell counts, a recom-
mendation to commence antiretroviral therapy [13] is
first based on the observed improvements in cognitive
function reported in subjects with lower CD4 cell counts
commencing therapy [10]; and secondly, in order to
avoid a future decline in CD4 cell count in such subjects,
given the well-described association between low nadir
CD4 cell count and NC impairment [8].
Sub-optimal adherence to therapy may occur more fre-
quently in subjects with NC impairment, hence adequate
support services to optimise adherence are essential.
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8.4.3 What to start with
8.4.3.1 Recommendations
• We recommend individuals with HIV-associated NC
disorders start standard combination ART regimens
(1C).
• We recommend avoiding efavirenz-containing regi-
mens in individuals with HIV-associated NC disorders
(1C).
8.4.3.2 Rationale
8.4.3.2.1 Including zidovudine in a regimen
Although during the earlier years of antiretroviral ther-
apy, clear benefits on cerebral function of individual
antiretroviral drugs such as zidovudine were reported
[14] and the benefits of combination therapy overall
described [10], data are sparse regarding any differences
in these benefits between individual agents or combina-
tions. Within cohort studies, the use of the NRTI class
within antiretroviral regimens has been associated with a
reduced risk of severe HAD [15] compared to the use of
other regimens; however, the confounders of a cohort
study limit the interpretation of these data.
The improvements in NC function observed with zido-
vudine monotherapy [14] and the greater improvements
in NC function observed with a zidovudine-containing
quadruple nucleoside regimen compared to other ART
regimens [16], raise the possibility of selecting a zidovu-
dine-containing antiretroviral regimen in subjects with
NC impairment. Conversely, a lack of comparator data for
zidovudine monotherapy, and potential toxicities arising
from zidovudine use, may limit the relevance of these
data. Of note, further to peripheral toxicities, which are
well described with zidovudine use, biomarker data sug-
gest there may also be central nervous system toxicities
associated with the use of zidovudine-containing regi-
mens [17].
8.4.3.2.2 Considerations regarding the CPE score
Recently, attempts have been made to establish a rela-
tionship between cognitive function and CNS antiretrovi-
ral drug delivery based on an antiretroviral scoring
system known as the clinical penetration effectiveness
(CPE) score [18]. The CPE score aims to rationally score
the cerebral effects of individual antiretroviral agents.
However the system is predominantly designed around
pharmacokinetic modelling rather than pharmacodynamic
endpoints such as data describing changes in NC func-
tion. Studies that have assessed the correlation between
the CPE scores of antiretroviral regimens with NC func-
tion report conflicting findings with some cohorts report-
ing a positive association [19,20] while other cohorts
describe a negative association [21,22]. In a small
prospective study no differences in cognitive outcomes
were observed in subjects randomised to higher CPE
score-containing antiretroviral regimens compared to
standard therapies [7]. Given these factors, the CPE score
should not influence therapeutic decisions in subjects
with NC impairment commencing antiretroviral therapy.
8.4.3.2.3 Considerations for not including efavirenz
Although early neuropsychiatric side effects are widely
recognised and common with efavirenz therapy, recent
reports have highlighted concerns regarding poorer NC
function being associated with efavirenz-containing regi-
mens. One cohort study has reported poorer cognitive
function to be associated with current efavirenz use [23].
Two randomised controlled studies have assessed the cog-
nitive effects of efavirenz. In one small study, improve-
ments in cognitive function were poorer in those
allocated efavirenz-containing therapy [16] and in a
recent large study, the time to development of cognitive
impairment was quicker in subjects allocated efavirenz-
containing therapy [24]. Antiretroviral switch studies
have reported improvement in central nervous system
symptomatology when modifying therapy to non-efavir-
enz-containing regimens [25,26]. Conversely, virological
efficacy and low pill burden are key components of ther-
apies for individuals with NC impairment. We therefore
only recommend avoiding efavirenz-containing regimens
in situations where other regimens with comparable viro-
logical efficacy and convenience can be initiated.
8.4.3.2.4 Novel antiretroviral strategies
Novel antiretroviral strategies, including protease-inhibi-
tor monotherapy continue to be of interest given the
potential for reduced long-term toxicities. Concerns
have been raised regarding the cerebral effects of PI
monotherapy [27], and dual therapies [28]. Such con-
cerns are based on the hypotheses that novel strategies
comprise only one or two effective antiretroviral agents
that may not adequately suppress ongoing HIV replica-
tion in sanctuary sites such as the CNS and are based
on pharmacokinetic modelling that suggests not all PIs
have optimal penetration across the blood–brain barrier
[18]. Furthermore, isolated cases describing the evolu-
tion of CNS disease in previously stable HIV-infected
subjects receiving PI monotherapy have been reported
[29].
One study was specifically designed to assess the cere-
bral effects of lopinavir/ritonavir monotherapy [30].
However, this study was terminated early due to a lack of
efficacy in the plasma compartment. Although cases of
CNS disease were reported within this study, such results
must be interpreted with caution as virological endpoints
in the plasma compartment were not met and therefore
such cases may be driven by poor antiretroviral efficacy
per se, rather than distinct CNS disease itself [31].
© 2016 British HIV Association HIV Medicine (2016), 17 (Suppl. 4), s2--s104
BHIVA guidelines for the treatment of HIV-1 positive adults with ART s77
In the PIVOT study, the largest study of PI monother-
apy to date, no differences in cognitive-function parame-
ters were noted over 5 years of follow up in subjects
randomised to continue standard therapy versus com-
mence PI monotherapy [32]. Although reassuring, this
study did not recruit neurologically symptomatic subjects
and only enrolled subjects on antiretroviral therapy with
undetectable viraemia.
Given the above theoretical concerns regarding the
CNS activity of novel antiretroviral strategies, and for the
majority of HIV-infected subjects it may be possible to
select other antiretroviral regimens, we suggest this
approach is currently avoided where possible in neuro-
logically symptomatic subjects.
8.4.4 Continuing or worsening NC impairment despite
ART
8.4.4.1 Recommendations
Best practice management should include (GPP):
• Reassessment for confounding conditions.
• Assessment of CSF HIV RNA and genotyping of CSF
HIV RNA.
• In subjects with detectable CSF HIV RNA, modifica-
tions to antiretroviral therapy should be based on
paired plasma and CSF genotypic results.
8.4.4.2 Rationale
Several randomised controlled studies, assessing both
intensification of antiretroviral therapy with new
antiretroviral agents [7,33] and with adjunctive therapies
[34–37] have been published. Unfortunately, none of
these studies describes improvements in cognition subse-
quent to the study interventions. Without evidence-based
interventions, a best-practice approach based on the cur-
rent literature is outlined.
As HIV-associated NC disorders are diagnoses of exclu-
sion, re-evaluation of subjects with ongoing NC impair-
ment despite antiretroviral therapy for confounding
conditions, with expert input from other clinical specialties
such as psychiatry, neurology and neuropsychology is rec-
ommended and, where possible, input from an HIV-neurol-
ogy service. Given the presence of non-infectious co-
morbidities reported to be a risk factor for NC impairment
[9], such conditions should be optimally managed.
Assessment of CSF HIV RNA and genotypic analysis of
CSF RNA may be useful tools in the management of sub-
jects with ongoing NC for the following reasons: first,
data from cohorts of untreated HIV-positive subjects
would suggest CSF HIV RNA to be greater in subjects
with HIV-associated dementia and cognitive decline [38–
40] and therefore suppression of CSF HIV RNA may be
beneficial for cognitive function. Secondly, in subjects
with ongoing NC impairment, higher degrees of genetic
diversity between HIV viral strains in the CSF and plasma
compartment may exist [41], even in subjects with unde-
tectable plasma HIV RNA [4,42]. Therefore, assessment
for CSF HIV resistance is justified in order to tailor
antiretroviral therapy.
Management should also involve consideration of any
potential antiretroviral toxicities and side effects. For
instance, a trial of switching from an efavirenz-contain-
ing regimen to an alternative may be considered along
with any potential disadvantages of treatment modifica-
tions as outlined above.
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8.5 Chronic kidney disease
8.5.1 When to start antiretroviral therapy
8.5.1.1 Recommendations
• We recommend individuals with HIV-associated
nephropathy (HIVAN) start ART immediately irrespec-
tive of CD4 cell count (1C).
• We recommend individuals with end-stage kidney dis-
ease who are suitable candidates for renal transplanta-
tion start ART immediately (1C).
8.5.1.2 Auditable outcome
• Proportion of individuals with HIVAN started on ART
within 2 weeks of diagnosis of chronic kidney disease.
8.5.1.3 Rationale
HIV-associated nephropathy (HIVAN) is typically encoun-
tered in black individuals with advanced immunodefi-
ciency and detectable HIV RNA levels [1–5]. The use of
ART has been associated with a decline in the incidence
of HIVAN in cohort studies [5], with renal histological
improvement in case reports [6], and with (a trend
towards) delayed progression to end-stage kidney disease
in case series [2–4,7]. For those with HIVAN, ART is indi-
cated and should be commenced as soon as possible.
PLWH at risk of HIVAN: black individuals with an esti-
mated glomerular filtration rate (eGFR) <60 mL/min/
1.73 m2 and/or significant proteinuria (>500–1000 mg/
24 h) should be referred to a nephrologist for a kidney
biopsy. Those found to have HIVAN should be offered
ART irrespective of CD4 cell count.
Immunodeficiency is a potent risk factor for chronic
kidney disease (CKD) [8,9]. Although HIV replication is a
risk factor for immune-complex kidney disease [2], and
HIV replication, immune activation and inflammation
may contribute to kidney disease progression [10,11],
several antiretrovirals have been associated with eGFR
decline [8,12]. There are currently insufficient data to
suggest that HIV-positive individuals with, or at risk of
CKD benefit specifically from earlier ART initiation.
Kidney transplantation is an attractive treatment
modality for subjects with end-stage kidney disease.
Excellent results have been achieved in those with sup-
pressed HIV RNA levels and CD4 cell counts >200 cells/
lL [13–15].
8.5.2 What to start
8.5.2.1 Recommendations
• We recommend against the use of ARV drugs that are
potentially nephrotoxic in individuals with stages 3–5
CKD if acceptable alternative ARV agents are available
(GPP).
• We recommend dose adjustment of renally cleared
ARV drugs in individuals with reduced renal function
(GPP).
8.5.2.2 Auditable outcomes
• Proportion of individuals with CKD stages 3–5 on
ARVs who commence tenofovir-DF disoproxil fumarate
or atazanavir and a record of the rationale.
• Record in medical notes of calculated dose of renally
cleared ARVs where eGFR <50 mL/min/1.73 m2.
8.5.2.3 Rationale
There are no data from randomised controlled trials to
inform ART decisions in individuals with CKD. Obser-
vational data suggest that kidney function improves in
those with impaired kidney function following initiation
of ART [16,17]. Nonetheless, an eGFR <60 mL/min/
1.73 m2 at baseline is a powerful predictor of kidney
disease progression [18,19], and ART with nephrotoxic
potential (tenofovir-DF [20–22] and atazanavir [22–24])
is probably best avoided in this population. Although
lopinavir/r has also been associated with an increased
risk of CKD in some cohorts [12,25], there are no
reports of lopinavir/r-induced renal injury in HIV-posi-
tive patients.
In individuals with impaired renal function, specific
ARV drugs (all NRTIs except abacavir) may need to be
dose-adjusted [26] (see also Appendix 5 Considerations
for antiretrovirals in renal impairment). Impaired survival
has been reported with ART prescription errors in indi-
viduals undergoing dialysis [27]. While the Cockcroft–
Gault formula has been most widely used in clinical prac-
tice to assess the need for dose reduction of renally
cleared drugs in individuals with impaired renal function,
recent data suggest that the eGFR (CKD-EPI equation)
provides superior concordance with measured GFR in
HIV-positive individuals and better performance in terms
of correct dosing of tenofovir-DF and emtricitabine [28].
Hence, we recommend dose adjustment of renally cleared
NRTIs in those with eGFR <50 mL/min/1.73 m2, and of
maraviroc eGFR <80 mL/min/1.73 m2 if co-administered
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with ritonavir or cobicistat. For further information and
advice, the reader should refer to the summary of product
characteristics for each ARV.
8.5.3 Need to switch
8.5.3.1 Recommendations
• We recommend against continued use of tenofovir-DF
and atazanavir in individuals with worsening renal
function who have developed or are approaching CKD
stages 3–5 if acceptable alternative ARV agents are
available (GPP).
8.5.3.2 Auditable outcome
• Number of individuals with CKD stages 3–5 on ARVs
who continue tenofovir-DF or atazanavir with eGFR
<60 mL/min/1.73 m2 and a record of the rationale.
8.5.3.3 Rationale
The risk of CKD is increased with older age, reduced
estimated glomerular filtration rate (eGFR), hyperten-
sion, diabetes and with exposure to tenofovir-DF
[8,9,11,29,30], atazanavir [8,30] and lopinavir [8,12].
Tenofovir-DF has been associated with reductions in
eGFR [8,12,29,30], accelerated decline in eGFR [9,31],
acute renal failure [32], tubulo-interstitial nephritis [22],
renal tubular dysfunction [33,34] and Fanconi syn-
drome [20,21]. Atazanavir has been associated with
reductions in eGFR (when co-administered with tenofo-
vir-DF) [35], nephrolithiasis and tubulo-interstitial
nephritis [22–24,33,36,37]. To date, no cases of lopina-
vir-associated kidney injury have been reported [38]. Of
note, several antiretroviral drugs, including rilpivirine,
ritonavir, cobicistat, raltegravir and dolutegravir inhibit
tubular creatinine excretion and thereby result in mod-
est plasma creatinine elevations and corresponding
reductions in eGFR. These changes in eGFR typically
manifest within 2–4 weeks, are non-progressive there-
after, not associated with haematuria, proteinuria or
glycosuria, and do not reflect clinically significant kid-
ney injury [38].
The nephrotoxic potential of tenofovir-DF appears to
be increased, and the reversibility of eGFR decline fol-
lowing tenofovir-DF discontinuation diminished, in those
with eGFR <90 mL/min/1.73 m2 [9,26,27]. Similarly, the
nephrotoxic potential of atazanavir may be increased
among individuals with eGFR <60 mL/min/1.73 m2 [23].
As CKD is a risk factor for death, AIDS, and non-AIDS
events including end-stage kidney disease and cardiovas-
cular disease events [18,39,40], we recommend that the
need for continued tenofovir-DF and atazanavir use is
reviewed in individuals with worsening renal function
who have developed or who are approaching CKD stages
3–5.
8.5.4 References
1 Post FA, Campbell LJ, Hamzah L et al. Predictors of renal
outcome in HIV-associated nephropathy. Clin Infect Dis
2008; 46: 1282–1289.
2 Foy MC, Estrella MM, Lucas GM et al. Comparison of risk
factors and outcomes in HIV immune complex kidney
disease and HIV-associated nephropathy. Clin J Am Soc
Nephrol 2013; 8: 1524–1532.
3 Bige N, Lanternier F, Viard JP et al. Presentation of HIV-
associated nephropathy and outcome in HAART-treated
patients. Nephrol Dial Transplant 2011.
4 Atta MG, Gallant JE, Rahman MH et al. Antiretroviral
therapy in the treatment of HIV-associated nephropathy.
Nephrol Dial Transplant 2006; 21: 2809–2813.
5 Lucas GM, Eustace JA, Sozio S et al. Highly active
antiretroviral therapy and the incidence of HIV-1-associated
nephropathy: a 12-year cohort study. AIDS 2004; 18: 541–
546.
6 Winston JA, Bruggeman LA, Ross MD et al. Nephropathy
and establishment of a renal reservoir of HIV type 1 during
primary infection. N Engl J Med 2001; 344: 1979–1984.
7 Szczech LA, Gupta SK, Habash R et al. The clinical
epidemiology and course of the spectrum of renal diseases
associated with HIV infection. Kidney Int 2004; 66: 1145–
1152.
8 Mocroft A, Kirk O, Reiss P et al. Estimated glomerular
filtration rate, chronic kidney disease and antiretroviral drug
use in HIV-positive patients. AIDS 2010; 24: 1667–1678.
9 Campbell LJ, Ibrahim F, Fisher M et al. Spectrum of chronic
kidney disease in HIV-infected patients. HIV Med 2009; 10:
329–336.
10 Choi AI, Shlipak MG, Hunt PW et al. HIV-infected persons
continue to lose kidney function despite successful
antiretroviral therapy. AIDS 2009; 23: 2143–2149.
11 Kalayjian RC, Lau B, Mechekano RN et al. Risk factors for
chronic kidney disease in a large cohort of HIV-1 infected
individuals initiating antiretroviral therapy in routine care.
AIDS 2012; 26: 1907–1915.
12 Ryom L, Mocroft A, Kirk O et al. Association between
antiretroviral exposure and renal impairment among HIV-
positive persons with normal baseline renal function: the D:
A: D study. J Infect Dis 2013; 207: 1359–1369.
13 Stock PG, Barin B, Murphy B et al. Outcomes of kidney
transplantation in HIV-infected recipients. N Engl J Med
2010; 363: 2004–2014.
14 Gathogo EN, Hamzah L, Hilton R et al. Kidney
transplantation in HIV-positive adults: the UK experience.
International journal of STD & AIDS 2014; 25: 57–66.
15 Gathogo E, Jose S, Jones R et al. End-Stage Kidney Disease
and Kidney Transplantation in HIV-Positive Patients: An
Observational Cohort Study. J Acquir Immune Defic Syndr
2014; 67: 177–180.
© 2016 British HIV Association HIV Medicine (2016), 17 (Suppl. 4), s2--s104
BHIVA guidelines for the treatment of HIV-1 positive adults with ART s81
16 Reid A, Stohr W, Walker AS et al. Severe renal dysfunction
and risk factors associated with renal impairment in HIV-
infected adults in Africa initiating antiretroviral therapy.
Clin Infect Dis 2008; 46: 1271–1281.
17 Kalayjian RC, Franceschini N, Gupta SK et al. Suppression
of HIV-1 replication by antiretroviral therapy improves
renal function in persons with low CD4 cell counts and
chronic kidney disease. AIDS 2008; 22: 481–487.
18 Ibrahim F, Hamzah L, Jones R et al. Baseline Kidney
function as predictor of mortality and kidney disease
progression in HIV-positive patients. Am J Kidney Dis 2012;
60: 539–547.
19 Ryom L, Mocroft A, Kirk O et al. Predictors of advanced
chronic kidney disease and end-stage renal disease in HIV-
positive persons. AIDS 2014; 28: 187–199.
20 Woodward CL, Hall AM, Williams IG et al. Tenofovir-
associated renal and bone toxicity. HIV Med 2009; 10: 482–
487.
21 Zimmermann AE, Pizzoferrato T, Bedford J et al. Tenofovir-
associated acute and chronic kidney disease: a case of
multiple drug interactions. Clin Infect Dis 2006; 42: 283–
290.
22 Schmid S, Opravil M, Moddel M et al. Acute interstitial
nephritis of HIV-positive patients under atazanavir and
tenofovir therapy in a retrospective analysis of kidney
biopsies. Virchows Arch 2007; 450: 665–670.
23 Rockwood N, Mandalia S, Bower M et al. Ritonavir-boosted
atazanavir exposure is associated with an increased rate of
renal stones compared with efavirenz, ritonavir-boosted
lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25:
1671–1673.
24 Couzigou C, Daudon M, Meynard JL et al. Urolithiasis in
HIV-positive patients treated with atazanavir. Clin Infect Dis
2007; 45: e105–108.
25 Mocroft A, Lundgren JD, Ross M et al. Development and
validation of a risk score for chronic kidney disease in HIV
infection using prospective cohort data from the D:A: D
study. PLoS Med 2015; 12: e1001809.
26 Brennan A, Evans D, Maskew M et al. Relationship between
renal dysfunction, nephrotoxicity and death among HIV
adults on tenofovir. AIDS 2011; 25: 1603–1609.
27 Jose S, Hamzah L, Campbell LJ et al. Incomplete
reversibility of estimated glomerular filtration rate decline
following tenofovir disoproxil fumarate exposure. J Infect
Dis 2014; 210: 363–373.
28 Okparavero AA, Tighiouart H, Krishnasami Z et al. Use of
glomerular filtration rate estimating equations for drug
dosing in HIV-positive patients. Antivir Ther 2013; 18:
793–802.
29 Scherzer R, Estrella M, Li Y et al. Association of tenofovir
exposure with kidney disease risk in HIV infection. AIDS
2012; 26: 867–875.
30 Rasch MG, Engsig FN, Feldt-Rasmussen B et al. Renal
function and incidence of chronic kidney disease in HIV
patients: a Danish cohort study. Scand J Infect Dis 2012;
44: 689–696.
31 Nishijima T, Kawasaki Y, Tanaka N et al. Long-term
exposure to tenofovir continuously decrease renal function
in HIV-1-infected patients with low body weight: results
from 10 years of follow-up. AIDS 2014; 28: 1903–1910.
32 Herlitz LC, Mohan S, Stokes MB et al. Tenofovir
nephrotoxicity: acute tubular necrosis with distinctive
clinical, pathological, and mitochondrial abnormalities.
Kidney Int 2010; 78: 1171–1177.
33 Dauchy FA, Lawson-Ayayi S, de La Faille R et al. Increased
risk of abnormal proximal renal tubular function with HIV
infection and antiretroviral therapy. Kidney Int 2011; 80:
302–309.
34 Labarga P, Barreiro P, Martin-Carbonero L et al. Kidney
tubular abnormalities in the absence of impaired glomerular
function in HIV patients treated with tenofovir. AIDS 2009;
23: 689–696.
35 Daar ES, Tierney C, Fischl MA et al. Atazanavir plus
ritonavir or efavirenz as part of a 3-drug regimen for
initial treatment of HIV-1. Ann Intern Med 2011; 154:
445–456.
36 Rakotondravelo S, Poinsignon Y, Borsa-Lebas F et al.
Complicated atazanavir-associated cholelithiasis: a report of
14 cases. Clin Infect Dis 2012; 55: 1270–1272.
37 Hamada Y, Nishijima T, Watanabe K et al. High incidence
of renal stones among HIV-infected patients on ritonavir-
boosted atazanavir than in those receiving other protease
inhibitor-containing antiretroviral therapy. Clin Infect Dis
2012; 55: 1262–1269.
38 Yombi JC, Pozniak A, Boffito M et al. Antiretrovirals and
the kidney in current clinical practice: renal
pharmacokinetics, alterations of renal function and renal
toxicity. AIDS 2014; 28: 621–632.
39 Choi AI, Li Y, Deeks SG et al. Association between kidney
function and albuminuria with cardiovascular events in
HIV-infected persons. Circulation 2010; 121: 651–658.
40 Mocroft A, Ryom L, Begovac J et al. Deteriorating renal
function and clinical outcomes in HIV-positive persons.
AIDS 2014; 28: 727–737.
© 2016 British HIV Association HIV Medicine (2016), 17 (Suppl. 4), s2--s104
s82 BHIVA Writing Group
8.6 Cardiovascular disease
8.6.1 Introduction
Cardiovascular disease (CVD) is a significant contributor
to the excess risk of non-AIDS disease and death in HIV-
positive populations [1–12] but there are encouraging
recent data that rates of ischaemic stroke [10] CVD-
related deaths may be falling over time [13].
The heightened risk of CVD has been attributed to
intersecting epidemics of smoking and inactivity, an age-
ing HIV-positive cohort, increased prevalence of surro-
gate markers of CVD (such as dyslipidaemia), HIV
viraemia, immune dysfunction and the pro-inflammatory
state associated with HIV infection. HIV-related factors
may be only partially mitigated by ART and may be
exacerbated by effects not fully explained by conven-
tional CVD risk factors. Therefore it would be wrong to
presume that interventions proven to reduce CVD risk in
the general population will have the same magnitude of
effect in HIV-positive individuals [14].
8.6.2 Definition and assessment of cardiovascular disease
risk
8.6.2.1 Recommendation
• We suggest that the coronary heart disease (CHD) risk
of HIV-positive adults of white ethnicity is estimated
as per the BHIVA guidelines for the routine investiga-
tion and monitoring of adult HIV-1-infected individu-
als (www.bhiva.org/monitoring-guidelines.aspx) (2C).
8.6.2.2 Rationale
For the purposes of these guidelines, individuals with an
elevated CVD risk are those with established atheroscle-
rotic CVD; diabetes mellitus type 1 over the age of
40 years; an estimated glomerular filtration rate (eGFR)
<60 mL/min/1.73 m2 and/or albuminuria; familial hyper-
cholesterolaemia; a high calculated CVD risk [15].
NICE recommends the QRISK2 calculator for the Eng-
lish population [15] but this may not be appropriate for
HIV-positive people. Myocardial infarction (MI) rates in
HIV-positive people parallel those predicted by the Fram-
ingham risk equation [16] but in US males it underesti-
mated risk of MI by 50% [9] while in D:A:D it appeared
to overestimate risk in never smokers but underestimate
it in women, diabetics and ex-smokers [17]. Although
absolute risk of CVD is lower in HIV-positive women
than men, the risk relative to HIV-negative women is sig-
nificantly higher [6,18,19]. The D:A:D calculator more
accurately predicted CHD risk among European/Australian
HIV-positive populations, defining 5-year risk as low
(<1%), moderate (1–5%), high (5–10%) and very high
(>10%) risk of CHD over a 5-year period [18]. However, it
has not been externally validated, it lacked power to
predict risk beyond 5 years and was underpowered for
women and those of non-white ethnicity [20]. There is no
HIV-specific CVD risk calculator for those of non-white
ethnicity; one approach might be to use the QRISK2 equa-
tion and apply a correction for HIV status of 1.6 [21] (2D).
Whether HCV co-infection is a CVD risk is unclear;
with studies reporting a significant association for acute
coronary events [22] and stroke [23], a non-significant
trend for MI [23], or no association [24].
8.6.3 Issues related to antiretroviral therapy
Two randomised controlled trials have included CVD end-
points: SMART and START; although neither were pow-
ered specifically for a CVD endpoint. In the SMART trial,
fewer major CVD events were observed in the viral sup-
pression arm but the difference was not statistically sig-
nificant [25]. In a post hoc analysis, neither viral load or
CD4 cell count was significantly associated with CVD
events [26]. In START, rates of CVD events were similar
in both arms; but this was a young population with a
low CVD risk (median 10-year Framingham risk 1.9%)
[27]. START does not answer the question of whether
HAART affects CVD incidence in those at high CVD risk.
A meta-analysis showed an increased risk of CVD events
in those on ARVs compared to treatment-na€ıve individuals,
but the source studies pre-dated currently available PIs
[21]. Several observational studies have examined changes
in rate of cardiovascular events in HIV-positive popula-
tions but there are no clear protective effects for those on
ART, those with a nadir or current CD4 cell count >350
cells/lL or suppressed viraemia (Table 8.6.1).
Carotid intima-media thickness (cIMT) may be increased
in HIV-positive adults [28–30] although this has not been a
consistent finding [31]. Non-calcified coronary arterial pla-
ques were more prevalent on CT in HIV-positive partici-
pants in the MACS cohort than among controls and severe
coronary arterial stenosis was associated with lower nadir
CD4 cell count and longer duration of ART, but not current
viral load or CD4 cell count [32].
8.6.4 What to start
8.6.4.1 Recommendations
In individuals with a high CVD risk:
• We recommend use of alternatives to fosamprenavir/r
(1C) and lopinavir/r (1C)
• We suggest that atazanavir/r is the preferred PI (2C).
• We suggest avoiding abacavir (2C) and maraviroc if an
acceptable alternative is available.
• First-line ARV therapy with tenofovir-DF plus (emtric-
itabine or lamivudine) with dolutegravir or raltegravir
or rilpivirine (if viral load <100,000 copies/mL) are
preferred first line regimens (GPP).
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• Adverse effects on lipid parameters should be consid-
ered when selecting ARVs (GPP).
8.6.4.2 Rationale
No randomised controlled trial has been powered for the
CVD risk associated with the use of individual ARVs and
a history of CVD may be an exclusion criterion. A sys-
tematic review found a harmful association with recent
PI exposure and cumulative increased risk per year of
exposure to lopinavir/r and indinavir [33]. Early studies
of PI exposure and risk of MI gave conflicting results,
some reporting an increased risk [3,34] while others did
not [2,35,36]. The D:A:D cohort, with longer follow-up,
reported an increasing risk of MI with years of PI expo-
sure (independent of measured metabolic effects) [37].
Cumulative exposure to indinavir and lopinavir/r were
associated with increasing risk of MI [38]. Case–control
studies reported similar associations for PIs [39], lopina-
vir/r [8,40] and fosamprenavir/r [40] although not all
controlled for established risk factors [8]. Others found no
association between PI use and cerebrovascular events
[10,11]. No association has been reported between use of
atazanavir/r and risk of MI [41] but there were insuffi-
cient data to include darunavir/r in this analysis. Prelimi-
nary data showed slower progression of cIMT in subjects
on atazanavir/r versus darunavir/r (raltegravir was inter-
mediate) [42] but whether this equates to a reduction in
CVD risk is unclear.
Four papers analysing pooled data from clinical trials
of abacavir [43–45] found no excess risk of MI for aba-
cavir, but there was significant overlap in the source
Table 8.6.1 Summary of observational studies reporting CVD risk independently associated with low CD4 cell count (cells/µL), elevated plasma
viral load (copies/mL) or ARV exposure.
Type of
study Year Outcome
First CD4 cell
count (cells/
µL)
Nadir CD4 (cells/
µL)
Recent CD4
cell count
(cells/µL)
First viral
load
(copies/mL)
Current VL
(copies/mL) ARVs Ref
Co 1993–
2001
Composite6 — — — — — ↔ [35]
Co 1999–
2002
MI No No — No — ↑ [58]
Co 1997–
2003
Death — — — — — ↑ [59]
Co 1996–
2004
Death — — — — — ↓ [60]
Co 2000–
2004
Admission/death — — No ↔ [61]
CC 2000–
2006
MI — Yes5 No 5 — Yes 5 — [39]
Co 1998–
2008
MI — No <200 No No ↔ [62]
RCT 2000–
2008
Composite1 — — No — — — [63]
Co 2000–
2008
MI or
Composite4
— — No — No — [17]
Co 2002–
2009
Composite7 <350 No — No — ↔ [64]
CC 2002–
2009
Composite7 No No <350 & 350–
500
No — ↔ [64]
Co 2003–
2009
MI No — <200 No >500 — [9]
Co 2003–
2010
Composite2 — — No — Prolonged
rebound
>400
— [65]
Co 1996–
2011
Ischaemic stroke No No <200 — No No
effect
[10]
Co 1996–
2011
MI — <200 & 200- 5003 No — No No
effect
[66]
Co: cohort study; CC: case-control study; RCT: randomised controlled trial.
1MI, stroke, and invasive coronary procedures.
2MI, stroke, and invasive coronary procedures, other fatal heart/vascular events and sudden death.
3Relative to HIV-negative population; the risk for 350–500 cells was not reported.
4MI, stroke, and invasive coronary procedures, other fatal heart/vascular events, sudden death and carotid endarterectomy.
5Lower nadir increased risk on univariate analysis only.
6Admissions with MI, angina, stroke, subarachnoid haemorrhage, transient cerebral ischaemia, invasive coronary procedures, other fatal cardiovascular
events.
7MI, stroke, coronary artery disease, angina and peripheral arterial disease.
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trials for these analyses. In contrast a post hoc analysis of
the SMART study did find an increased risk (although use
of abacavir was not randomised) [46]. A systematic
review of CVD events associated with ARVs did find a
harmful association with recent abacavir exposure [33].
Two cohorts found a strong association between recent
abacavir use and MI [38,47,48] while others did not [49–
51]; all were limited in their ability to adjust for presence
of CVD risk factors. One case–control study, which did
not adjust for important CVD risk factors, did find an ele-
vated risk of MI associated with abacavir use [8] but
others did not [38,52]. Cerebrovascular events were more
common in individuals exposed to abacavir in two cohort
studies [11,51] while another found a protective effect
[49]. These divergent findings may be explained by
unmeasured confounding, detectable viraemia (in studies
of people commencing ARVs), younger participants in tri-
als than in cohorts, lack of power in trials due to smaller
number of MI events and differences in case ascertain-
ment [14,53]. In view of the uncertainty about the safety
of abacavir in individuals with a high CVD risk, we sug-
gest the use of alternative agents where possible.
In the MOTIVATE studies for treatment-experienced
individuals, coronary artery disease events were only
reported in the maraviroc arm (11 in 609 patient years ver-
sus 0 in 111 patient years in controls). No such signal was
found in the MERIT study for treatment-na€ıve individuals.
Maraviroc has also been associated with postural hypoten-
sion when used at higher than recommended doses in
healthy volunteers; people with a history of postural
hypotension, renal impairment or taking antihypertensive
agents may be at increased risk [54]. In view of the limited
data available, caution should be exercised in the use
of maraviroc in individuals with a high CVD risk and
use of alternative agents, where possible, considered.
For those with a high CVD risk, the newer agents
dolutegravir, raltegravir and rilpivirine offer advantages
including their lack of effect on plasma lipids (Table 8.6.2)
and absence of interactions with statins. However, as yet,
there is insufficient experience in their use to exclude an
unexpected adverse CVD risk.
The effects on plasma lipids reported in randomised
controlled trials of first line antiretrovirals are shown in
Table 8.6.2. The studies were not usually powered for
these comparisons and it is not possible to make cross-
study comparisons are as they differed in their popula-
tions, baseline lipids and length of follow up. Low high-
density lipoprotein (HDL) cholesterol is a common finding
in untreated HIV infection and may persist on ART [55].
Several studies report increases in both total and HDL
cholesterol and no effect on total cholesterol (TC)/HDL
ratio. However, HDL rises due to ARVs may not have the
same cardioprotective effect as untreated HDLs as they
may be larger, less stable and bind less readily to hepato-
cyte receptors relative to HIV-negative normolipaemic
subject [56]. Moreover other pharmacological interven-
tions to increase HDL in HIV-negative individuals on sta-
tins have failed to reduce CVD risk [57]. Therefore,
favourable changes in HDL on treatment should be inter-
preted cautiously.
Table 8.6.2 Increases in plasma lipids in randomised controlled trials of first-line antiretroviral exposure. Where a significant difference was
reported, the mean is shown in mmol/L.
Class Drug Versus TC LDL HDL TC/HDL TGs Ref
NRTIs ABC/3TC TDF/FTC 0.88 vs. 0.49 0.44 vs. 0.16 0.31 vs. 0.23 NS NS [67]
NNRTIs EFV 600 mg EFV 400 mg NS NS NS — NS [68]
NVP EFV NS NS 0.3 vs. 0.2 3.7 vs. 4.2 0.0 vs. 0.2 [69]
RPV Baseline NS NS — NS NS [70]
RPV EFV 0.03 vs. 0.63 0.04 vs. 0.31 0.07 vs. 0.24 NS 0.01 vs. 0.16 [70]
ETV EFV 0.4 vs. 1.0 0.2 vs. 0.6 0.1 vs. 0.3 NS — [71]
PIs ATV/r EFV 0.25 vs. 0.49 0.18 vs. 0.54 0.10 vs. 0.2 0.1 vs. 0.3 NS [72]
ATV/r NVP 0.51 vs. 0.63 0.27 vs. 0.39 0.10 vs. 0.25 0.13 vs. 0.24 0.31 vs. 0.00 [73]
ATV/r RAL ATV/r 0.31 higher ATV/r 0.18 higher NS — ATV/r 0.32 higher [74]
DRV/r ATV/r NS NS NS — NS [74]
DRV/r RAL DRV/r 0.28 higher DRV/r 0.18 higher NS — DRV/r 0.27 higher [74]
LPV/r ATV/r 0.93 vs. 0.52 NS NS — 0.62 vs. 0.16 [75]
INI RAL Baseline NS NS NS NS [76]
RAL Baseline NS NS 0.16 NS [74]
RAL EFV 0.26 vs. 0.85 0.15 vs. 0.42 0.11 vs. 0.26 NS 0.03 vs. 0.42 [77]
ELV/c EFV 0.41 vs. 0.52 0.31 vs. 0.47 0.16 vs. 0.23 NS NS [78]
ELV/c ATV/r NS NS NS NS NS [79]
DTG Baseline NS NS NS NS NS [76]
CCR5 MVC EFV 0.05 vs. 0.93 0.23 vs. 0.54 0.18 vs. 0.35 — 0.10 v 0.24 [80]
NS: difference not statistically significant; ATV/r: atazanavir/ritonavir; DRV/r: darunavir/ritonavir; EFV: efavirenz; ELV/c: elvitegravir/cobicistat; ETV:
etravirine; LPV/r: lopinavir/ritonavir; NVP: nevirapine; RAL: raltegravir; RPV: rilpivirine; RPV/TDF/FTC: rilpivirine/tenofovir-DF/emtricitabine.
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8.6.5 Modification of CVD risk factors
8.6.5.1 Recommendations
In patients with a high CVD risk:
• We recommend that traditional modifiable risk factors
should be minimised; smoking cessation is of critical
importance (1A).
• We suggest that that this should include switching
ARVs to those with a more favourable metabolic pro-
file but only where there is minimal risk of treatment
failure (2C).
8.6.5.2 Rationale
There is no clinical trial evidence that interventions to
modify plasma lipids will reduce CVD risk in the context of
HIV disease. However, there is good evidence from the gen-
eral population that reducing total and LDL cholesterol
reduces CVD risk. Switching ARVs in order to contribute to
this reduction may therefore be beneficial. Switch studies
that have reported lipid outcomes are shown in Table 8.6.3
and the same caveats apply as to Table 8.6.2 (above). In
addition, the data are expressed in terms of the mean;
whether the effect size differed in those with the most
adverse lipid profiles is not reported. A switch should only
be considered if the risk of treatment failure is minimal.
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8.7 Women
8.7.1 Introduction
The following guidance considers issues concerning the
initiation and choice of ART for HIV-positive women
who are not currently pregnant. For guidance on the
management of pregnancy in HIV-positive woman please
refer to the BHIVA guidelines for the management of HIV
infection in pregnant women [1].
There are few specific data on ART treatment in
women other than in pregnancy. Data available are lar-
gely from a meta-analysis, post hoc analyses or derived
from cohort studies. The majority of the randomised clin-
ical trial data on ART comes from studies that have
enrolled mostly male subjects. If randomised controlled
trials do enrol women, the numbers are often too small to
draw significant gender-based conclusions.
Approximately one-third of people diagnosed with, and
accessing care, for HIV in the UK are women [2]. The major-
ity are of childbearing age but the age range is increasing,
adding the complexity of menopause and its sequelae to the
management of HIV-positive women. Many HIV-positive
women in the UK are of African heritage and face overlap-
ping challenges to their health and well being [3].
Women’s experience of HIV reflects multiple social and
cultural influences, which when combined with sex-spe-
cific biological factors influence individual responses to
HIV.
8.7.2 When to start
8.7.2.1 Recommendations
• We recommend therapy-na€ıve HIV-positive women
who are not pregnant start ART (see Section 4) (1A).
8.7.2.2 Auditable measure
• Proportion of HIV-positive women not on ART.
8.7.2.3 Rationale
Gender differences in HIV viral load and CD4 cell count
at different stages of infection have been observed [4] but
have not been consistently associated with long-term
clinical outcomes for HIV-positive women. Based on cur-
rent data, the indications for starting ART do not differ
between non-pregnant women and men.
Gender-specific socio-economic and cultural factors
may impact on women’s ability to access care and man-
age their medication, compromising their ability to initi-
ate and adhere to therapy, necessitating support from the
multidisciplinary team.
8.7.3 What to start
8.7.3.1 Recommendations
• There are insufficient data to support specific recom-
mendations for HIV-positive non-pregnant women. We
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therefore recommend therapy-na€ıve HIV-positive
women start ART as per general guidelines (1A).
• We recommend both HIV-positive women of childbear-
ing potential and healthcare professionals who pre-
scribe ART are conversant with the benefits and risks
of ARV agents for both the health of the HIV-positive
woman and for that of an unborn child (GPP).
• We recommend that potential pharmacokinetic interac-
tions between ARVs, hormonal contraceptive agents
and hormone replacement therapy are checked before
administration (GPP).
8.7.3.2 Rationale
8.7.3.2.1 Efficacy
There are few data to guide prescribing of initial ART
specifically for women as no randomised controlled trial
in PLWH starting ART has been powered to detect gen-
der-based differences in efficacy. From the limited data
available, virological outcomes within clinical trial set-
tings generally appear to be no different between men
and women.
WAVES is a women-only randomised controlled trial
that demonstrated superiority of Stribild over Truvada +
atazanavir/ritonavir; this was driven predominantly by
more adverse event discontinuations in the atazanavir
arm [5].
A meta-analysis of FDA registrational randomised con-
trolled trials analysed data from 20,328 HIV-positive
individuals participating in 40 trials for 16 ARVs. Overall,
20% of study participants were women and there were no
clinically or statistically significant differences in week
48 virological outcomes between men and women [6].
A subanalysis of a randomised controlled trial compar-
ing atazanavir/r and lopinavir/r in ART-na€ıve individuals
of whom 31% were women, showed comparable virologi-
cal efficacy at week 96 between the two treatment arms
in women [7], although virological response rates were
lower in women when compared with men.
In a study comparing atazanavir/r and efavirenz in 1857
ART-na€ıve individuals of whom 17% were women, female
gender was associated with increased virological failure on
atazanavir/r compared with efavirenz [8]. No difference
was seen with efavirenz between men and women.
The efficacy and tolerability of raltegravir were similar
in men and women at 48 weeks in one cohort of treat-
ment-na€ıve and -experienced individuals [9]. First-line
rilpivirine-based ART showed no difference in rates of
virological suppression at 48 and 96 weeks between men
and women, but the number of women included was low
and the study was not designed to investigate gender dif-
ferences [10,11].
Cohort studies in the UK have reported similar virolog-
ical outcomes during the first year of treatment in
heterosexual men and women [12]. An Italian cohort
study reported no significant effect of gender on clinical
progression or the risk of developing a clinical event
[13]. Data from Spain, which included both na€ıve and
ARV-experienced women, showed them with similar viro-
logical responses to men [14].
HIV-positive women starting ART should use ARVs
from the list of preferred and alternative drugs outlined
in Section 5.1.
8.7.3.2.2 Toxicity, discontinuation and adherence
Several studies have suggested that gender may influence
the frequency, presentation and severity of selected ART-
related adverse events. Although data are limited, evidence
exists that phamacokinetics for some ART drugs may differ
between men and women because of factors such as body
weight, plasma volume, plasma protein levels, cytochrome
P450 activity and drug transporter function [15,16].
Adverse events and treatment discontinuations within
ART clinical trials and cohort studies published between
2002 and 2007 have been systematically reviewed. The
overall event rate is often the same but the adverse event
profile may be different. Women were reported to be
more likely than men to experience ART-related lipodys-
trophy, rash and nausea, and to discontinue therapy [4].
Data from the USA have shown that women are more
likely than men to discontinue ART for poor adherence,
dermatological symptoms, neurological reasons, constitu-
tional symptoms and concurrent medical conditions [16].
UK cohort data found that 11.4% of men compared with
19.3% of women discontinued treatment in the first year
of ART (adjusted relative hazard 0.72, 95% CI 0.63–0.83,
P = 0.0001) [12].
An randomised controlled trial of atazanavir/r versus
lopinavir/r found worse virological outcomes in treatment-
na€ıve women compared with men due to higher discontinu-
ation rates in women in both treatment arms [7]. CNS side
effects of varying severity can occur with efavirenz, partic-
ularly at the initiation of therapy. This may be partly
explained by the greater efavirenz exposure associated with
a CYP2B6 variant, more commonly found in Africans and
African Americans [17]. In the UK population, this is of par-
ticular relevance to women, the majority of whom are of
African ethnicity. Nevirapine-associated rash occurs more
frequently in women than men [18]. Hepatotoxicity associ-
ated with nevirapine is more common in women with a
CD4 cell count >250 cells/lL, or elevated baseline transami-
nases, and restricts women’s use of the drug [19].
Compared with HIV-positive men, women are more
likely to experience an increase in central fat with ART
[20]. Women have an increased risk of osteopenia/osteo-
porosis, especially after menopause, and this risk may be
exacerbated by HIV and ART [21].
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At present, these observed differences do not require
women-specific recommendations.
A systematic review of studies on gender and ART
adherence published between 2000 and 2011 in the
resource-rich world concluded that overall reported adher-
ence is lower in women than men [22]. However, of over
1000 studies initially identified for review, only 44 had
adequate data on gender to allow any comparisons to be
made. The authors identified the particular factors for lower
adherence in women were depression, lack of supportive
interpersonal relationships, young age, drug and alcohol
use, black ethnicity, ART of six or more pills per day,
higher numbers of children, self-perception of abdominal
fat gain, sleep disturbances and increased levels of distress.
8.7.3.2.3 Fetal safety
All women of child-bearing potential should be offered
reproductive health counselling including advice around
conception, prevention of mother-to-child transmission
and contraception as a component of routine medical
care [23].
Concerns about potential fetal toxicity of ARVs have
influenced prescribing practice in HIV-positive women.
Of note, other than zidovudine in the third trimester, no
ARV drug has a licence for use in pregnancy.
Pregnancy in women living with HIV who are already
on effective therapy is increasing; 80% of HIV-positive
pregnant women in the UK in 2013 were diagnosed
before the current pregnancy, of whom 60% were already
on ART at conception [24]. Where newer drugs are avail-
able, women are conceiving on these agents, with zido-
vudine now rarely used as first-line therapy for adults.
European cohort data comparing pregnancies that were
managed with zidovudine-containing regimens vs. those
without zidovudine found no difference in risk of detect-
able viral load at delivery, mother-to-child transmission
or congenital abnormality when comparing zidovudine-
sparing with zidovudine-containing ART [25].
The most robust data on teratogenicity and first trime-
ster ART exposure are from the Antiretroviral Pregnancy
Registry (APR) [26]. This international prospective report-
ing system records rates of congenital birth defects in
babies born to women with exposure to ART at any stage
of pregnancy. Approximately 200 or more reports need
to be received for a particular compound before data are
reported for that compound by the APR. There are now
over 200 prospective reports in the APR of first trimester
exposure for abacavir, atazanavir, darunavir, efavirenz,
emtricitabine, lamivudine, lopinavir, nevirapine, ritonavir,
tenofovir-DF and zidovudine. No signal of increased risk
of congenital abnormality has been demonstrated, and a
greater than twofold higher rate than in the general pop-
ulation has been excluded. There are, so far, fewer than
200 prospective reports for raltegravir and rilpivirine
within the APR and hence reports on these agents are not
yet available.
Despite previous concerns over the safety of efavirenz
based on preclinical animal studies and retrospective case
reports in human subjects, the current data do not provide
evidence of excess teratogenicity above the expected base-
line for infants exposed to efavirenz in the first trimester.
Sufficient numbers of first-trimester exposures of efavir-
enz have been monitored to detect at least a twofold
increase in risk of overall birth defects within the APR, and
no such increases have been detected to date [26].
Data from Co^te d’Ivoire found no significant increased
risk of unfavourable pregnancy outcome in women with
first-trimester exposure to efavirenz compared with nevi-
rapine [27]. A systematic review and meta-analysis of
observational cohorts carried out in 2010 [28] and further
updated in 2014 [29] reported birth outcomes among
women exposed to efavirenz during the first trimester. No
increased risk of overall birth defects among the babies
of women exposed to efavirenz during the first trimester
compared with exposure to other ARV drugs was found.
The prevalence of overall birth defects with first-trimester
efavirenz exposure was similar to the ranges reported in
the general population.
A review of live births to women with HIV in a large
unselected UK population between 1990 and 2007 found
no increased risk of abnormalities in infants exposed to
efavirenz in the first trimester, providing further reassur-
ance that ART in utero does not pose a major risk of fetal
anomaly [30]. Mathematical modelling using North
American cohort data has demonstrated a theoretical loss
of life expectancy in women who delay efavirenz at initi-
ation of ARV [31].
Based on current evidence, efavirenz can be initiated
in women of childbearing potential, can be continued in
women who conceive on the drug and commenced in
pregnancy but the data should be discussed in detail with
the individual woman when deciding on her preferred
treatment regimen. Given that no ARV drug is licensed
for use in pregnancy apart from zidovudine in the third
trimester, a discussion regarding the potential unknown
long- and short-term effects on an unborn child should
be had with any woman of childbearing potential who
commences any ARV drug regimen. Further details can
be found in the BHIVA pregnancy guidelines [1].
8.7.3.2.4 Hormone interactions
Significant pharmacokinetic and pharmacodynamic inter-
actions have been reported between ARV drugs and hor-
monal agents and these should be taken into consideration
when selecting an ART regimen for women using hor-
monal contraception. We suggest prescribers refer to the
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summary of product characteristics for individual drugs,
the University of Liverpool drug interaction website
(www.hiv-interactions.org) or specialist pharmacy advice
within their unit/network. Importantly, in addition to cases
of contraceptive failure in women on efavirenz-based ART
using a contraceptive implant [32], there are now pharma-
cokinetic data to show a significant reduction in levonor-
gestrel concentrations in women on efavirenz [33].
8.7.3.2.5 Menopause
As the average age of the female population living with
HIV increases, more women with HIV reach menopause.
The menopause raises a number of issues for women with
HIV including menopausal symptoms and increased risk
of co-morbidities such as cardiovascular disease and
osteoporosis. Although data are limited, there is no evi-
dence that menopause has a direct effect on ART efficacy.
A subanalysis of responses to ART among a small num-
ber of treatment-na€ıve pre- and post-menopausal women
in a US study found no significant differences in the
immunological and virological responses between the two
groups [34].
8.7.4 HIV-positive women experiencing virological failure
There is very little evidence to guide prescribing ART in
HIV-positive women experiencing virological failure on
ART, with most studies recruiting approximately 10% of
women. One study investigating darunavir/r in ART-
experienced individuals recruited a large proportion of
women and was powered to show a difference in virolog-
ical efficacy between men and women; this showed
higher discontinuation rates among women than men,
with nausea being cited as a particular problem, but
overall there was no difference in virological efficacy
[35]. A further study has reported similar efficacy and
tolerability of raltegravir in ART-experienced HIV-posi-
tive women [9].
In HIV-positive women experiencing virological failure
on ART, the same principles of management and recom-
mendations apply as per HIV-positive men experiencing
virological failure.
8.7.4.1 Psychosocial issues
Women living with HIV often have additional vulnerabil-
ity factors (psychological and social) that can impact on
access to and engagement with care and also adherence
and treatment outcomes. Such factors include HIV-related
stigma, low socio-economic status, culturally defined
gender roles and high levels of intimate partner violence.
There are higher levels of mental health problems, partic-
ularly depression and post-traumatic stress disorder, in
women living with HIV compared with the general popu-
lation, which can also adversely affect outcomes. These
issues need to be recognised and identified by healthcare
professionals and effective interventions offered, in par-
ticular psychosocial and peer support
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8.8 Mental health
8.8.1 Recommendations
• What to start: we recommend that efavirenz-contain-
ing regimens be avoided in individuals with a current
or past history of depression, psychosis, suicidal idea-
tion or attempted suicide, or at risk of self-harm (1C).
• Switching therapy: we recommend that efavirenz-con-
taining regimens should be switched promptly to a
viable alternative when PLWH present with depression,
psychosis, suicidal ideation or attempted suicide, or
self-harm (1C).
8.8.2 Rationale
The summary of product characteristics for efavirenz cau-
tions that ‘patients with a prior history of psychiatric dis-
orders appear to be at greater risk of serious psychiatric
adverse reactions’ with a 2% risk of both severe depres-
sion and suicidal ideation [1]. In view of this warning,
studies exploring efavirenz and risk of depression or sui-
cide are inevitably subject to confounding by indication
because individuals most at risk will not have been pre-
scribed efavirenz or entered into randomised controlled
trials where one of the arms included efavirenz.
A meta-analysis of four ACTG randomised controlled
trials with efavirenz in one arm included 5000 PLWH [2].
‘Suicidality’ was defined as suicidal ideation or attempted
or completed suicide. The incidence of suicidality was 8/
1000 patient years (PY) on efavirenz versus 4/1000 PY
without it (hazard ratio [HR] 2.3, P = 0.006). Rates of
attempted or completed suicide were 3 versus 1/1000 PY
respectively (HR 2.6, P = 0.065) (eight suicides on efavirenz
versus one on comparator regimens). In a secondary analysis
of time to suicidal ideation, attempted or completed suicide,
or death attributed to substance abuse, homicide or accident
(to capture possible under-reporting of suicide) rates were 9
and 5/1000 PY respectively (HR 2.06, P = 0.007). Incidence
of suicidality did not change over length of follow up indi-
cating that risk could emerge at any time.
A number of studies has examined the CNS effects of
switching away from efavirenz but did not detect an
effect on mood. However, it should be noted that the
event rates reported in the ACTG studies were low (<1/
100 patient years) and hence the switch studies may have
lacked power to detect an effect on mood.
A small Spanish cohort study found no association
between depression or suicide attempts and efavirenz but
the overall event rate was unusually low and the propor-
tion of those with depression prescribed efavirenz was
half that in the main cohort suggesting significant con-
founding by indication (i.e. less use of efavirenz where
there was a concern about mental health) [3]. No associa-
tion was found in the D:A:D cohort study between efavir-
enz use and suicide as a reported cause of death, possibly
for similar confounding reasons [4].
A retrospective analysis performed by the manufacturer
of the US Food and Drug Administration’s Adverse Event
Reporting System (FAERS) (i.e. post-marketing surveil-
lance data of spontaneous adverse-event reports from
PLWH and healthcare workers) explored the ratio of
observed to expected number of suicidality events (O/E
ratio) for a variety of drugs [5]. Such data are inevitably
subject to reporting biases that make them difficult to
interpret. They concluded that there was no association
between efavirenz exposure and suicidality because the
O/E ratio did not exceed the arbitrarily predefined thresh-
old of 2, while it did for other drugs with a known sui-
cide risk (e.g. fluoxetine). Nevertheless, the O/E ratio for
efavirenz was significantly higher than for other ARVs,
which is consistent with an increased risk for this drug.
Completed suicide must rank among the most adverse
possible effects of any treatment. Unfortunately, depres-
sion is under-recognised by PLWH and poorly elicited by
healthcare workers [6]. The above data support a precau-
tionary stance of avoiding efavirenz in those with a cur-
rent or past history of depression or suicidality.
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8.9 Adolescents
Adolescents include all young people defined by WHO as
those aged between 10 and 19 years, and young adults
aged between 20 and 24 years [1]. For the purposes of
these guidelines we will consider adolescents living with
HIV by route of transmission: perinatally acquired HIV
infection (PaHIV) and behaviourally infected HIV (BaHIV).
For behaviourally infected young people >18 years of
age, the management of their HIV disease and associated
considerations should be in accordance with BHIVA adult
guidelines. The management of adolescents aged less than
16 years within paediatric care should be in accordance
with Children’s HIV Association (CHIVA) guidelines
(http://www.chiva.org.uk/professionals/health/guidelines/
index.html) and the Paediatric European Network for
Treatment of AIDS (PENTA) treatment guidelines [2].
There are limited data and no randomised controlled trial
data on long-term complications of PaHIV and ART
exposure throughout physical maturity, and the following
recommendations are based on pragmatic and good clini-
cal practice.
8.9.1 Recommendations for management of HIV, ART
and sexual and reproductive health specifically for
perinatally acquired HIV
• Avoid standard-dose (600 mg) efavirenz-based regimens
in any young person <50 kg, with any history of mental
health or psychological or neurocognitive problems.
Young adults and adolescents (YAA) represent a
uniquely vulnerable group who have poor health out-
comes compared to younger children and older adults liv-
ing with the same condition. This is a feature of lifestyle,
adolescent behaviour, lack of engagement in health care
services and primary care and often lack of social support.
As such, any service providing care for YAA living with
HIV must offer appropriate youth-centred services, with
an open-door policy, non-judgemental care provision, and
opening hours consistent with educational commitments.
8.9.2 UK epidemiology for YAA with PaHIV
With antiretroviral therapy, the significant fall in HIV-
associated morbidity and mortality for perinatally
infected children has resulted in increasing numbers
entering adolescence and transitioning towards adult ser-
vices [3,4]. Over 90% of children diagnosed in the UK
and reported to the National study of HIV and Pregnancy
(NSHPC) are followed prospectively in the Collaborative
HIV Paediatric Study (CHIPS; www.chipscohort.ac.uk).
Data to the end of March 2014 shows that of 1873 chil-
dren ever reported, 595 have already transferred to adult
services, at a median age of transfer of 17 years [4].
8.9.3 Transition process for YAA with PaHIV
Transfer to adult services had been associated with
increased disease-related morbidity and mortality for a
wide range of chronic conditions of childhood prompting
the National Service Framework (NSF) 2004 to set stan-
dards for the healthcare of young people [5]. Subsequently
the Department of Health (DH) has produced a wealth of
resources to guide the development of transitional care
services [6–8]. Transition is defined as ‘A planned, pur-
poseful, process resulting in the point of transfer to adult
services’. While several different transition models are
described, the key to a successful transition is communi-
cation, forward planning and maintaining a young per-
son-centred approach [9,10]. HIV-specific transitional care
guidance is available through CHIVA and set within the
CHIVA Standards (www.chiva.org.uk) [10].
8.9.4 UK epidemiology for YAA with BaHIV
Public Health England (PHE) surveillance data reveals
736/5,967 (12%) of new HIV diagnoses in 2013 were in
young adults aged 15–24 years. Routes of transmission
were: sex between men (n = 462); heterosexual contact
(n = 152); and IVDU (n = 4). Both the proportion and
number of new HIV diagnoses among MSM aged 15–
24 years have increased over the past decade, from 8.7%
(250/2,420) in 2004 to 16% (460/2,950) in 2013 [11].
8.9.5 Neurocognitive impact of HIV in YAA
The neurocognitive impact of living with HIV on the
developing adolescent brain is becoming increasingly
apparent, with poorer school performance, increased psy-
chiatric diagnoses and particular difficulties in executive
functioning for PaHIV YAA [12–14]. Recent data suggest
that more than two-thirds of treatment-na€ıve BaHIV YAA
meet criteria for a diagnosis of HIV-associated neurocog-
nitive disorders, with the most common deficits being in
memory and fine motor skills [15]. Optimising virological
control with further investigation and referral to expert
neurology HIV clinics is recommended.
8.9.6 Antiretroviral therapy
8.9.6.1 Adherence
Poorer adherence to ART is reported with increasing age
in childhood and in behaviourally infected young people
when compared to older adults [16–18]. PHE data sug-
gests that those aged 15–24 with a CD4 cell count <350
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cells/lL are less likely than older adults to be on treat-
ment and for those taking ART, YAA are less likely to
achieve viral suppression when compared to older adults
[11]. YAA initiating ART therefore require additional
adherence support with specific guidance for this popula-
tion available in the HIV Young Peoples Network Adher-
ence Guidelines (www.hypnet.org.uk). We suggest starting
with a robust regimen initially (once daily boosted PI
plus two NRTIs) then switching to an NNRTI or integrase
single fixed-dose combination for those who achieve
virological suppression. PI-based regimens are now the
recommended first-line therapy for adolescents in the
2014 PENTA guidelines [2] .
8.9.6.2 Toxicity
At standard dose, increased efavirenz toxicity associated
with higher plasma drug levels has been reported in
adults of lower weight, a weight band that will include
many YAA [19]. Additionally, reports of a potential
increase in suicidal risk associated with efavirenz is of
concern in an age group where suicide is the second most
common cause of death in the UK, and is more than three
times as common in males when compared to females
[20]. Rates of suicide more than double in those aged
20–24 compared with those aged 15–19; suicide has been
reported in PaHIV YAA in adult care [20,21].
Prolonged ART exposure resulting in lipodystrophy, at
an age when body image is so important, may have a
negative impact on psychological wellbeing and a poten-
tial impact on adherence to ART [22,23]. Growth stunting
and delayed puberty in PaHIV YAA and dermatological
conditions associated with HIV, such as scaring from
shingles, molluscum contagiosum and seborrhoeic der-
matitis may further exacerbate issues around body image
and self worth. Multidisciplinary team assessment that
includes dietetics, psychology and where appropriate,
referral for cosmetic surgery is required.
8.9.6.3 Resistance
Within the UK paediatric cohort, half of the PaHIV adoles-
cents are triple-class experienced and almost one-tenth of
the young people who have ever started ART are off therapy
due to poor adherence/refusal, with the risk of onward
transmission of resistant virus to partners and offspring
[22,24]. Decisions as to the optimal regimen for YAA require
an individualised approach considering baseline resistance,
predicted adherence, substance use and mental health.
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8.10 Bone disease and antiretroviral therapy
8.10.1 Introduction
HIV-1-positive individuals have lower bone mineral den-
sity (BMD) at the femoral neck, hip and lumbar spine. In a
recent study, HIV was found to be an independent risk
factor for low BMD [1]. Among HIV-positive individuals,
25–33% of those >40 years had osteopenia and 5–9% had
osteoporosis [1]. Low BMD in HIV-positive individuals has
been associated with traditional risk factors (i.e. older age,
female gender, low BMI, smoking and glucocorticoids –
including use as part of the treatment of Pneumocystis jir-
ovecii pneumonia) and with HIV-specific factors (i.e. lower
nadir CD4 cell count, longer duration of HIV infection
and exposure to ART [2]. Similar rates of osteopenia and
osteoporosis were observed in a small cohort (n = 33) of
men with primary HIV-1 infection [3] and men who have
sex with men (MSM), irrespective of HIV status or use of
amphetamines and other recreational drugs associated
with an increased risk of low BMD [4,5]. Several studies
have reported an increased rate of fracture of the spine,
hip and wrist, with the most pronounced increase in older
people living with HIV (>50–60 years) [6–8].
It is important that treatment decisions relative to
co-morbidities such as low BMD are placed in context.
PLWH may have several co-morbidities and each of these
should be considered and weighted appropriately during
the treatment-decision process. Furthermore, dual X-ray
absorptiometry (DXA) is unable to distinguish low BMD
due to osteoporosis from osteomalacia. Vitamin D and
parathyroid hormone status should be evaluated and
optimised in individuals with low BMD in whom ART or
non-ART interventions are being considered.
8.10.2 When to start antiretroviral therapy
8.10.2.1 Recommendation
• We recommend that general recommendations for the
timing of ART are followed in patients with, or at risk
of osteoporosis (1D).
8.10.2.2 Rationale
Initiation of ART is associated with a reduction in BMD
of 2–6%; bone loss is generally restricted to the first year
with a relatively stable pattern thereafter [9,10]. Intermit-
tent use of ART (as compared with continuous, uninter-
rupted ART) in the SMART study was associated with
reduced bone loss during follow up [11]. There are no
data to suggest that initiation of ART reduces the rate of
bone loss or the risk of fracture [12]; general recommen-
dations for the timing of ART should be followed in HIV
populations with, or at risk of, osteoporosis.
8.10.3 What to start
8.10.3.1 Recommendations
• We recommend against the use of tenofovir-DF diso-
proxil fumarate in individuals aged >40 years with
osteoporosis, a history of fragility fracture, or a FRAX
score of >20% (major osteoporotic fracture) if accept-
able alternative ARV agents are available (1B).
8.10.3.2 Rationale
In clinical trials, ART-na€ıve individuals who initiated
tenofovir-DF-containing regimens experienced greater
reductions in BMD than those initiating tenofovir-DF-
sparing regimens. For example, in the Gilead 903 study,
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observed reductions in lumbar spine and hip BMD at
144 weeks were 2.2% and 2.8% in the tenofovir-DF arm
and 1.0% and 2.4% in the stavudine arm (each co-admi-
nistered with lamivudine and efavirenz) [13]. In the
ASSERT study, the reduction in BMD at the lumbar spine
and hip at 48 weeks was 2.4% and 3.6% in the tenofovir-
DF/emtricitabine arm and 1.6% and 1.9% in the abacavir/
lamivudine arm (each given with efavirenz) [14], while in
the ACTG5224s study, in which the third agent consisted
of efavirenz or ritonavir-boosted atazanavir, the observed
reductions at 96 weeks were 3.3% and 4.0% with tenofo-
vir-DF/emtricitabine and 1.3% and 2.6% with abacavir/
lamivudine [15]. When analysed together with two other
ACTG studies, randomisation to tenofovir-DF was associ-
ated with a 1.4% greater reduction in total BMD [12].
Considerably smaller BMD reductions (0.6–1%) were
observed following the initiation of tenofovir alafenamide
(TAF), a new formulation currently undergoing Phase 3
clinical trial, as compared with tenofovir disoproxil
fumarate (2.4–3.4%) when co-administered with emtric-
itabine, cobicistat and elvitegravir [16].
Several studies have examined the effects on BMD of
PIs as part of initial ART. Greater bone loss at the lumbar
spine (3.1 vs. 1.7%) but not at the hip (3.4% vs 3.1%)
was observed with atazanavir/ritonavir as compared with
efavirenz in ACTG 5224s [15]. When analysed together
with two other ACTG studies, randomisation to ritonavir-
boosted protease inhibitors resulted in a 0.8% greater
reduction in total BMD [12]. A Danish study observed no
differences in BMD change between those who were ran-
domised to zidovudine/lamivudine or lopinavir/r, each
given with efavirenz. At 144 weeks, lumbar spine BMD
had decreased by 1.9% and 2.5%, respectively, and hip
BMD by 5.0% and 6.1% [17]. Several recent trials in
treatment-na€ıve subjects showed more favourable BMD
changes with raltegravir plus lopinavir/r or darunavir/r
as compared with tenofovir-DF/emtricitabine [18–20].
There are currently insufficient data to make recommen-
dations regarding the third agent in terms of their effect
on BMD.
8.10.4 Switching treatment
8.10.4.1 Recommendations
• We recommend against continued use of tenofovir-DF
in individuals >40 years who are diagnosed with
osteoporosis, have sustained a fragility fracture, or
have a FRAX score of >20% (major osteoporotic frac-
ture) if acceptable alternative ARV agents are available
(1C).
8.10.4.2 Rationale
Tenofovir-DF and PIs have been associated with low
BMD and bone loss in cohort studies [21–25], and use of
tenofovir-DF and lopinavir/r or any PI with an increased
incidence of fractures [26,27]. In individuals who were
virologically suppressed on ART, a switch from zidovu-
dine/lamivudine to tenofovir-DF/emtricitabine resulted in
a 2.1% reduction in BMD at the lumbar spine and hip at
48 weeks, compared with no change (+0.6% and +0.3%)
following a switch to abacavir/lamivudine [28]. Similar,
albeit statistically not significant reductions in lumbar
spine and hip BMD were observed in the PREPARE study
in which PLWH were randomised to switch from zidovu-
dine/lamivudine to tenofovir-DF/emtricitabine or remain
on their zidovudine/lamivudine-containing regimen [29].
Smaller reductions (~1.9%) in lumbar spine and total hip
BMD have been observed with raltegravir vs. 2–3 NRTI
(each administered with lopinavir/ritonavir) as second
line ART [30], and improvements of 2.5–3% following a
switch from tenofovir-DF to raltegravir [31] or a switch
from tenofovir-DF/emtricitabine/efavirenz to darunavir/r
[32]. There are no data from ART switch studies to sug-
gest that PI discontinuation improves BMD.
Of the non-nucleoside reverse transcriptase inhibitors,
efavirenz has been associated with vitamin D deficiency
in cohort studies and clinical trials [9]. There are no data
to suggest that the initiation of efavirenz containing ART
results in greater initial bone loss, or that efavirenz-
containing ART is associated with the development of
osteoporosis or fractures. A single case of osteomalacia
has been reported with the use of efavirenz [33]. Use of
PI has been associated with avascular necrosis of bone
and these agents may thus be best avoided in those who
have developed this complication [34].
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8.11 Considerations for later life
8.11.1 Introduction
PLWH are not only living into older age but older people
are also acquiring HIV as they maintain sexually active
lifestyles. The proportion of PLWH in the UK aged 50 and
over has more than doubled in the last decade: in 2013,
27% (21,910/81,512) were aged 50 years or above com-
pared with 13% (5,286/41,153) in 2004 [1]. Thirty percent
(10,730/25,380) of MSM seen for HIV care were aged
50 years or above in 2013 compared to one in five (21%,
5,390/36,230) in 2008 [1]. Older PLWH are more likely to
experience co-morbidities and be receiving non-ARV
medication. In addition, increased age may be associated
with mental health issues, social isolation and financial
challenges; HIV-treating clinicians should be mindful of
these factors and familiar with appropriate sources of
support.
8.11.2 When to start ART
8.11.2.1 Recommendation
• We recommend standard criteria are used to determine
when to commence antiretroviral therapy in older
PLWH (1C).
8.11.2.2 Rationale
The following factors should be specifically considered.
8.11.2.2.1 Rate of CD4 cell count decline
Older age has been found to be strongly associated with
faster CD4 cell count declines [2–4]. A more recent analy-
sis from the COHERE dataset demonstrated older age was
significantly associated with higher viral load, which is
in turn associated with CD4 cell count decline [5]. As
such, older individuals with a high CD4 cell count may
experience more rapid decline so older age may be con-
sidered an additional factor when deciding how quickly
to commence ART at high CD4 strata.
8.11.2.2.2 Absolute risk of disease progression at a given
CD4 cell count
The absolute risk of disease progression is significantly
higher for a given CD4 cell count in older people, a fac-
tor to consider when counselling older individuals about
starting ART.
8.11.2.2.3 CD4 cell recovery on commencing antiretrovi-
ral therapy
CD4 cell recovery on commencing ART may be limited in
the older person [5,6], possibly due to age-associated
effects on thymic function or lower baseline CD4 cell
counts [5,7,8]. Some studies suggest this is a short-term
phenomenon attenuated with longer duration of ART [9]
and others suggest that CD4 cell recovery and virological
suppression are not affected by age [10,11].
8.11.2.2.4 The presence of non-infectious co-morbid-
ities
HIV infection itself may accelerate age-related conditions.
PLWH may therefore develop non-infectious co-morbid-
ities at an earlier age; ‘accelerated frailty’ may be
associated with a lower CD4 count and high viral load.
While increased frailty has been observed in ART-na€ıve
individuals, and ART may limit this accelerated ageing,
long-term ART exposure may also contribute to certain
phenotypes associated with co-morbidities, including fat
changes, atherosclerosis and sarcopenia [12].
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8.11.3 What to start
8.11.3.1 Recommendation
• We recommend standard antiretroviral regimens are
commenced in older PLWH (1C).
8.11.3.2 Rationale
The factors below should be specifically considered when
commencing therapy in older PLWH.
8.11.3.2.1 Non-infectious comorbidities
Non-infectious comorbidities are more prevalent in older
individuals and are reported to occur more frequently
and at a younger age in PLWH compared to matched
control populations [1]. Considerations regarding the
presence of end-organ disease should be taken into
account when tailoring antiretroviral therapy for older
individuals.
8.11.3.2.2 Concomitant medication
The use of concomitant medication, both over-the-coun-
ter preparations and prescription medication is highly
prevalent in older PLWH [2]. Consideration regarding
drug–drug interactions with concomitant medications is
required when commencing antiretroviral therapy in
older PLWH.
8.11.3.2.3 Clinical pharmacology and ageing
All aspects of drug pharmacology, namely absorption,
metabolism, distribution and elimination are reported to
change with age. Specifically, for the currently available
antiretroviral drugs, effects on hepatic metabolism and
elimination may be relevant [3]. Regarding hepatic meta-
bolism, CYP3A4 activity may wane with age and there-
fore, for drugs metabolised via this pathway, plasma
exposure may increase with age. In pharmacokinetic
studies, exposure of the boosted-protease inhibitors has
been reported to increase with age [4], with these effects
not reported with other classes such as the integrase inhi-
bitors [5]. Although theoretically this could lead to
increased toxicity in older PLWH, this has not been
reported in clinical practice. Regarding elimination, renal
elimination of drugs reduces with increasing age. Phar-
macokinetic studies have described increased exposure of
tenofovir-DF in older PLWH compared to younger PLWH,
which was thought to be due to reduced renal clearance
[6]. Again, here there is a theoretical risk of increased
toxicity from higher drug exposure; however, clinical
data are lacking.
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